UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
(Mark One)
☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended
December 31, 2022
OR
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission file number 001-34375
PLUS THERAPEUTICS, INC.
(Exact name of Registrant as Specified in Its Charter)
DELAWARE
(State or Other Jurisdiction of
Incorporation or Organization)
4200 MARATHON BLVD. SUITE 200, AUSTIN, TX
(Address of principal executive offices)
33-0827593
(I.R.S. Employer
Identification No.)
78756
(Zip Code)
Registrant’s telephone number, including area code: (737) 255-7194
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Common Stock, par value $0.001 per share
Trading Symbol(s)
PSTV
Name of each exchange on which registered
Nasdaq Capital Market
Securities registered pursuant to Section 12(g) of the Act:
None.
Indicate by check mark if the registrant is a well-known seasoned issuer as defined in Rule 405 of the Securities Act. Yes ☐ No ☒
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes ☐ No ☒
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for
such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter)
during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See
definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large Accelerated Filer
Non-Accelerated Filer
Emerging growth company
☐
☒
☐
Accelerated Filer
Smaller reporting company
☐
☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicacheck mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section
404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to
previously issued financial statements. ☐
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive
officers during the relevant recovery period pursuant to §240.10D-1(b). ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
The aggregate market value of the common stock of the registrant held by non-affiliates of the registrant on June 30, 2022, the last business day of the registrant’s most recently completed second
fiscal quarter, was $12.1 million based on the closing sales price of the registrant’s common stock on June 30, 2022 as reported on the Nasdaq Capital Market, of $0.54 per share.
As of February 17, 2023, there were 35,109,885 shares of the registrant’s common stock outstanding.
DOCUMENTS INCORPORATED BY REFERENCE:
Portions of the registrant’s definitive proxy statement for its 2023 Annual Meeting of Stockholders, which will be filed with the United States Securities and Exchange Commission within 120
days of December 31, 2022, are incorporated by reference into Part III of this Annual Report on Form 10-K.
TABLE OF CONTENTS
PART I
Business
Risk Factors
Unresolved Staff Comments
Properties
Legal Proceedings
Mine Safety Disclosures
PART II
Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
[Reserved]
Management’s Discussion and Analysis of Financial Condition and Results of Operations
Quantitative and Qualitative Disclosures About Market Risk
Financial Statements and Supplementary Data
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
Controls and Procedures
Other Information
Disclosure Regarding Foreign Jurisdictions that Prevent Inspection
PART III
Item 1.
Item 1A.
Item 1B.
Item 2.
Item 3.
Item 4.
Item 5.
Item 6.
Item 7.
Item 7A.
Item 8.
Item 9.
Item 9A.
Item 9B.
Item 9C.
Item 10.
Item 11.
Item 12.
Item 13.
Item 14.
Directors, Executive Officers and Corporate Governance
Executive Compensation
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Certain Relationships and Related Transactions, and Director Independence
Principal Accounting Fees and Services
Item 15.
Item 16.
Exhibits, Financial Statement Schedules
Form 10-K Summary
PART IV
Page
6
24
46
46
46
47
48
49
50
60
61
83
83
83
84
84
84
84
84
84
85
85
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
This report contains certain statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws. All statements, other
than statements of historical fact, that address activities, events or developments that we intend, expect, project, believe or anticipate and similar
expressions or future conditional verbs such as will, should, would, could or may occur in the future are forward-looking statements. Such statements are
based upon certain assumptions and assessments made by our management in light of their experience and their perception of historical trends, current
conditions, expected future developments and other factors they believe to be appropriate.
These statements include, without limitation, statements about our anticipated expenditures, including research and development, and general and
administrative expenses; our strategic collaborations and license agreements, intellectual property, FDA and EMA approvals and interactions and
government regulation; the potential size of the market for our product candidates; our research and development efforts; results from our pre-clinical and
clinical studies and the implications of such results regarding the efficacy or safety of our product candidates; the safety profile, pathways, and efficacy of
our product candidates and formulations; anticipated advantages of our product candidates over other products available in the market and being
developed; the populations that will most benefit from our product candidates and indications that will be pursued with each product candidate;
anticipated progress in our current and future clinical trials; plans and strategies to create novel technologies; our IP strategy; competition; future
development and/or expansion of our product candidates and therapies in our markets; sources of competition for any of our product candidates; our
pipeline; our ability to generate product or development revenue and the sources of such revenue; our ability to effectively manage our gross profit
margins; our ability to obtain and maintain regulatory approvals; expectations as to our future performance; portions of the “Liquidity and Capital
Resources” section of this report, including our potential need for additional financing and the availability thereof; our ability to continue as a going
concern; our ability to remain listed on the Nasdaq Capital Market; our ability to repay or refinance some or all of our outstanding indebtedness and our
ability to raise capital in the future; our ability to transfer the drug product manufacture to a contract drug manufacturing organization; and the potential
enhancement of our cash position through development, marketing, and licensing arrangements. The forward-looking statements included in this report are
also subject to a number of additional material risks and uncertainties, including but not limited to the risks described under the “Risk Factor Summary”
below.
We encourage you to read the risks described under “Risk Factor Summary” and elsewhere in this report carefully. We caution you not to place undue
reliance on the forward-looking statements contained in this report. These statements, like all statements in this report, speak only as of the date of this
report (unless an earlier date is indicated) and we undertake no obligation to update or revise the statements except as required by law. Such forward-
looking statements are not guarantees of future performance.
3
RISK FACTOR SUMMARY
Below is a summary of the principal factors that may affect our business, financial condition, and results of operations. This summary does not address all
of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, and other risks that we face, can be found below under
the heading “Risk Factors” and should be carefully considered, together with other information in this Form 10-K and our other filings with the SEC.
Risks Related to Our Financial Position and Capital Requirements
•
•
•
•
We have incurred losses since inception and expect to incur significant net losses in the foreseeable future and therefore may never become
profitable and our operating results have been and will likely continue to be volatile.
We could be delisted from Nasdaq, which would seriously harm the liquidity of our stock and our ability to raise capital.
We will need substantial additional funding to develop our product candidates and conduct our future operations and to repay our outstanding
debt obligations. If we are unable to obtain the funds necessary to do so, we may be required to delay, scale back or eliminate our product
development activities or may be unable to continue our business operations. Furthermore, the volatility in the global capital markets may
negatively impact our ability to obtain additional debt financings and modify our existing debt facilities and may increase the risk of non-
compliance with covenants under our existing loan agreement.
Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.
Risks Related to Our Business and Industry
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Our future success is in large part dependent upon our ability to successfully develop our nanomedicine platform and commercialize rhenium
(186Re) obisbemeda and 188RNL-BAM and any failure to do so could significantly harm our business and prospects.
If we are unable to successfully partner with other companies to commercialize our product candidates, our business could materially suffer.
Our success depends in substantial part on our ability to obtain regulatory approvals for our rhenium (186Re) obisbemeda and 188RNL-BAM
product candidates. However, we cannot be certain that we will receive regulatory approval for these product candidates or our other product
candidates.
Reliance on government funding for our programs may impose requirements that limit our ability to take certain actions, and subject it to
potential financial penalties, which could materially and adversely affect its business, financial condition and results of operations.
If our competitors market or develop products that are marketed more effectively, approved more quickly than our product candidates, or
demonstrated to be safer or more effective than our product candidates, our commercial opportunities could be reduced or eliminated.
Product development involves a lengthy and expensive process, with an uncertain outcome. We may incur additional costs or experience
delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.
Pre-clinical studies and preliminary and interim data from clinical trials of our product candidates are not necessarily predictive of the results
or success of ongoing or future clinical trials of our product candidates.
Clinical trial results may fail to support approval of our product candidates.
If third parties we engage are not able to successfully perform, we may not be able to successfully complete clinical development, obtain
regulatory approval or commercialize our product candidates and our business could be substantially harmed.
We may have difficulty enrolling, or fail to enroll patients in our clinical trials, which could delay or prevent clinical trials of our drug
candidates.
If a particular product candidate causes significant adverse events, then we may be unable to receive regulatory approval or market
acceptance for such product candidate.
If our product candidates and technologies receive regulatory approval but do not achieve broad market acceptance, especially by physicians,
the revenue that we generate will be limited.
All potential applications of our product candidates are investigational, which subjects us to development and marketing risks.
We and our product candidates are subject to extensive regulation, and the requirements to obtain regulatory approvals in the United States
and other jurisdictions can be costly, time-consuming, and unpredictable. If we or our partners are unable to obtain timely regulatory
approval for our product candidates, our business may be substantially harmed.
We will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant expense, and if we or
our collaborators fail to comply with such requirements, regulatory agencies may take action against us or them, which could significantly
harm our business.
4
•
•
•
•
•
•
Changing, new and/or emerging government regulations, including healthcare legislative reform measures, may adversely affect us.
Adequate coverage and reimbursement from third party payors may not be available for our products and we may be unable to successfully
contract for coverage from pharmacy benefit managers and other organizations; conversely, to secure coverage from these organizations, we
may be required to pay rebates or other discounts or other restrictions to reimbursement, either of which could diminish our sales or
adversely affect our ability to sell our products profitably.
Some intellectual property that we have in-licensed have been discovered through government funded programs and thus may be subject to
federal regulations such as "march-in" rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with
such regulations may limit our exclusive rights, and limit our ability to contract with non-U.S. manufacturers.
Orphan drug designation may not ensure that we will enjoy market exclusivity in a particular market, and if we fail to obtain or maintain
orphan drug designation or other regulatory exclusivity for some of our product candidates, our competitive position could be harmed.
If we experience an interruption in supply from a material sole source supplier, our business may be harmed.
We may engage in strategic transactions that could impact our liquidity, increase our expenses, and present significant distractions to our
management.
Risks Relating to Our Intellectual Property
•
•
•
•
Our success depends in part on our ability to protect our intellectual property. We may not be able to protect our trade secrets.
We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.
We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights, and we
may be unable to protect our rights to our product candidates and technology.
If we are sued for infringing intellectual property rights of third parties, it will be costly and time consuming, and an unfavorable outcome in
that litigation would have a material adverse effect on our business.
Risks Relating to the Securities Markets and an Investment in Our Common Stock
•
•
•
Our stockholders may experience substantial dilution in the value of their investment if we issue additional shares of our capital stock,
including in connection with the sale or issuance of our common stock to Lincoln Park and the sale of the shares of common stock acquired
by Lincoln Park and the sale of our common stock by Canaccord.
The market price of our common stock may be volatile and fluctuate significantly, which could result in substantial losses for stockholders,
and future sales of our common stock may depress our share price.
We may issue debt and equity securities or securities convertible into equity securities, any of which may be senior to our common stock as
to distributions and in liquidation, which could negatively affect the value of our common stock.
5
PART I
Item 1. Business
References to “Plus,” the “Company,” “we,” “us” and “our” refer to Plus Therapeutics, Inc. References to “Notes” refer to the Notes to Financial
Statements included herein (refer to Item 8).
General
Plus Therapeutics, Inc. is a U.S. pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central
nervous system ("CNS") cancers. Our novel radioactive drug formulations and therapeutic candidates are designed to deliver safe and effective doses of
radiation to tumors. To achieve this, we have developed innovative approaches to drug formulation, including encapsulating radionuclides such as Rhenium
isotopes with nanoliposomes and microspheres. Our formulations are intended to achieve elevated patient absorbed radiation doses and extend retention
times such that the clearance of the isotope occurs after significant and essentially complete radiation decay, which will contribute and provide less normal
tissue/organ exposure and improved safety margins.
Traditional approaches to radiation therapy for cancer, such as external beam radiation, have many disadvantages including continuous treatment
for four to six weeks (which is onerous for patients), that the radiation damages healthy cells and tissue, and that the amount of radiation delivered is very
limited and, therefore, is frequently inadequate to fully destroy the cancer.
Our targeted radiotherapeutic platform and unique investigational drugs have the potential to overcome these disadvantages by directing higher,
more powerful radiation doses at the tumor—and only the tumor—potentially in a single treatment. By minimizing radiation exposure to healthy tissues
while simultaneously maximizing locoregional delivery and, thereby, efficacy, we hope to reduce the radiation toxicity for patients, improving their quality
of life and life expectancy. Our radiotherapeutic platform, combined with advances in surgery, nuclear medicine, interventional radiology, and radiation
oncology, affords us the opportunity to target a broad variety of cancer types.
Our lead radiotherapeutic candidate, rhenium (186Re) obisbemeda (formerly, “186RNL”), is designed specifically to CNS cancers including
recurrent glioblastoma ("GBM"), leptomeningeal metastases ("LM"), and pediatric brain cancers ("PBC") by direct localized delivery utilizing approved
standard-of-care tissue access such as with convection-enhanced delivery (“CED”) and intraventricular brain(Ommaya reservoir) catheters. Our recently
acquired radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (“188RNL-BAM”) is designed to treat many solid
organ cancers including primary and secondary liver cancers by intra-arterial injection.
Our headquarters and manufacturing facilities are in Texas and are in proximity to world-class cancer institutions and researchers. Our dedicated
team of engineers, physicians, scientists, and other professionals are committed to advancing our targeted radiotherapeutic technology for the benefit of
cancer patients and healthcare providers worldwide and our current pipeline is focused on treating rare and difficult-to-treat cancers with significant unmet
medical needs.
In addition to its headquarters in Austin, we have an established, GMP-validated research and development and manufacturing facility in San
Antonio, Texas, tailored to produce cGMP rhenium (186Re) obisbemeda. We have built a robust supply chain through strategic partnerships that enable the
development, manufacturing and future potential commercialization of our products. Our current supply chain and key partners are positioned to supply
cGMP rhenium (186Re) obisbemeda for ongoing and planned Phase 2 and Phase 3 clinical trials in patients with GBM, LM and PBC..
Pipeline
Our most advanced investigational drug, rhenium (186Re) obisbemeda, is a patented radiotherapy potentially useful for patients with CNS and
other cancers. Preclinical study data describing the use of rhenium (186Re) obisbemeda for several cancer targets have been published in peer-reviewed
journals and reported at a variety of medical society peer-reviewed meetings. Besides GBM, LM and PBC, rhenium (186Re) obisbemeda has been reported
to have potential applications for head and neck cancer, ovarian cancer, breast cancer and peritoneal metastases.
The Rhenium (186Re) Obisbemeda technology was part of a licensed radiotherapeutic portfolio that we acquired from NanoTx, Corp.
(“NanoTx”) on May 7, 2020. The licensed radiotherapeutic has been evaluated in preclinical studies for several cancer targets and we have an active $3.0
million award from U.S. National Institutes of Health/National Cancer Institute which is expected to provide financial support for the continued clinical
development of rhenium (186Re) obisbemeda for recurrent GBM through the completion of a Phase 2 clinical trial, including enrollment of up to 55
patients. As of February 23, 2023, 26 patients have been treated in the Phase 1 clinical trial and the Phase 2 clinical trial has been initiated with the first
patient treated. In addition, we anticipate obtaining FDA IND approval for the ReSPECT-PBC clinical trial for PBC in early 2023.
6
On August 29, 2022, we announced feedback from a Type C meeting with the FDA regarding Chemistry, Manufacturing and Controls (“CMC”)
practices. The meeting focused on our Current Good Manufacturing Practice (“cGMP”) clinical and commercial manufacturing process for our lead
investigational targeted radiotherapeutic, BMEDA-chelated Rhenium (186Re) Obisbemeda, for recurrent GBM.
The FDA indicated agreement with our proposed application of cGMP guidance for radiotherapeutics, small molecule drug products and
liposome drug products for our novel rhenium (186Re) obisbemeda in support of ongoing and future GBM clinical trials, manufacturing scale up, and
commercialization. Alignment with the FDA includes support of our proposed controls and release strategy for new drug substance and new drug product.
Because this product is identical for recurrent GBM and LM adult development and pediatric brain tumors, we believe this FDA alignment and feedback
will apply to rhenium (186Re) obisbemeda used in other clinical development programs, including LM and PBC.
Rhenium (186Re) obisbemeda versus External Beam Radiation Therapy for Recurrent GBM
Rhenium (186Re) obisbemeda is a novel injectable radiotherapy designed to deliver targeted, high dose radiation directly into GBM tumors in a
safe, effective, and convenient manner that may ultimately prolong patient survival. rhenium (186Re) obisbemeda is composed of the radionuclide Rhenium-
186 and a nanoliposomal carrier, and is infused in a highly targeted, controlled fashion, directly into the tumor via precision brain mapping and CED
catheters. Potential benefits of rhenium (186Re) obisbemeda compared to standard external beam radiotherapy or EBRT include:
•
•
•
•
•
The rhenium (186Re) obisbemeda radiation dose delivered to patients may be up to 20 times greater than what is possible with commonly
used external beam radiation therapy (“EBRT”), which, unlike EBRT and proton beam devices, spares normal tissue and the brain from
radiation exposure.
Rhenium (186Re) obisbemeda can be visualized in real-time during administration, possibly giving clinicians better control of radiation
dosing, distribution and retention.
Rhenium (186Re) obisbemeda potentially more effectively treats a bulk tumor and microscopic disease that has already invaded healthy
tissue.
Rhenium (186Re) obisbemeda is infused directly into the targeted tumor by CED catheter insertion using MRI guided software to avoid
critical patient neurological structures and neural pathways and also bypasses the blood brain barrier, which delivers the therapeutic product
where it is needed. Importantly, it reduces radiation exposure to healthy cells, in contrast to EBRT which passes through normal tissue to
reach the tumor, continuing its path through the tumor, hence being less targeted and selective.
Rhenium (186Re) obisbemeda is given during a single, short, in-patient hospital visit, and is available in all hospitals with nuclear medicine
and neurosurgery, while EBRT requires out-patient visits five days a week for approximately four to six weeks.
ReSPECT-GBM Trial for Recurrent GBM
Recurrent GBM is the most common, complex, and aggressive primary brain cancer in adults. In the U.S., there are more than 13,000 GBM
cases diagnosed and approximately 10,000 patients succumb to the disease each year. The average length of overall survival ("OS") for GBM patients is
eight months, with a one-year survival rate of 40.8% and a five-year survival rate of only 6.8% and these estimates varies and are lower in some
publications. GBM routinely presents with headaches, seizures, vision changes and other significant neurological complications, with a significant
compromise in quality of life. Despite the best available medical treatments, the disease remains incurable. Even after efforts to manage the presenting
signs and symptoms and completely resect the initial brain tumor, some microscopic disease almost always remains and tumor regrowth occurs within
months. Approximately 90% or more of patients with primary GBM experience tumor recurrence. Complete surgical removal of GBM is usually not
possible and GBM is often resistant or quickly develops resistance to most available current and investigational therapies. Even today, the treatment of
GBM remains a significant challenge and it has been nearly a decade since the FDA approved a new therapy for this disease, and these more recent
approvals have not improved GBM patients OS over past decades, and a significant unmet medical need persists.
For recurrent GBM, there are few currently approved treatments, which in the aggregate, provide only marginal survival benefit. Furthermore,
these therapies are associated with significant side effects, which limit dosing and prolonged use.
While EBRT has been shown to be safe and has temporary efficacy in many malignancies including GBM, typically at absorbed, fractionated
radiation dose of ~30 Gray in GBM, this maximum possible administered dose is always limited by toxicity to the normal tissues surrounding the
malignancy and because EBRT requires fractionation to manage toxicity and maximum EBRT limits are typically reached before long-term efficacy
reached. Because of this limitation EBRT cannot provide a cure or long term control of GBM and GBM always recurs within months after EBRT. In
contrast, locally delivered and targeted radiopharmaceuticals that precisely deliver radiation in the form of beta particles such as Iodine-131 for thyroid
cancer, are known to be safe and effective and minimize exposure to normal cells and tissues especially with optimal targeting and avoidance of normal
tissue. The locally delivered rhenium (186Re) obisbemeda is designed for and provides patient tolerability and safety. Though no head-to-head trial with
chemo, immune,
7
EBRT or systemic radiopharmaceutical products have been conducted, patient tolerability and safety considerations have been reported as expected.
Interim results from our ongoing Phase 1/2a ReSPECT-GBM trial (ClinicalTrials.gov NCT01906385) show that the beta particle energy from our
lead investigational drug rhenium (186Re) obisbemeda has provided preliminary positive data and utility in treating GBM and potential other malignancies.
More specifically, the preliminary data from our Phase 1/2a ReSPECT-GBM trial suggests that radiation, in the form of high energy beta particles or
electrons, can be effective against GBM. Thus far, we have been able to deliver up to 740 Gy of absorbed radiation to tumor tissue in humans, without
significant or dose limiting toxicities and with what we believe has the capability to go higher if required. In comparison, current EBRT protocols for
recurrent GBM typically recommend a total maximum radiation dose of about ~30-35 Gray.
In September 2020, the FDA granted both Orphan Drug designation and Fast Track designations to rhenium (186Re) obisbemeda for the treatment
of patients with GBM. In November 2021, the FDA granted Fast Track designation for rhenium (186Re) obisbemeda for the treatment of LM.
Rhenium (186Re) obisbemeda is under clinical investigation in a multicenter, sequential cohort, open-label, volume and dose escalation study of the
safety, tolerability, and distribution of rhenium (186Re) obisbemeda given by CED catheters to patients with recurrent or progressive malignant glioma
after standard surgical, radiation, and/or chemotherapy treatment (NCT01906385). The study uses a standard, modified 3x3 Fibonacci dose escalation,
followed by a planned Phase 2 expansion trial at the maximum tolerated dose (“MTD”) / maximum feasible dose (“MFD”) or non-dose limiting toxicity
(“DLT”) if MTD is not reached, to determine efficacy. The trial is funded through Phase 2 in large part by a NIH/NCI grant. These investigations have not
reached DLT or MTD/MFD and the study is in its eighth dosing administration cohort. Due to the observation of a preliminary efficacy signal, we have
initiated in parallel a Phase 2, non-DLT dose trial pursuant to the currently funded NIH/NCI Grant. This trial will begin at the current non-DLT rhenium
(186Re) obisbemeda dose and will expand exploring higher radiation doses in larger volumes to treat larger tumors. Additionally, two or more rhenium
(186Re) obisbemeda administrations, if indicated, will be evaluated, and reviewed with the FDA, as well as expanded safety, imaging and efficacy data to
support a planned future registrational trial. This in turn will provide a path to a registration trial.
On September 6, 2022, we announced a summary of our Type C clinical meeting with the FDA that focused on the ReSPECT-GBM trial. The
FDA agreed with us that the ReSPECT-GBM clinical trial should proceed to the planned Phase 2. The key focus areas of clinical investigation of the Phase
2 trial will be 1) further dose exploration, including both increased dosing and multiple doses, and 2) collecting additional safety and efficacy data to
inform the design of a future registrational trial. Because no DLT administered doses were observed, the FDA and we also agreed to continue to dose
cohort eight. There was further agreement with the FDA that in a planned future registrational trial, overall survival should be used as the primary endpoint.
We agreed with the FDA to hold future meeting(s) to consider the use of external data to augment the use of a control arm in the registrational trial.
At the European Society for Medical Oncology Congress, held September 9 to 13, 2022, we presented updated data from the ReSPECT-GBM
trial, which evaluated 23 adult patients with recurrent GBM across eight cohorts of increasing dose and treated over a seven-year period. Key findings
include:
•
•
•
•
•
No DLTs have been observed and the procedure was very well tolerated with a strong safety profile. Minimal systemic radiation has been
observed and the majority of adverse events have been mild or moderate and considered causally unrelated to rhenium (186Re) obisbemeda.
Improved median overall survival (“OS”) rates correlated with the absorbed radiation tumor dose. When patients were stratified based on
receipt of either a therapeutic or a subtherapeutic absorbed dose of radiation to the tumor, a statistically significant improvement in survival
was observed. Specifically, patients receiving a therapeutic absorbed radiation dose (>100 Gray) had a median OS of 22.9 months (95% CI of
8.8-42.3) compared to those receiving a subtherapeutic absorbed radiation dose (<100 Gray) whose median OS was 5.6 months (95% CI of
1.6-9.4). Currently, three patients remain alive, all in the therapeutic group.
Feasibility to deliver up to at least 20 times more radiation to the tumor than the standard of care, EBRT. A maximum of 32.2 mCi in 12.3
mL of volume has been delivered in and near the tumors, and a maximum average absorbed dose of radiation of 740 Gray was successfully
administered in a single procedure.
Average absorbed radiation dose to the tumor increased in latter dosing cohorts with greater administered doses of rhenium (186Re)
obisbemeda β-particle radiation, larger drug CED infusate volumes, more catheters used (up to four versus one), and higher convection flow
rates. In cohorts five and later, 82% of patients received a therapeutic radiation dose of >100Gray.
Single-photon emission computerized tomography and (SPECT)/CT scanning were used during treatment to compute tumor coverage and
dosimetry. Post treatment imaging analyses, including MRI, relative cerebral blood volume (rCBV) analysis
8
and treatment response assessment maps (TRAMs) correlated with a positive tumor response and confirmed the presence of
pseudoprogression in patients with positive tumor responses.
At the Society for Neuro-Oncology Annual Meeting in November 2022, we presented patient data, which at that time included the results for 24
patients treated in the ReSPECT-GBM trial. As of the date of this report, rhenium (186Re) obisbemeda given by CED in recurrent GBM patients was
observed in the trial to be feasible and well tolerated. Across all subjects in the first eight cohorts (n=24), the median absorbed dose to the tumor volume
increased as cohorts evaluated progressed, with patients receiving >100Gy absorbed dose showing significant survival benefit versus patients receiving
<100Gy absorbed dose. Importantly, in a subset of patients where tumor coverage was greater than or equal to 75%, the median absorbed dose was 405 Gy
(range 146-593). By contrast, given the protocol dose escalation design where early cohorts often had much lower doses, the absorbed doses were adequate
for small tumors even with low doses. Small, absorbed doses to specific organs and whole body, are typically well-tolerated. Based on observed and
reported patient protocol activity and all available adverse event (AE) data, rhenium (186Re) obisbemeda has been well-tolerated with AEs related to CED
insertion that were limited and fully recovered. No AEs with an outcome of death, study discontinuation or study drug-related serious AEs have been
reported. All AEs have been mild or moderate (Grade 1 or 2) in intensity, except for one case of Grade 3 vasogenic edema, which was considered by the
investigator to be unrelated to the study drug. AEs considered by the investigator to be at least possibly related to rhenium (186Re) obisbemeda have
included Grade 1 to 2 skin and soft tissue infection, intermittent cephalgia, neck and jaw pain, nausea with or without vomiting, constipation, increased
lethargy, difficulty walking (gait disturbance), worsening double vision, and dysuria. Scalp discomfort and tenderness related to the surgical procedure has
also been reported.
In the 24 subjects with recurrent GBM receiving a single administration of rhenium (186Re) obisbemeda, the median OS for all 24 patients as of
November 2022 was 8.8 months, with four patients alive. In a subset of 13 patients receiving a presumed therapeutic absorbed radiation dose to the tumor
(>100 Gy), the mean OS was 22.9 months, respectively, with seven of 13 patients alive. In contrast, in nine patients receiving a presumed sub-therapeutic
absorbed radiation dose to the tumor (<100 Gy), the mean and median OS was 23.9 and 22.3 weeks, respectively. A Kaplan-Meier curve comparing
patients with presumed therapeutic (>100 Gy) versus sub-therapeutic (<100 Gy) radiation dose to the tumor showed a statistically significant difference
between the groups (p=.0003). It is hypothesized that targeted infusion of rhenium (186Re) obisbemeda into the tumor by CED, which exposure and
potential toxicity and concentrates radiation to the tumor and surrounding region of interest. On January 18, 2023, we announced that the first patient has
been dosed in the ReSPECT-GBM Phase 2b dose expansion clinical trial evaluating rhenium obisbemeda for the treatment of recurrent GBM. The Phase 2b
trial is expected to enroll up to 31 total patients with small- to medium-sized tumors in approximately 24 months.
ReSPECT-LM Clinical Trial for Leptomeningeal Metastases (LM)
LM is a rare complication of cancer in which the disease spreads to the membranes (meninges) surrounding the brain and spinal cord. The
incidence of LM is growing and occurs in approximately 5%, or more, of people with late-stage cancer, or 110,000 people in the U.S. each year. It is highly
lethal with an average one-year survival of just 7%. All solid cancers have the potential to spread to the central nervous system and leptomeninges resulting
in LM.
The ReSPECT-LM Phase 1 clinical trial (ClinicalTrials.gov NCT05034497) is predicated in part upon preclinical studies in which tolerance to
doses of rhenium (186Re) obisbemeda as high as 1,075 Gy was shown in animal models with LM without significant observed toxicity. Furthermore,
treatment led to a marked reduction in tumor burden in both C6 and MDA-231 LM models.
Upon receiving acceptance of our Investigational New Drug application and Fast Track designation by the FDA for rhenium (186Re)
obisbemeda for the treatment of LM, we initiated the trial and began screening patients for the ReSPECT-LM Phase 1 clinical trial in Q4 2021.
The ReSPECT-LM is a multi-center, sequential cohort, open-label, dose escalation study evaluating the safety, tolerability, and efficacy of a
single-dose application of rhenium (186Re) obisbemeda administered through intrathecal infusion to the ventricle of patients with LM after standard
surgical, radiation, and/or chemotherapy treatment. The primary endpoint of the study is the incidence and severity of adverse events and dose limiting
toxicities.
On March 31, 2022, we entered into a Sales Order (the “Sales Order”) with Medidata Solutions, Inc. (“Medidata”), pursuant to which Medidata
built a Synthetic Control Arm® (SCA) platform that facilitates the use of historical clinical data to incorporate into our Phase 2 clinical trial of rhenium
(186Re) obisbemeda in GBM. The Sales Order had a term of six (6) months. Work under this Sales Order has been completed.
On September 19, 2022, we entered into a Cancer Research Grant Contract (the “CPRIT Contract”), effective as of August 31, 2022, with
CPRIT, pursuant to which CPRIT will provide us a grant of up to $17.6 million (the “CPRIT Grant”) over a three-year period to fund the continued
development of rhenium (186Re) obisbemeda for the treatment of patients with LM through Phase 2 of the ReSPECT LM clinical trial. The CPRIT Grant is
subject to customary CPRIT funding conditions, including, but not limited to, a matching fund requirement (one dollar from us for every two dollars
awarded by CPRIT), revenue sharing obligations upon
9
commercialization of rhenium (186Re) obisbemeda based on specific dollar thresholds until CPRIT receives the aggregate amount of 400% of the proceeds
awarded under the CPRIT Grant, and certain reporting requirements.
Interim results showed that treatment with rhenium (186Re) obisbemeda decreased CSF tumor cell count/ml and was well tolerated by all four
LM patients. rhenium (186Re) obisbemeda was administered through a standard intraventricular catheter (Ommaya Reservoir), redistributed throughout the
CSF, and was retained in the leptomeninges at least through day seven. All four patients have shown prompt and durable rhenium (186Re) obisbemeda
distribution throughout the subarachnoid space. A single dose of rhenium (186Re) obisbemeda at 6.6 millicurie ("mCi") in 5.0 mL, in Cohort 1, achieved
absorbed doses of 18.7 to 29.0 Gy to the ventricles and cranial subarachnoid spaces, respectively. Cohort 2 is in progress with a 13.2 mCi administered
dose in 5ml and was also well tolerated. All four patients experienced a decreased CSF cell count ranging from 46% to 92%. Three patients remain alive, as
the first patient in Cohort 1 has died, due to primary tumor progression. A single dose of rhenium (186Re) obisbemeda was well-tolerated with limited AEs
and no patients had definite treatment related AEs. Additionally, there were no AEs greater than Grade 1 that were even possibly related to treatment.
Cohort 2 was completed on January 26, 2023 and Cohort 3 is expected to enroll in late February/early March 2023 after a protocol defined follow-up 28-
day period. Besides continued dose escalation, repeated dosing will be explored.
ReSPECT-PBC Clinical Trial for Pediatric Brain Cancer
In August 2021, we announced plans for treating pediatric brain cancer at the 2021 American Association of Neurological Surgeons (AANS)
Annual Scientific Meeting. In July 2021, we reported that we had received FDA feedback pertaining to a pre-IND meeting briefing package in which the
FDA stated that we are not required to perform any additional preclinical or toxicology studies.
It is estimated that in 2022 there were approximately 25,050 new brain and other central nervous system cases diagnosed (1.3% of all cancers)
and 18,280 deaths (3.0% of all cancer related deaths). The average annual age adjusted mortality rate (“AAAMR”) for children aged 0-14 for malignant
brain (and other CNS) tumors is 0.71/100,000, making it the most common cause of death and cancer death in this age group. The 2021 World Health
Organization Classification of CNS Tumors (“WHO CNS5”) classifies gliomas, glioneuronal tumors, and neuronal tumors into six different families: (1)
adult-type diffuse gliomas; (2) pediatric-type diffuse low-grade gliomas; (3) pediatric-type diffuse high-grade gliomas (“HGG”); (4) circumscribed
astrocytic gliomas; (5) glioneuronal and neuronal tumors; and (6) ependymomas.
Since the initial FDA feedback and receiving important adult GBM data and experience with rhenium (186Re) obisbemeda and follow-up
communications with the FDA, we plan to submit a pediatric brain tumor IND to investigate the use of rhenium (186Re) obisbemeda in two pediatric brain
cancers in early 2023.
Pediatric high-grade gliomas can be found almost anywhere within the CNS; however, they are most commonly found within the supratentorium.
The highest incidence of supratentorial, high-grade gliomas in pediatrics appears to occur in children aged 15 to 19 years, with a median age of
approximately nine years. Overall, pediatric high grade glioma confers a three-year progression free survival (“PFS”) of 11 ± 3% and three-year overall
survival (“OS”) of 22% ±5%. One-year PFS is as low as 40% in recent trials. Ependymomas are slow-growing central nervous system tumors that involve
the ventricular system. Diagnosis is based on MRI and biopsy and survival rate depends on tumor grade and how much of the tumor can be removed.
Grade II pathology was associated with significantly improved OS compared to Grade III (anaplastic) pathology (five-year OS = 71 ± 5% vs. 57 ± 10%; p
= 0.026). Gross total resection compared to subtotal resection was associated with significantly improved OS (five-year OS = 75 ± 5% vs. 54 ± 8%; p =
0.002).
Overall, pediatric HGG and ependymoma are extremely difficult-to-treat pediatric brain tumors, frequently aggressive, and in recurrent settings,
carry an extremely poor prognosis.
Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere Technology
In January 2022, we announced that we licensed Biodegradable Alginate Microsphere (“BAM”) patents and technology from The University of
Texas Health Science Center at San Antonio (“UT Health Science Center at San Antonio”) to expand our tumor targeting capabilities and precision
radiotherapeutics pipeline. We intend to combine our Rhenium NanoLiposome technology with the BAM technology to create a novel radioembolization
technology. Initially, we intend to utilize the Rhenium-188 isotope, 188RNL-BAM for the intra-arterial embolization and local delivery of a high dose of
targeted radiation for a variety of solid organ cancers such as hepatocellular cancer, hepatic metastases, pancreatic cancer and many others.
Preclinical data from an ex vivo embolization experiment in which Technetium99m-BAM was intra-arterially delivered to a bovine kidney
perfusion model was presented at the recent 2021 Society of Interventional Radiology (“SIR”) Annual Scientific Meeting. The study concluded that the
technology required for radiolabeling BAM could successfully deliver, embolize and retain radiation in the target organ. 188RNL-BAM is a preclinical
investigational drug we intend to further develop and move into clinical trials. Specifically, in 2022 we transferred the 188RNL-BAM technology from UT
Health Science Center at San Antonio, and began planning to develop the drug product and complete early preclinical studies to support a future FDA IND
submission. Our intended initial clinical target is liver
10
cancer which is the sixth most common and third deadliest cancer worldwide. It is a rare disease with increasing U.S. annual incidence (42,000) and deaths
(30,000).
Licensing
On June 22, 2022, we announced a multi-year laboratory services agreement with Biocept, Inc. (“Biocept”) to employ their cerebrospinal fluid
(“CSF”) assay, CNSide, in Plus Therapeutics’ ReSPECT-LM Phase 1/2a dose-escalation trial of Rhenium-186 NanoLiposome for the treatment of patients
with (“LM”).
On December 31, 2021, we entered into a Patent and Technology License Agreement (the “UTHSA License Agreement”) with UT Health
Science Center at San Antonio, pursuant to which UT Heath Science Center at San Antonio granted us an irrevocable, perpetual, exclusive, fully paid-up
license, with the right to sublicense and to make, develop, commercialize and otherwise exploit certain patents, know-how and technology related to the
development of BAM containing nanoliposomes loaded with imaging and/or therapeutic payloads. Therapeutic payloads may include radiotherapeutics,
chemotherapeutics, or thermotherapeutics.
The BAM technology is delivered directly into the intra-arterial vascular system via commonly utilized and standard interventional vascular
catheters and techniques that allow precise placement into the arterial blood vessels feeding tumors. Once injected, BAM technology provides a dual
therapeutic delivery—blocking blood flow to the tumors by alginate microsphere tumor capillary embolization with simultaneous delivery of very high
doses of cytotoxic compounds including radiation, such as nanoliposome encapsulated bi-functionally chelated Re-188, for an extended time. Weeks later,
the delivered BAM are physiologically metabolized allowing excretion from the body. Rhenium-188 is an attraction and ideal therapeutic isotope for this
application because of it’s 16.9 hour half-life, 2.12MEV β-decay and ~3.8mm tissue path-length, and simultaneous 155Kev γ-decay that allow
simultaneous SPECT/CT imaging with commonly available imaging equipment to easily and non-invasively monitor product administration, delivery and
dosimetry absorbed dose evaluation.
We currently anticipate that we will initially focus on developing 188RNL-BAM as a next-generation radioembolization therapy for liver cancer,
in which BAM blocks the hepatic artery segments that supply blood to the malignant tumor while also providing 188RNL radiotherapy directly to the tumor
and surrounding tissue. According to the American Cancer Society, liver cancer is a rare disease with an increasing annual incidence and five-year overall
survival of only 20%. We estimate that the global opportunity for localized embolization, chemoembolization, and radioembolization therapies for primary
(hepatocellular carcinoma) and secondary (typically metastatic colorectal cancer, for example) liver cancer is $1.3 billion.
The financial terms of the exclusive license agreement are primarily success-based with milestone and royalty payments contingent on achieving
key clinical, regulatory and sales milestones.
The initial inventions and work behind the licensed patents and technologies were developed and led by William Phillips MD, Professor of
Nuclear Medicine, and team at UT Health Science Center at San Antonio. The 188RNL-BAM technology incorporates Rhenium-188, or 188Re, a unique
isotope for radiotherapeutic embolization owing to its emission of a high energy [2.12Mev] electron (beta particle, 16.9 hour half-life with a 3.8mm decay
path length. 188Re also emits 155kev gamma energy that permits high quality, real-time imaging of the BAM construct delivery localization and
confirmation. BAMs are not permanent and are anticipated to degrade over time, allowing restoration of blood flow, decreasing radiation resistance, and
allowing for safer physiological clearance of 188Re through the kidneys, which may minimize bone marrow toxicity.
The transaction terms include an upfront payment in cash. We are also required to pay development and sales milestone payments, if achieved,
and a tiered single-digit royalty on U.S. and European sales. In addition, we may be obligated to pay an annual maintenance fee beginning in 2024.
On March 29, 2020, we entered into a Patent and Know-How License Agreement (the “NanoTx License Agreement”) with NanoTx, pursuant to
which NanoTx granted us an irrevocable, perpetual, exclusive, fully paid-up license, with the right to sublicense and to make, develop, commercialize and
otherwise exploit certain patents, know-how and technology related to the development of radiolabeled nanoliposomes.
The transaction terms included an upfront payment of $0.4 million in cash and $0.3 million in our voting stock. The transaction terms also
included success-based milestone and royalty payments contingent on key clinical, regulatory and sales milestones, as well as the requirement to pay 15%
of any non-dilutive monetary awards or grants received from external agencies to support product development of the nanoliposome encapsulated
BMEDA-chelated radioisotope, which includes grants from the CPRIT.
The licensed NanoTx portfolio benefits from proprietary nanoliposome-encapsulated technology to encapsulate radionuclides allowing direct
local delivery for several cancer targets.
11
The licensed radiolabeled nanoliposome platform was developed by a multi-institutional consortium based in Texas at the Mays Cancer Center /
UT Health Science Center at San Antonio MD Anderson Cancer Center led by Dr. Andrew Brenner, MD, PhD, who is the Kolitz Chair in Neuro-Oncology
Research and Co-Leader of the Experimental and Developmental Therapeutics Program. The technology was previously owned by NanoTx and funded by
both the National Institutes of Health/National Cancer Institute ("NIH"/"NCI") and the Cancer Prevention and Research Institute of Texas ("CPRIT").
There is an active $3 million award from NIH/NCI which is expected to financially support the continued clinical development of rhenium (186Re)
obisbemeda for recurrent glioblastoma.
Manufacturing
We have a dedicated nanoparticle research & development facility located in San Antonio, Texas. The facility and processes are designed to
comply with current good manufacturing practices (“cGMP”) per FDA and EMA regulations for the manufacture of drug candidates for clinical trials,
research, and development. As described below, upon completion of the research and development phase of a drug candidate, certain parts of the
manufacturing processes for such candidate may be transferred to contract manufactures to support clinical trials and commercial release. Upon approval of
our drug candidates, we expect our manufacturing capabilities to include validated manufacturing processes for the drug product as well as a quality
assurance product release process with the ability to ultimately scale-up the process to meet increasing market demands. We believe our strategic
investments in our analytical, development and manufacturing capabilities, including personnel with expertise from drug discovery through drug
development, will allow us to advance our product candidates more quickly. Expertise gained in manufacturing our drug products may be applied to other
formulations in the future, further leveraging our capabilities. Our San Antonio facility is designed to enable us to develop drug substances, and drug
products, in a cost-effective manner while retaining control over the intellectual property, process and timing of development activities. The use of a
qualified Contract Drug Manufacturing Organization (“CDMO”) is entitled to be utilized to perform various manufacturing processes as we deem
appropriate to meet our operational objectives. In addition, we have entered into master services agreements (“MSAs”) with third parties, including
Piramal Pharma Solutions, Inc. (“Piramal”), ABX Advanced Biochemical Compounds GmbH, IsoTherapeutics Group, LLC, and Radiomedix, Inc. in
connection with the development, manufacture, and supply of our rhenium (186Re) obisbemeda drug product.
Competition
We will compete primarily on the basis of the safety and efficacy of our therapies across a broad range of clinical indications to address
significant unmet medical and market needs, supported by our brand name, pricing, products, published clinical data, regulatory approvals, and
reimbursement. We believe that our continued success depends on our ability to:
•
•
•
•
•
•
•
•
•
develop and innovate our product and technology platforms;
initiate new and advance existing clinical development programs;
secure and maintain regulatory agency approvals;
build and expand our commercial footprint;
produce high quality products per our specifications and in line with customer expectations;
achieve improved economies of scale;
generate and protect intellectual property;
hire and retain key talent; and
successfully execute acquisition, licensing, and partnership activities.
Competition for rhenium (186Re) obisbemeda may come from a single or combination therapy in the future.
Recurrent Glioblastoma
EnGeneIC, Berg, Istari, AstraZeneca, Novartis, PharmAbcine, Kairos, Midatech, Oncovir, Infuseon, Astellas, NanoPharmaceuticals, Erasca,
OX2, Crimson BioPharm, TMUNITY, Pfizer, Arcus, Photolitec, Samus, DNAtrix, ImmVira, BerGenBio, Boston Scientific, BeiGene, GSK, Bristol Myers
Squibb, Lilly, Sumitomo, QED, Chimerix, Accenda, Oblato, VBI, INIGHTEC, Sonalasense, VBL, Medicenna, Mimiva, Carthera, Gilead, CNS
Pharmaceuticals, VAXIMM, Incyte, Celularity, Medicinova, Karyopharm, Nerviano Medical Sciences, Merck, Telix, Neonc, Nuvation Bio, Aadi, ERC,
Kazia, Xoft, Basilea, Vigo, Biohaven, Bayer, Kintara, and others have reported drug development programs at various clinical stages for recurrent GBM.
Leptomeningeal Metastases
Angiochem, Y-mAbs, Roche, Bristol Myers Squibb, Merck, Kazia, AstraZeneca, Pfizer, Memorial Sloan Kettering, University of Virginia, Wake
Forest University, University of Alabama Birmingham, and others have reported drug development programs at various clinical stages for LM.
12
Pediatric Brain Cancer
AstraZeneca, Bristol Myers Squibb, Chimerix, Celgene, Eli Lilly, Nektar Therapeutics, Istari Oncology, Novartis, NovoCure, Takeda, Y-mAbs,
Cellectar, and others have reported drug development programs at various clinical stages for PBC.
Competition for 188RNL-BAM may come from a single or combination therapy in the future.
Liver Cancer
Boston Scientific, SIR-TEX, Terumo, ABK Biomedical, and others have reported radioembolization therapy product development programs for
liver cancer.
Intellectual Property
Our success depends in large part on our ability to protect our proprietary technology, and to operate without infringing on the proprietary rights
of third parties. We rely on a combination of patent, trade secret, copyright and trademark laws, as well as confidentiality agreements, licensing agreements
and other agreements, to establish and protect our proprietary rights. Our success also depends, in part, on our ability to avoid infringing patents issued to
others.
We license the proprietary formulation and proprietary methods of manufacture of the nanoliposome-encapsulated radionucleotides. rhenium
(186Re) obisbemeda and 188RNL are covered by U.S. Patent No. 7,718,160, (the “‘160 Patent”) which will expire in December 2026. Patent term
extension, codified in 35 U.S.C. §156, provides a means of recapturing time lost during the regulatory approval process. Based upon this regulation, we
will apply for patent term extension for the ‘160 Patent for the time equal to the regulatory review period for rhenium (186Re) obisbemeda. This has the
potential to extend patent coverage for this product for up to another five years. The ‘160 Patent covers rhenium (186Re) obisbemeda and 188RNL and their
method of manufacture. The patent family also contains granted patents in Canada (Patent No. 2,490,959), Europe (Patent No. EP1536843), and Australia
(Patent No. 2003241598), which are expected to expire in May 2023.
188RNL is also covered by U.S. Patent Appl. No. 17/611,929 titled Radiotherapeutic Microspheres, to which we have a license. This application
is directed to a method of producing liposome containing alginate microspheres. This application was filed on November 17, 2021, and any patent granted
from or claiming priority to it is expected to expire in May 2040, not including any patent term adjustment or patent term extension. The patent family also
contains applications in Canada, Israel, India, Japan, Mexico, Saudi Arabia, Thailand, South Africa, Vietnam, Philippines, China, European Patent Office,
Brazil, Singapore, Indonesia, Malaysia, Australia, and New Zealand.
188RNL is also covered by PCT/US2022/018992 titled Loading Alginate Microspheres, to which we have a license. This application is directed
to a method for post-manufacture loading of a liposome-containing hydrogel microsphere. This application was filed March 4, 2022, and any patent
granted from or claiming priority to it is expected to expire in March 2042.
We co-own and license PCT Application No. PCT/US2021/059969 and U.S. Patent Appl. No. 17/746,853, titled Radiolabeled Liposomes and
Methods of Use Thereof, which are directed to methods of treating cancer comprising administering 186Re and 188Re nanoliposomes via CED. These
applications were filed on November 18, 2021 and May 17, 2022, respectively, and any patents issued from or claiming priority to them are expected to
expire in November 2041, not including any patent term adjustment or patent term extension.
We co-own and license PCT Application No. PCT/US2023/11564, titled Radiolabeled Liposomes and Methods of Use for Treating
Leptomeningeal Metastases, which is directed to methods of treating Leptomeningeal Metastases comprising administering 186Re and/or 188Re
nanoliposomes via an intraventricular reservoir. This application was filed on January 25, 2023, and any patent issued claiming priority to it is expected to
expire in January 2043, not including any patent term adjustment or patent term extension.
Government Regulation and Product Approval
Government authorities in the United States, at the federal, state and local level, and in other countries and jurisdictions, including the European
Union, extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, packaging, storage,
recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting, and import and export of pharmaceutical
products. The processes for obtaining regulatory approvals in the United States and in foreign countries and jurisdictions, along with compliance with
applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources. Our nanoparticle
oncology drug candidates must receive regulatory approvals from the EMA and the FDA and from other government authorities prior to sale of the product
candidates in their respective jurisdictions.
13
FDA Approval Process
In the United States, pharmaceutical products are subject to extensive regulation by the FDA. Manufactures of pharmaceutical products may also
be subject to state and local regulation. The Federal Food, Drug, and Cosmetic Act, or the FDC Act, and other federal and state statutes and regulations,
govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing,
distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products. Failure to comply with applicable U.S.
requirements may subject a company to a variety of administrative or judicial sanctions, such as the imposition by the FDA or an institutional review
board, or IRB, of a clinical hold, FDA refusal to approve pending new drug applications, or NDAs, or supplements, withdrawal of approval, warning or
untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties, and criminal
investigation, penalties, or prosecution.
Product development for a new product or certain changes to an approved product in the United States typically involves:
•
•
•
•
•
•
•
•
Completion of preclinical laboratory studies, formulation studies, and animal studies, some in compliance with the FDA’s Good
Laboratory Practices, or GLP, regulations, and the Animal Welfare Act administered and enforced by the United States Department of
Agriculture;
Submission to the FDA of an investigational new drug application, or IND, to support human clinical testing, which must become
effective before clinical testing may commence;
Approval by an IRB before each trial may be initiated at each clinical site;
Performance of adequate and well-controlled clinical trials under protocols submitted to the FDA and reviewed and approved by each
IRB, conducted in accordance with federal regulations and current Good Clinical Practices, or GCP, to establish the safety and
effectiveness of the drug for each indication for which FDA approval is sought;
Submission of an NDA to the FDA;
Satisfactory completion of an FDA Advisory Committee review, if applicable;
Satisfactory completion of an FDA inspection of the manufacturing facilities at which the product candidate is produced to assess
compliance with current good manufacturing practices, or cGMP, and to assure that the facilities, methods and controls are adequate;
and
FDA review and approval of the NDA.
Satisfaction of FDA pre-market approval requirements typically takes many years and the actual time required may vary substantially based
upon the type, complexity, and novelty of the product or disease.
Preclinical tests include laboratory evaluation of product chemistry, formulation, and toxicity, as well as animal trials to assess the characteristics
and potential safety and efficacy of the product candidate. The conduct of some preclinical tests must comply with federal regulations and requirements,
including as applicable, GLP and the Animal Welfare Act. The results of preclinical testing are submitted to the FDA as part of an IND along with other
information, including information about product chemistry, manufacturing and controls, and a proposed clinical trial protocol. Additional preclinical tests,
such as animal tests of reproductive toxicity and carcinogenicity, may continue after the IND is submitted. A 30-day waiting period after the submission of
each IND is required prior to the commencement of clinical testing in humans. If the FDA has neither commented on nor questioned the IND within this
30-day period, the clinical trial proposed in the IND may begin.
Clinical trials involve the administration of the investigational drug product to healthy volunteers or patients under the supervision of a qualified
investigator. Clinical trials must be conducted: (i) in compliance with federal regulations; (ii) in compliance with GCP, an international standard meant to
protect the rights and health of patients and to define the roles of clinical trial sponsors, administrators, and monitors; as well as (iii) under protocols
detailing the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. Each protocol involving
testing on U.S. patients and subsequent protocol amendments must be submitted to the FDA as part of the IND. Foreign studies conducted under an IND
generally must meet the same requirements that apply to studies being conducted in the United States. The informed written consent of each study patient
must be obtained before the patient may begin participation in the clinical trial. The study protocol, study plan, and informed consent forms for each
clinical trial must be reviewed and approved by an IRB for each clinical site, and the study must be conducted under the auspices of an IRB for each trial
site. Investigators and IRBs must also comply with FDA regulations and guidelines, including those regarding oversight of study patient informed consent,
complying with the study protocol and investigational plan, adequately monitoring the clinical trial, and timely reporting of adverse events.
14
Clinical trials to support drug products for marketing approval are typically conducted in three sequential phases, but the phases may overlap.
Phase 1 involves the initial introduction of the drug product into healthy human subjects or patients. In Phase 1 trials, the product is tested to assess safety,
metabolism, pharmacokinetics, pharmacological actions, side effects associated with increasing doses, and, if possible, early evidence on effectiveness.
Phase 2 usually involves trials in a limited patient population to determine the effectiveness of the drug for a particular indication, dosage tolerance, and
optimal dosage, and to identify common adverse effects and safety risks. If a compound demonstrates evidence of effectiveness and an acceptable safety
profile in Phase 2 evaluations, Phase 3 trials are undertaken to obtain the additional information about clinical efficacy and safety in a larger number of
patients, typically at geographically dispersed clinical trial sites, to permit the FDA to evaluate the overall benefit-risk relationship of the drug and to
provide adequate information for the labeling of the product. In most cases, the FDA requires two adequate and well-controlled Phase 3 clinical trials to
demonstrate the efficacy of the drug product. A single Phase 3 trial with other confirmatory evidence may be sufficient in certain instances.
The decision to suspend or terminate development of a product candidate may be made by either a health authority body, such as the FDA, by an
IRB, or by a company for various reasons and during any phase of clinical trials. The FDA may order the temporary or permanent discontinuation of a
clinical trial at any time or impose other sanctions if it believes that the clinical trial either is not being conducted in accordance with FDA requirements or
presents an unacceptable risk to the clinical trial patients. In most cases, in addition to sponsor oversight clinical trials are also overseen by an independent
data safety monitoring board, or DSMB, which is a separate, independent group of qualified experts organized by the trial sponsor to evaluate at designated
points in time whether or not a trial may move forward and/or should be modified. These decisions are based on unblinded access to data from the ongoing
trial and generally involve determinations regarding the benefit-risk ratio for study patients and the scientific integrity and validity of the clinical trial.
In addition, the manufacturer of an investigational drug in a Phase 2 or Phase 3 clinical trial for a serious or life-threatening disease is required to
make available, such as by posting on its website, its policy on evaluating and responding to requests for expanded access to such investigational drug.
After completion of the required clinical testing, a drug product application is prepared and submitted to the FDA to request marketing approval
for the product candidate in specific indications. FDA approval of the drug product is required before marketing of the product may begin in the United
States. The drug product must include all relevant results of preclinical, clinical, and other testing and a compilation of data relating to the product
candidate’s pharmacology, chemistry, manufacture, and controls, including negative or ambiguous results as well as positive findings. To support marketing
approval, the data submitted must be sufficient in quality and quantity to establish the safety and effectiveness of the product candidate to the satisfaction of
the FDA. The cost of preparing and submitting a drug product application is substantial. Under the Prescription Drug User Fee Act, or PDUFA, the
submission of most drug product applications is subject to a substantial application user fee, and the applicant under an approved drug product is also
subject to an annual program fee for each prescription product, subject to certain limited deferrals, waivers and reductions that may be available. These fees
are typically increased annually. The FDA has 60 days from its receipt of an NDA to determine whether the application will be accepted for filing based on
the agency’s threshold determination that it is sufficiently complete to permit substantive review. The FDA may refuse to accept for filing any NDA that it
deems incomplete or not properly reviewable at the time of submission, in which case the NDA will have to be updated and resubmitted. Once the
submission is accepted for filing, the FDA begins an in-depth review. The FDA has agreed to certain performance goals in the review of NDAs. The FDA’s
PDUFA review goal is to review 90% of priority applications within six months of filing and 90% of standard applications within 10 months of filing.
Priority review may be granted to an application for a product candidate that the FDA determines has the potential to treat a serious or life-threatening
condition and, if approved, would be a significant improvement in safety or effectiveness compared to available therapies. The review process for both
standard and priority review may be extended by the FDA for three additional months to consider certain late-submitted information, or information
intended to clarify information already provided in the submission.
The FDA may also refer applications for drug candidates that present difficult questions of safety or efficacy, to an advisory committee—
typically a panel that includes clinicians and other experts—for review, evaluation, and a recommendation as to whether the application should be
approved. The FDA is not bound by the recommendation of an advisory committee, but it consider such recommendations carefully when making
decisions. Before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. Additionally, the FDA will
inspect the facility or the facilities at which the drug product is manufactured. The FDA will not approve the product unless compliance with cGMP is
satisfactory and the NDA contains data that provide substantial evidence that the drug candidate is safe and effective in the intended indication.
After the FDA evaluates the NDA and the manufacturing facilities, it issues either an approval letter or a complete response letter. A complete
response letter generally outlines the deficiencies in the submission and may require substantial additional testing, or information, in order for the FDA to
reconsider the application. If and when those deficiencies have been addressed to the FDA’s satisfaction in a resubmission of the NDA, the FDA may issue
an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information included.
Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory
criteria for approval and deny approval of a resubmitted NDA.
15
An approval letter authorizes commercial marketing of the drug candidate with specific prescribing information for specific indications. As a
condition of approval, the FDA may require a risk evaluation and mitigation strategy, or REMS, to help ensure that the benefits of the drug candidate
outweigh the potential risks. REMS can include medication guides, communication plans for healthcare professionals, and elements to assure safe use, or
ETASU. ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain
circumstances, special monitoring, and the use of patient registries. The requirement for a REMS can materially affect the potential market and profitability
of the product. Moreover, product approval may require substantial post-approval testing and surveillance to monitor the product’s safety or efficacy.
Once granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained or problems are identified
following initial marketing. For example, quality control and manufacturing procedures must conform, on an ongoing basis, to cGMP requirements, and the
FDA periodically inspects manufacturing facilities to assess compliance with cGMP. Accordingly, manufacturers must continue to spend time, money and
effort to maintain cGMP compliance. Changes to some of the conditions established in an approved application, including changes in indications, labeling,
or manufacturing processes or facilities, require submission and FDA approval of a new NDA or NDA supplement before the change can be implemented.
An NDA supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures
and actions in reviewing NDA supplements as it does in reviewing an NDA.
Expedited Programs
In the United States, a product may be granted Fast Track designation if it is intended for the treatment of a serious or life-threatening condition
and demonstrates the potential to address unmet medical needs for such condition. With Fast Track designation, the sponsor may be eligible for more
frequent opportunities to obtain the FDA’s feedback, and the FDA may initiate review of sections of an NDA before the application is complete. This
rolling review is available if the applicant provides and the FDA approves a schedule for the remaining information. Even if a product receives Fast Track
designation, the designation can be rescinded and provides no assurance that a product will be reviewed or approved more expeditiously than would
otherwise have been the case, or that the product will be approved at all.
The FDA may designate a product candidate as a breakthrough therapy if it finds that the product candidate is intended, alone or in combination
with one or more other product candidates or approved products, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence
indicates that the product candidate may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. For
product candidates designated as breakthrough therapies, more frequent interaction and communication between the FDA and the sponsor can help to
identify the most efficient path for clinical development. Product candidates designated as breakthrough therapies by the FDA may also be eligible for six
month priority review. The receipt of a breakthrough therapy designation for a product candidate may not result in a faster development process, review or
approval compared to product candidates considered for approval under conventional FDA procedures and, in any event, does not assure ultimate approval
by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the product
candidates no longer meet the conditions for designation.
Accelerated approval under FDA regulations allows a product designed to treat a serious or life-threatening disease or condition that
provides a meaningful therapeutic advantage over available therapies to be approved on the basis of either an intermediate clinical endpoint or a surrogate
endpoint that is reasonably likely to predict clinical benefit. Approvals of this kind typically include requirements for confirmatory clinical trials to be
conducted with due diligence to validate the surrogate endpoint or otherwise confirm clinical benefit and for all promotional materials to be submitted to
the FDA for review prior to dissemination.
The FDA may grant priority review to a product candidate, which sets the target date for FDA action on the application at six months from
FDA filing, or eight months from the sponsor’s submission. Priority Review may be granted where a product is intended to treat a serious or life-
threatening disease or condition and, if approved, has the potential to provide a safe and effective therapy where no satisfactory alternative therapy exists or
a significant improvement in safety or efficacy compared to available therapy. If criteria are not met for Priority Review, the standard FDA review period is
ten months from FDA filing or 12 months from sponsor submission. Priority Review designation does not change the scientific/medical standard for
approval or the quality of evidence necessary to support approval.
Orphan Drug Designation
Under the Orphan Drug Act, the FDA may grant orphan drug designation to drug candidate products intended to treat a rare disease or condition
that affects fewer than 200,000 individuals in the United States, or if it affects more than 200,000 individuals in the United States, there is no reasonable
expectation that the cost of developing and making a product available in the United States for such disease or condition will be recovered from sales of the
product in the United States.
After the FDA grants orphan drug designation, the generic identity of the drug product and its potential orphan use are disclosed publicly by the
FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. However, orphan
drug designation does entitle a party to financial incentives, such as opportunities for grant funding towards clinical trial costs, tax credits for certain
research and user fee waivers under certain circumstances. In addition, if a product
16
receives the first FDA approval for the indication for which it has orphan designation, the product is entitled to seven years of market exclusivity, which
means the FDA may not approve any other application for a biologic for the same indication for a period of seven years, except in limited circumstances,
such as a showing of clinical superiority over the product with orphan exclusivity. The FDA can revoke a product’s orphan drug exclusivity under certain
circumstances, including when the product sponsor is unable to assure the availability of sufficient quantities of the product to meet patient needs. Orphan
drug exclusivity does not prevent the FDA from approving a different drug for the same disease or condition, or the same biologic for a different disease or
condition.
Rare Pediatric Disease Priority Review Voucher Program
Under the Rare Pediatric Disease Priority Review Voucher program, the FDA may grant Rare Pediatric Disease designation for serious and life-
threatening diseases that primarily affect children aged 18 years or younger and fewer than 200,000 individuals in the United States. The FDA may award
a priority review voucher to the sponsor of an approved marketing application for a product that treats or prevents a Rare Pediatric Disease. The voucher
entitles the sponsor to priority review of one subsequent marketing application.
A voucher may be awarded only for an application that:
•
•
•
•
•
•
is a human drug application for the prevention or treatment of a Rare Pediatric Disease and does not contain an active ingredient
(including any ester or salt of the active ingredient) that has been previously approved in any other application;
FDA deems eligible for priority review;
is an original NDA or BLA;
relies on clinical data derived from studies examining a pediatric population and dosages of the drug intended for that population;
does not seek approval for an adult indication in the original rare pediatric disease product application; and
is approved after September 30, 2016.
Before NDA or IND approval, the FDA may designate a product in development as a product for a rare pediatric disease, but such designation is
not required to receive a voucher.
To receive a rare pediatric disease priority review voucher, a sponsor must notify the FDA, upon submission of the NDA or IND, of its intent to
request a voucher. If the FDA determines that the NDA or IND is a rare pediatric disease product application, and if the NDA or IND is approved, the FDA
will award the sponsor of the NDA or IND a voucher upon approval of the NDA or IND. The FDA may revoke a rare pediatric disease priority review
voucher if the product for which it was awarded is not marketed in the U.S. within 1 year of the product’s approval.
The voucher, which is transferable to another sponsor, may be submitted with a subsequent application and entitles the holder to priority review
of the application. The sponsor submitting the priority review voucher must notify the FDA of its intent to submit the voucher with the application at least
90 days prior to submission of the application and must pay a priority review user fee in addition to any other required user fee. The FDA must take action
on an application under priority review within six months of receipt of the application.
The Rare Pediatric Disease Priority Review Voucher program was renewed as part of the 2021 Coronavirus Response and Relief Supplemental
Appropriations Act, allowing a product that is designated as a product for a rare pediatric disease prior to September 30, 2024 to be eligible to receive a
rare pediatric disease priority review voucher upon approval of a qualifying NDA after September 30, 2024. After September 30, 2026, the FDA may not
award any rare pediatric disease priority review vouchers.
Disclosure of Clinical Trial Information
Sponsors of clinical trials of the FDA-regulated products are required to register and disclose certain clinical trial information. Information
related to the product, patient population, phase of investigation, trial sites and investigators, and other aspects of the clinical trial is then made public as
part of the registration. Sponsors are also obligated to discuss the results of their clinical trials after completion. Disclosure of the results of these trials can
be delayed in certain circumstances for up to two years after the date of completion of the trial. Competitors may use this publicly available information to
gain knowledge regarding the progress of development programs.
17
Pediatric Information
Under the Pediatric Research Equity Act, or PREA, certain NDAs must include an assessment, generally based on clinical trial data, of the safety
and effectiveness of the product candidate in relevant pediatric populations. The FDA may waive or defer the requirement for a pediatric assessment, either
at a company’s request or by its own initiative, including waivers for certain products not likely to be used in a substantial number of pediatric patients.
Products with orphan drug designation are exempt from these requirements for orphan-designated indications with no formal waiver process required. Any
original NDA submitted on or after August 18, 2020 for a new active ingredient must contain reports on molecularly targeted pediatric cancer
investigations, unless the requirement is waived or deferred, if the drug that is the subject of the application is intended for the treatment of an adult cancer
and is directed at a molecular target that the FDA has determined is substantially relevant to the growth or progression of a pediatric cancer. This
requirement applies even if the adult cancer indication does not occur in the pediatric population, and even if the drug is for an adult indication for which
orphan designation has been granted.
Under the Pediatric Research Equity Act, or PREA, certain NDAs must include an assessment, generally based on clinical trial data, of the safety
and effectiveness of the product candidate in relevant pediatric populations. The FDA may waive or defer the requirement for a pediatric assessment, either
at a company’s request or by its own initiative, including waivers for certain products not likely to be used in a substantial number of pediatric patients.
Products with orphan drug designation are exempt from these requirements for orphan-designated indications with no formal waiver process required. Any
original NDA submitted on or after August 18, 2020 for a new active ingredient must contain reports on molecularly targeted pediatric cancer
investigations, unless the requirement is waived or deferred, if the drug that is the subject of the application is intended for the treatment of an adult cancer
and is directed at a molecular target that the FDA has determined is substantially relevant to the growth or progression of a pediatric cancer. This
requirement applies even if the adult cancer indication does not occur in the pediatric population, and even if the drug is for an adult indication for which
orphan designation has been granted.
Patent Term Restoration
After approval, owners of relevant drug patents may apply for up to a five-year patent extension as compensation for patent term lost during
product development and the FDA regulatory review process. The allowable patent term extension is calculated as one half of the drug’s testing phase—the
time between the effective date of an IND and NDA submission—and all of the review phase—the time between NDA submission and approval, up to a
maximum of five years. The time can be shortened if the FDA determines that the applicant did not pursue approval with due diligence. The total patent
term after the extension may not exceed 14 years. Only one patent applicable to an approved product is eligible for the extension and the application for
the extension must be submitted prior to the expiration of the patent. The United States Patent and Trademark Office, or USPTO, in consultation with the
FDA, reviews and approves the application for any patent term extension or restoration.
For patents that might expire during the application phase, the patent owner may request an interim patent extension. An interim patent extension
increases the patent term by one year and may be renewed up to four times. For each interim patent extension granted, the post-approval patent extension is
reduced by one year. The director of the USPTO must determine that approval of the drug covered by the patent for which a patent extension is being
sought is likely. Interim patent extensions are not available for a drug for which an NDA has not been submitted.
Market Exclusivity
In the United States and elsewhere, certain regulatory exclusivities and patent rights can provide an approved drug product with protection from
certain competitors’ products for a period of time and within a certain scope. In the United States, those protections include regulatory exclusivity under
the Hatch-Waxman Act, which provides periods of exclusivity for a branded drug product that would serve as an RLD for a generic drug applicant filing an
ANDA under section 505(j) of the FD&C Act or as a listed drug for an applicant filing an NDA under section 505(b)(2) of the FD&C Act. If such a
product is a “new chemical entity” (“NCE”) generally meaning that the active moiety has never before been approved in any drug, there is a period of five
years from the product’s approval during which the FDA may not accept for filing any ANDA or 505(b)(2) application for a drug with the same active
moiety. An ANDA or 505(b)(2) application may be submitted after four years, however, if the sponsor of the application makes a Paragraph IV
certification (as described above). Such a product that is not an NCE may qualify for a three-year period of exclusivity if its NDA contains new clinical
data (other than bioavailability studies), derived from studies conducted by or for the sponsor, that were necessary for approval. In this instance, the three-
year exclusivity period does not preclude filing or review of an ANDA or 505(b)(2) application; rather, the FDA is precluded from granting final approval
to the ANDA or 505(b)(2) application until three years after approval of the RLD. This three-year exclusivity applies only to the conditions of approval that
required submission of the clinical data.
Post-Approval Regulation
Once approved, drug products are subject to continuing extensive regulation by the FDA. If ongoing regulatory requirements are not met, or if
safety problems occur after a product reaches market, the FDA may take actions to change the conditions under which
18
the product is marketed, such as requiring labeling modifications, restricting distribution, or even withdrawing approval. In addition to FDA regulation, our
business is also subject to extensive federal, state, local and foreign regulation.
Good Manufacturing Practices. Companies engaged in manufacturing drug products or their components must comply with applicable cGMP
requirements, which include requirements regarding organization and training of personnel, building and facilities, equipment, control of components and
drug product containers, closures, production and process controls, packaging and labeling controls, holding and distribution, laboratory controls and
records and reports. The FDA inspects equipment, facilities and manufacturing processes before approval and conducts periodic re-inspections after
approval. If, after receiving approval, a company makes a material change in manufacturing equipment, location, or process (all of which are, to some
degree, incorporated in the NDA), additional regulatory review and approval may be required. Failure to comply with applicable cGMP requirements or the
conditions of the product’s approval may lead the FDA to take enforcement actions, such as issuing a warning letter, or to seek sanctions, including fines,
civil penalties, injunctions, suspension of manufacturing operations, imposition of operating restrictions, withdrawal of FDA approval, seizure or recall of
products, and criminal prosecution. Although we periodically monitor FDA compliance of the third parties on which we rely for manufacturing our
product candidates, we cannot be certain that our present or future third-party manufacturers will consistently comply with cGMP or other applicable FDA
regulatory requirements.
Sales and Marketing. Once a product is approved, the advertising, promotion and marketing of the product will be subject to close regulation,
including with regard to promotion to healthcare practitioners, direct-to-consumer advertising, communications regarding unapproved uses, industry-
sponsored scientific and educational activities and promotional activities involving the internet. In addition to FDA restrictions on marketing of
pharmaceutical products, state and federal fraud and abuse laws have been applied to restrict certain marketing practices in the pharmaceutical industry.
Failure to comply with applicable requirements in this area may subject a company to adverse publicity, investigations and enforcement action by the FDA,
the Department of Justice, the Office of the Inspector General of the Department of Health and Human Services, and/or state authorities. This could
subject a company to a range of penalties that could have a significant commercial impact, including civil and criminal fines and agreements that materially
restrict the manner in which a company promotes or distributes drug products.
Other Requirements. Companies that manufacture or distribute drug products pursuant to approved NDAs must meet numerous other regulatory
requirements, including adverse event reporting, submission of periodic reports, and record-keeping obligations.
Other U.S. Healthcare Laws and Compliance Requirements
In the United States, our activities are potentially subject to regulation by various federal, state and local authorities in addition to the FDA,
including but not limited to, the Centers for Medicare and Medicaid Services, or CMS, other divisions of the U.S. Department of Health and Human
Services (e.g., the Office of Inspector General), the U.S. Department of Justice, or DOJ, and individual U.S. Attorney offices within the DOJ, and state and
local governments. For example, sales, marketing and scientific/educational grant programs must comply with the anti-fraud and abuse provisions of the
Social Security Act, the false claims laws, the privacy provisions of the Health Insurance Portability and Accountability Act, or HIPAA, and similar state
laws, each as amended.
The federal Anti-Kickback Statute prohibits, among other things, any person or entity, from knowingly and willfully offering, paying, soliciting
or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for purchasing, leasing, ordering or
arranging for the purchase, lease or order of any item or service reimbursable under Medicare, Medicaid or other federal healthcare programs. The term
remuneration has been interpreted broadly to include anything of value. The Anti-Kickback Statute has been interpreted to apply to arrangements between
pharmaceutical manufacturers on one hand and prescribers, purchasers, and formulary managers on the other. There are a number of statutory exceptions
and regulatory safe harbors protecting some common activities from prosecution. The exceptions and safe harbors are drawn narrowly and practices that
involve remuneration that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not
qualify for an exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does
not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis
based on a cumulative review of all of its facts and circumstances. Our practices may not in all cases meet all of the criteria for protection under a statutory
exception or regulatory safe harbor.
Additionally, the intent standard under the Anti-Kickback Statute was amended by the Affordable Care Act, or ACA, to a stricter standard such
that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In
addition, the ACA codified case law that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a
false or fraudulent claim for purposes of the federal False Claims Act (discussed below).
19
The civil monetary penalties statute imposes penalties against any person or entity who, among other things, is determined to have presented or
caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed
or is false or fraudulent.
The federal False Claims Act prohibits, among other things, any person or entity from knowingly presenting, or causing to be presented, a false
claim for payment to, or approval by, the federal government or knowingly making, using, or causing to be made or used a false record or statement
material to a false or fraudulent claim to the federal government. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a
claim includes “any request or demand” for money or property presented to the U.S. government. Recently, several pharmaceutical and other healthcare
companies have been prosecuted under these laws for allegedly providing free product to customers with the expectation that the customers would bill
federal programs for the product. Other companies have been prosecuted for causing false claims to be submitted because of the companies’ marketing of
the product for unapproved, and thus generally non-reimbursable, uses.
HIPAA created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud or to
obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of, any
healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up by trick, scheme or
device, a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare
benefits, items or services.
Also, many states have similar fraud and abuse statutes or regulations that apply to items and services reimbursed under Medicaid and other state
programs, or, in several states, apply regardless of the payor. We may be subject to data privacy and security regulations by both the federal government
and the states in which we conduct our business. HIPAA, and its implementing regulations, imposes requirements relating to the privacy, security and
transmission of individually identifiable health information. In addition, state laws govern the privacy and security of health information in specified
circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.
Additionally, the federal Physician Payments Sunshine Act within the ACA, and its implementing regulations, require that certain manufacturers
of drugs, devices, biological and medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program
(with certain exceptions) to report information related to certain payments or other transfers of value made or distributed to physicians and teaching
hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians and teaching hospitals and to report annually certain
ownership and investment interests held by physicians and their immediate family members. The reported data are posted in searchable form on a public
website on an annual basis. Failure to submit required information may result in civil monetary penalties. Effective January 1, 2022, we are required to
report on transfers of value to physician assistants, nurse practitioners or clinical nurse specialists, certified registered nurse anesthetists, and certified
nurse-midwives.
In order to distribute products commercially, we must comply with state laws that require the registration of manufacturers and wholesale
distributors of drug and biological products in a state, including, in certain states, manufacturers and distributors who ship products into the state even if
such manufacturers or distributors have no place of business within the state. Some states also impose requirements on manufacturers and distributors to
establish the pedigree of product in the chain of distribution, including some states that require manufacturers and others to adopt new technology capable
of tracking and tracing product as it moves through the distribution chain. Several states have enacted legislation requiring pharmaceutical and
biotechnology companies to establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on sales,
marketing, pricing, clinical trials and other activities, and/or register their sales representatives, as well as to prohibit pharmacies and other healthcare
entities from providing certain physician prescribing data to pharmaceutical and biotechnology companies for use in sales and marketing, and to prohibit
certain other sales and marketing practices. All of our activities are potentially subject to federal and state consumer protection and unfair competition laws.
If our operations are found to be in violation of any of the federal and state healthcare laws described above or any other governmental
regulations that apply to us, we may be subject to penalties, including without limitation, civil, criminal and/or administrative penalties, damages, fines,
disgorgement, exclusion from participation in government programs, such as Medicare and Medicaid, injunctions, private “qui tam” actions brought by
individual whistleblowers in the name of the government, or refusal to allow us to enter into government contracts, contractual damages, reputational harm,
administrative burdens, diminished profits and future earnings, and the curtailment or restructuring of our operations, any of which could adversely affect
our ability to operate our business and our results of operations.
Coverage, Pricing and Reimbursement
Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval. In
the United States and markets in other countries, sales of any products for which we receive regulatory approval
20
for commercial sale will depend, in part, on the extent to which third-party payors provide coverage, and establish adequate reimbursement levels for such
products. In the United States, third-party payors include federal and state healthcare programs, private managed care providers, health insurers and other
organizations. The process for determining whether a third-party payor will provide coverage for a product may be separate from the process for setting the
price of a product or for establishing the reimbursement rate that such a payor will pay for the product. Third-party payors may limit coverage to specific
products on an approved list, also known as a formulary, which might not include all of the FDA-approved products for a particular indication. Third-party
payors are increasingly challenging the price, examining the medical necessity and reviewing the cost-effectiveness of medical products, therapies and
services, in addition to questioning their safety and efficacy. We may need to conduct expensive pharmaco-economic studies in order to demonstrate the
medical necessity and cost-effectiveness of our product candidates, in addition to the costs required to obtain the FDA approvals. Our product candidates
may not be considered medically necessary or cost-effective. A payor’s decision to provide coverage for a product does not imply that an adequate
reimbursement rate will be approved. Further, one payor’s determination to provide coverage for a product does not assure that other payors will also
provide coverage for the product. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an
appropriate return on our investment in product development.
Different pricing and reimbursement schemes exist in other countries. In the EU, governments influence the price of pharmaceutical products
through their pricing and reimbursement rules and control of national health care systems that fund a large part of the cost of those products to consumers.
Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed. To
obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost-effectiveness of a
particular product candidate to currently available therapies. Other member states allow companies to fix their own prices for medicines, but monitor and
control company profits. The downward pressure on health care costs has become very intense. As a result, increasingly high barriers are being erected to
the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a
country.
The marketability of any product candidates for which we receive regulatory approval for commercial sale may suffer if the government and
third-party payors fail to provide adequate coverage and reimbursement. In addition, emphasis on managed care in the United States has increased and we
expect will continue to increase the pressure on healthcare pricing. Coverage policies and third-party reimbursement rates may change at any time. Even if
favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage
policies and reimbursement rates may be implemented in the future.
Healthcare Reform
The ACA has substantially changed some aspects of healthcare financing and delivery by both governmental and private insurers. The ACA has
affected existing government healthcare programs and resulted in the development of new programs.
Among the ACA provisions of importance to the pharmaceutical and biotechnology industries, in addition to those otherwise described above,
are the following:
•
•
•
•
•
•
an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents
apportioned among these entities according to their market share in some government healthcare programs, that began in 2011;
an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program, retroactive to January 1,
2010, to 23.1% and 13% of the average manufacturer price for most branded and generic drugs, respectively and capped the total rebate
amount for innovator drugs at 100% of the Average Manufacturer Price, or AMP (which cap is now set to be removed effective January 1,
2024, which could increase our rebate liability particularly as we could be subject to an additional rebate in the amount that our AMP has
exceeded the pace of inflation, if any);
a Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 70% point-of-sale discounts off negotiated
prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturers’ outpatient
drugs to be covered under Medicare Part D;
extension of manufacturers’ Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care
organizations;
expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional
individuals beginning in 2014 and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal
poverty level, thereby potentially increasing manufacturers’ Medicaid rebate liability;
expansion of the entities eligible for discounts under the 340B drug discount program; and
21
•
a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research,
along with funding for such research.
The Tax Cuts and Jobs Act was signed into law in December 2017, which eliminated certain requirements of the ACA, including the individual
mandate. We cannot predict whether these challenges will continue or whether other proposals will be made or adopted, or what impact these efforts may
have on us. It is possible that the ACA, as currently enacted or may be amended in the future, as well as other healthcare reform measures that may be
adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, and new payment
methodologies and in additional downward pressure on coverage and payment and the price that we receive for any approved product. Any reduction in
reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of
cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our
products. We cannot be sure whether additional legislative changes will be enacted in the United States or outside of the United States, or whether
regulatory changes, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates,
if any, may be.
Other legislative changes relating to reimbursement have been adopted in the U.S. since the ACA was enacted. For example, on August 2, 2011,
the Budget Control Act of 2011, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals for
spending reductions. The Joint Select Committee did not achieve a targeted deficit reduction, which triggered the legislation’s automatic reductions. In
concert with subsequent legislation, this has resulted in aggregate reductions to Medicare payments to providers of, on average, 2% per fiscal year through
2030 (with the exception of a temporary suspension from May 1, 2020 through March 31, 2022 due to the COVID-19 pandemic). The law provides for 1%
Medicare sequestration in the second quarter of 2022 and allows the full 2% sequestration thereafter until 2030. To offset the temporary suspension during
the COVID-19 pandemic, in 2030, the sequestration will be 2.25% for the first half of the year, and 3% in the second half of the year. As long as these cuts
remain in effect, they could adversely impact payment for any products we may commercialize in the future. We expect that additional federal healthcare
reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and
services, and in turn could significantly reduce the projected value of certain development projects and reduce our profitability.
Additional legislative changes, regulatory changes, or guidance could be adopted, which may impact the marketing approvals and reimbursement
for our product candidates. For example, there has been increasing legislative, regulatory, and enforcement interest in the United States with respect to drug
pricing practices. There have been several Congressional inquiries and proposed and enacted federal and state legislation and regulatory initiatives designed
to, among other things, bring more transparency to product pricing, evaluate the relationship between pricing and manufacturer patient programs, and
reform government healthcare program reimbursement methodologies for drug products. If healthcare policies or reforms intended to curb healthcare costs
are adopted or if we experience negative publicity with respect to pricing of our products or the pricing of pharmaceutical drugs generally, the prices that
we charge for any approved products may be limited, our commercial opportunity may be limited and/or our revenues from sales of our products may be
negatively impacted. CMS issued a final regulation, which became effective on April 1, 2016, to implement the changes to the Medicaid Drug Rebate
Program under the ACA. On December 31, 2020, CMS issued a final regulation that modified prior Medicaid Drug Rebate program regulations to permit
reporting multiple best price figures with regard to value‑based purchasing arrangements (beginning in 2022); provide definitions for “line extension,”
“new formulation,” and related terms, with the practical effect of expanding the scope of drugs considered to be line extensions that are subject to an
alternative rebate formula (beginning in 2022); and revise best price and average manufacturer price exclusions of manufacturer-sponsored patient benefit
programs, specifically regarding applicability of such exclusions in the context of pharmacy benefit manager “accumulator” programs (beginning in 2023).
Federal law also requires that a company that participates in the Medicaid Drug Rebate Program report average sales price information each
quarter to CMS for certain categories of drugs that are paid under the Medicare Part B program. For calendar quarters beginning January 1, 2022,
manufacturers are required to report the average sales price for certain drugs under the Medicare program regardless of whether they participate in the
Medicaid Drug Rebate Program. Manufacturers calculate average sales price based on a statutorily defined formula as well as regulations and
interpretations of the statute by CMS. CMS uses these submissions to determine payment rates for drugs under Medicare Part B. Starting in 2023,
manufacturers must pay refunds to Medicare for single source drugs or biologicals, or biosimilar biological products, reimbursed under Medicare Part B
and packaged in single-dose containers or single-use packages, for units of discarded drug reimbursed by Medicare Part B in excess of 10 percent of total
allowed charges under Medicare Part B for that drug. Manufacturers that fail to pay refunds could be subject to civil monetary penalties of 125 percent of
the refund amount.
Statutory or regulatory changes or CMS guidance could affect the pricing calculations for our approved products, and could negatively impact
our results of operations. For example, Congress could enact a Medicare Part B inflation rebate, under which manufacturers would owe additional rebates if
the average sales price of a drug were to increase faster than the pace of inflation. In addition, Congress could enact a drug price negotiation program under
which the prices for certain high Medicare spend single source
22
drugs would be capped by reference to the non-federal average manufacturer price. This or any other legislative change could impact the market conditions
for our products. We further expect continued scrutiny on government price reporting and pricing more generally from Congress, agencies, and other
bodies.
The Foreign Corrupt Practices Act
The Foreign Corrupt Practices Act, or FCPA, prohibits any U.S. individual or business from paying, offering, or authorizing payment or offering
of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the
foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed
in the United States to comply with accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all
transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for
international operations.
Additional Regulation
In addition to the foregoing, state and federal laws regarding environmental protection and hazardous substances, including the Occupational
Safety and Health Act, the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, affect our business. These and other laws
govern our use, handling and disposal of various biological, chemical and radioactive substances used in, and wastes generated by, our operations. If our
operations result in contamination of the environment or expose individuals to hazardous substances, we could be liable for damages and governmental
fines. We believe that we are in material compliance with applicable environmental laws and that continued compliance therewith will not have a material
adverse effect on our business. We cannot predict, however, how changes in these laws may affect our future operations.
Europe / Rest of World Government Regulation
In addition to regulations in the United States, we will be subject to a variety of regulations in other jurisdictions governing, among other things,
clinical trials and any commercial sales and distribution of our product candidates. Whether or not we obtain FDA approval of a product, we must obtain
the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those
countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application much like the IND
prior to the commencement of human clinical trials. In the EU, for example, a clinical trial application must be submitted to each country’s national health
authority and an independent ethics committee, much like the FDA and IRB, respectively. Once the clinical trial application is approved in accordance with
a country’s requirements, clinical trial development may proceed.
The requirements and process governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to
country. In all cases, the clinical trials are conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that
have their origin in the Declaration of Helsinki.
To obtain regulatory approval of an investigational drug product under EU regulatory systems, we must submit a marketing authorization
application. The application used to file the drug product in the United States is similar to that required in the EU, with the exception of, among other
things, country-specific document requirements.
For other countries outside of the EU, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of
clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical trials are conducted in accordance
with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.
If we or our potential collaborators fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things,
fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.
Employees and Human Capital
As of December 31, 2022, we had 17 full-time employees. Of these full-time employees, ten were engaged in research and development, and
seven were engaged in management, finance and administration. From time to time, we also employ independent contractors to support our operations. Our
employees are not represented by any collective bargaining agreements and we have never experienced an organized work stoppage.
23
We believe that we must offer and maintain market competitive compensation and benefit programs for our employees in order to attract and
retain qualified personnel. In addition to cash compensation, we provide equity compensation, a company-matched 401(k) Plan, healthcare and insurance
benefits, health savings and flexible spending accounts, paid time off, family leave, and employee assistance programs.
Corporate Information
We were initially formed as a California general partnership in July 1996 and incorporated in the State of Delaware in May 1997. We were
formerly known as Cytori Therapeutics, Inc., before that as MacroPore Biosurgery, Inc. and before that as MacroPore, Inc. On July 20, 2019, we changed
our name from Cytori Therapeutics, Inc. to Plus Therapeutics, Inc. Our corporate offices are located at 4200 Marathon Blvd., Suite 200, Austin, TX. Our
telephone number is (737) 255-7194. We maintain a website at www.plustherapeutics.com.
Item 1A. Risk Factors
The risk factors described below, as well as statements described elsewhere in this Annual Report on Form 10-K, including our audited Financial
Statements and the related notes and “Management’s Discussion and Analysis of Financial Conditions and Results of Operations”, or in other SEC filings,
describe risks that could materially and adversely affect our business, financial condition, and results of operations, which could also cause the trading
price of our equity securities to decline. These risks are not the only risks that we face. Our business, financial condition and results of operations could
also be affected by additional factors that are not presently known to us or that we currently consider to be immaterial to our operations.
Risks Related to our Financial Position and Capital Requirements
We have incurred losses since inception, we expect to incur significant net losses in the foreseeable future and we may never become profitable and our
operating results have been and will likely continue to be volatile.
We generated negative cash flows from operations and have incurred net operating losses each year since we started business. For the year ended
December 31, 2022, we incurred net losses of $20.3 million and our net cash used in operating activities was $13.0 million. As of December 31, 2022, our
accumulated deficit was $467.2 million. We expect to continue to incur net losses and negative cash flow from operating activities for at least the next
twelve months. As our focus on development of nanomedicine and the development of therapeutic applications has increased, losses have resulted
primarily from expenses associated with research and development and clinical trial-related activities, as well as general and administrative expenses.
While we have implemented and continue to implement cost reduction measures where possible, we nonetheless expect to continue operating in a loss
position and expect that recurring operating expenses will be at higher levels for the year ended December 31, 2022 as we perform clinical trial and other
development activities for our nanomedicine product candidates.
Our ability to generate sufficient revenue from any of our products, product candidates or technologies to achieve profitability will depend on a
number of factors including, but not limited to:
•
•
•
•
•
•
our ability to manufacture, test and validate our product candidates in compliance with applicable laws and as required for submission to
applicable regulatory bodies, including manufacturing, testing and validation of our RNL candidates;
our or our partners’ ability to successfully complete clinical trials of our product candidates;
our ability to obtain necessary regulatory approvals for our product candidates;
our or our partners’ ability to negotiate and receive favorable reimbursement for our product candidates, including for our product
candidates that have been granted or may be granted orphan drug status or otherwise command currently anticipated pricing levels;
our ability to negotiate favorable arrangements with third parties to help finance the development of, and market and distribute, our
products and product candidates; and
the degree to which our approved products are accepted in the marketplace.
Because of the numerous risks and uncertainties associated with our commercialization and product development efforts, we are unable to
predict the extent of our future losses or when or if we will become profitable and it is possible we will never become profitable. If we do not generate
significant sales from any of our product candidates that receive regulatory approval, there would be a material adverse effect on our business, results of
operations, financial condition and prospects, which in turn could result in our inability to continue operations.
Our prospects must be evaluated in light of the risks and difficulties frequently encountered by emerging companies and particularly by such
companies in rapidly evolving and technologically advanced biotech, pharmaceutical and medical device fields. In
24
addition, our budgeted expense levels are based in part on our expectations concerning future research and development activities. We may be unable to
reduce our expenditures in a timely manner to compensate for any unexpected events. Accordingly, unexpected events could have an immediate and
material impact on our business and financial condition. From time to time, we have tried to update our investors’ expectations as to our operating results.
If we revise any timelines we may give with respect to our clinical trials, it could materially harm our reputation and the market’s perception of us and
could cause our stock price to decline.
We could be delisted from Nasdaq, which would seriously harm the liquidity of our stock and our ability to raise capital.
Nasdaq requires listing issuers to comply with certain standards in order to remain listed on its exchange. If, for any reason, Nasdaq should delist
our securities from trading on its exchange and we are unable to obtain listing on another reputable national securities exchange, a reduction in some or all
of the following may occur, each of which could materially adversely affect our stockholders.
On May 24, 2022, we received written notice (the “Notification Letter”) from the Listings Qualifications Department of The Nasdaq Stock
Market LLC (“Nasdaq”) that because the closing bid price for our common stock has fallen below $1.00 per share for 30 consecutive business days, we no
longer complied with the minimum bid price requirement pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Requirement”). Nasdaq’s notice
had no immediate effect on the listing or trading of our common stock. The Notification Letter stated that we had 180 days, or until November 21, 2022, to
demonstrate our compliance with the Minimum Bid Requirement. On November 22, 2022, we received a second letter from Nasdaq advising that we had
been granted an additional 180 calendar days, or to May 22, 2023, to regain compliance with the Minimum Bid Requirement, in accordance with Nasdaq
Listing Rule 5810(c)(3)(A).
We intend to continue to actively monitor the closing bid price of our common stock and will evaluate available options to regain compliance
with the Minimum Bid Requirement. Specifically, we have confirmed to Nasdaq that, if necessary, we will implement a reverse stock split of our
outstanding common stock (if approved by our stockholders) to attempt to regain compliance. If we do not regain compliance within the additional
compliance period, Nasdaq will provide notice that our common stock will be subject to delisting. We would then be entitled to appeal that determination to
a Nasdaq hearings panel. There can be no assurance that we will regain compliance with the Minimum Bid Requirement during the 180-day additional
compliance period or maintain compliance with the other Nasdaq listing requirements.
If, for any reason, Nasdaq were to delist our securities from trading on its exchange and we are unable to obtain listing on another reputable
national securities exchange, a reduction in some or all of the following may occur, each of which could materially adversely affect our stockholders:
•
•
•
•
•
•
•
the liquidity and marketability of our common stock;
the market price of our common stock;
our ability to obtain financing for the continuation of our operations;
the number of institutional and general investors that will consider investing in our common stock;
the number of market makers in our common stock;
the availability of information concerning the trading prices and volume of our common stock; and
the number of broker-dealers willing to execute trades in shares of our common stock.
In addition, if we cease to be eligible to trade on Nasdaq, we may have to pursue trading on a less recognized or accepted market, such as the
over the counter markets, our stock may be traded as a “penny stock” which would make transactions in our stock more difficult and cumbersome, and we
may be unable to access capital on favorable terms or at all, as companies trading on alternative markets may be viewed as less attractive investments with
higher associated risks, such that existing or prospective institutional investors may be less interested in, or prohibited from, investing in our common
stock. This may also cause the market price of our common stock to further decline.
25
We will need substantial additional funding to develop our product candidates and conduct our future operations and to repay our outstanding debt
obligations. If we are unable to obtain the funds necessary to do so, we may be required to delay, scale back or eliminate our product development
activities or may be unable to continue our business operations.
We have had, and we will continue to have, an ongoing need to raise additional cash from outside sources to continue funding our operations,
including our continuing substantial research and development expenses and potential commercialization activities. We do not currently believe that our
cash balance will be sufficient to fund the development and marketing efforts required to reach profitability without raising additional capital from
accessible sources of financing in the near future. Our future capital requirements will depend on many factors, including:
•
•
•
•
•
•
•
•
our ability to raise capital to fund our operations on terms acceptable to us, or at all;
our perceived capital needs with respect to our development programs, and any delays in, adverse events and excessive costs of such
programs beyond what we currently anticipate;
our ability to establish and maintain collaborative and other arrangements with third parties to assist in bringing our product candidates to
market and the cost of such arrangements at the time;
costs associated with operating at our San Antonio, Texas facility;
the cost of manufacturing our product candidates, including compliance with good manufacturing practices applicable to our product
candidates;
expenses related to the establishment of sales and marketing capabilities for product candidates awaiting approval or products that have
been approved;
competing technological and market developments; and
our ability to introduce and sell new products.
The amount and timing of our future funding requirements will depend on many factors, including the pace and results of its clinical
development efforts.
We have secured capital historically from grant revenue, collaboration proceeds, and debt and equity offerings. To obtain additional capital, we
may pursue debt and/or equity offering programs, strategic corporate partnerships, state and federal development programs, licensing arrangements, and
sales of assets or debt or equity securities. We cannot be certain that additional capital will be available on terms acceptable to us, or at all. If we are
unsuccessful in our efforts to raise any such additional capital, we may be required to take actions that could materially and adversely harm our business,
including a possible significant reduction in our research, development and administrative operations (including reduction of our employee base), the
surrender of our rights to some technologies or product opportunities, delay of our clinical trials or regulatory and reimbursement efforts, or curtailment or
cessation of operations.
Depending on the type and the terms of any financing we pursue, stockholders’ rights and the value of their investment in our common stock
could be reduced. A financing could involve one or more types of securities including common stock, convertible debt or warrants to acquire common
stock. These securities could be issued at or below the then prevailing market price for our common stock. In addition, if we issue secured debt securities,
the holders of the debt would have a claim to our assets that would be prior to the rights of stockholders until the debt is paid. Interest on these debt
securities would increase costs and negatively impact operating results. If the issuance of new securities results in diminished rights to holders of our
common stock, the market price of our common stock could be negatively impacted.
On September 9, 2022, we entered into an Equity Distribution Agreement (the “September 2022 Distribution Agreement”) with Canaccord
Genuity LLC ("Canaccord”), pursuant to which we may issue and sell, from time to time, shares of our common stock having an aggregate offering price
of up to $5,000,000, depending on market demand, with Canaccord acting as an agent for sales. Sales of our common stock may be made by any method
permitted by law deemed to be an “at the market offering” as defined in Rule 415(a)(4) of the Securities Act of 1933, as amended (the “Securities Act”),
including, without limitation, sales made directly on or through the NASDAQ Capital Market.
On August 2, 2022, we entered into a purchase agreement (the “2022 Purchase Agreement”) and registration rights agreement pursuant to which
Lincoln Park Capital Fund ("Lincoln Park") committed to purchase up to $50.0 million shares of our common stock. Under the terms and subject to the
conditions of the 2022 Purchase Agreement, we have the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase up
to $50.0 million shares of our common stock, provided that we cannot sell more than 57.5 million shares pursuant to the 2022 Purchase Agreement. Sales
of common stock by us are subject to certain limitations, and can occur from time to time, at our sole discretion, over the 36-month period commencing on
August 17, 2022, subject to the satisfaction of certain conditions. As consideration for Lincoln Park’s irrevocable commitment to purchase shares of our
common stock upon the terms of and subject to satisfaction of the conditions set forth in the Purchase Agreement, we paid $0.1 million in cash as an Initial
Commitment Fee and issued 492,698 Commitment Shares to Lincoln Park in consideration for its commitment to purchase shares of our common stock at
our direction under the Purchase Agreement.
On August 17, 2022, a registration statement was declared effective covering the resale of up to 9,500,000 shares of our common stock
comprised of (i) the 492,698 Commitment Shares, and (ii) up to 9,007,302 shares that we have reserved for issuance and
26
sale to Lincoln Park under the Purchase Agreement. We cannot sell more shares under the 2022 Purchase Agreement without registering additional shares.
Even with the arrangements described above, we will need to complete additional financing transactions in order to continue operations. These
arrangements may also not be sufficient in the near-term. Given, among other things, the current status of the capital markets and our recent stock price
performance, the September 2022 Distribution Agreement and the 2022 Purchase Agreement and other financing strategies we may pursue may not be
sufficient to fund our operations in the near term. There can be no assurances that we will be able to secure additional financing, or if available, that it will
be sufficient to meet our needs or be on favorable terms. Additionally, our cost of capital will depend upon numerous factors including, but not limited to,
the strength of the financial markets, global market conditions, including inflationary pressures, interest rate fluctuations, our recovery and financial
performance, the recovery and performance of our industry in general and the size, scope and timing of our financial needs. If we are unable to access
current financings or secure future financings, including for any of the foregoing reasons, it will have a negative impact on our cash flows and our ability to
meet our financial obligations. Failure to raise capital as and when needed, on favorable terms or at all, would have a significant negative impact on our
financial condition and our ability to develop our product candidates.
The volatility in the global capital markets may negatively impact our ability to obtain additional debt financings and modify our existing debt facilities
and may increase the risk of non-compliance with covenants under our existing loan agreement.
Under the Loan and Security Agreement, dated May 29, 2015 (the “Loan and Security Agreement”), as amended, with Oxford Finance, LLC
(“Oxford”), Oxford made a term loan to us in an aggregate principal amount of $17.7 million (the “Term Loan”) subject to the terms and conditions set
forth therein. As of December 31, 2022, the outstanding principal balance of the Term Loan was $2.4 million. In addition, we are obligated to pay a final
payment fee of $3.2 million at the earlier of the maturity date, acceleration, or payment of the Term Loan.
The Term Loan accrues interest at a floating rate equal to the three-month LIBOR rate (with a floor of 1.00%) plus 7.95% per annum. Beginning
November 1, 2021, we began to make payments of principal and accrued interest in equal monthly installments as required, to amortize the Term Loan
through June 1, 2024.
As security for our obligations under the Loan and Security Agreement, we granted a security interest in substantially all of our existing and
after-acquired assets, excluding our intellectual property assets, subject to certain exceptions set forth in the Loan and Security Agreement. If we are
unable to discharge these obligations, Oxford could foreclose on these assets, which would, at a minimum, have a severe material adverse effect on our
ability to operate our business.
Our indebtedness to Oxford could adversely affect our operations and liquidity, by, among other things:
•
•
•
causing us to use a larger portion of our cash flow to fund interest and principal payments, reducing the availability of cash to fund
working capital and capital expenditures and other business activities;
making it more difficult for us to take advantage of significant business opportunities, such as acquisition opportunities, and to react to
changes in market or industry conditions; and
limiting our ability to borrow additional monies in the future to fund working capital and capital expenditures and for other general
corporate purposes.
The Loan and Security Agreement, as amended, includes certain reporting and other covenants, that, among other things, restrict our ability to (i)
dispose of assets, (ii) change the business we conduct, (iii) make acquisitions, (iv) engage in mergers or consolidations, (v) incur additional indebtedness,
(vi) create liens on assets, (vii) maintain any collateral account, (viii) pay dividends, (ix) make investments, loans or advances, (x) engage in certain
transactions with affiliates, and (xi) prepay certain other indebtedness or amend other financing arrangements. If we fail to comply with any of these
covenants or restrictions, such failure may result in an event of default, which if not cured or waived, could result in Oxford causing the outstanding loan
amount to become immediately due and payable. If the maturity of our indebtedness is accelerated, we may not have, or be able to timely procure,
sufficient cash resources to satisfy our debt obligations, and such acceleration would adversely affect our business and financial condition.
The global markets have experienced significant volatility and a continued downturn may affect our business, liquidity position, and financial
results. This in turn may negatively impact our ability to remain in compliance with the financial and operating covenants under the Loan and Security
Agreement and may restrict our ability to obtain covenant waivers, restructure or amend the terms of our existing debt, or obtain additional debt financing.
If the maturity of our indebtedness is accelerated or if we are unable to amend the terms or obtain any necessary waivers under our debt facilities or obtain
additional debt or other financing, it would materially and adversely affect our liquidity position and ability to fund our operations. This in turn would
materially harm our business and financial conditions.
Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.
We do not expect to make profits in the near future. Under Section 382 of the Internal Revenue Code of 1986, as amended, if a corporation
undergoes an “ownership change” (generally defined as a greater than 50% change, by value, in its equity ownership over
27
a three year period), the corporation’s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes to offset its post-
change taxable income and taxes may be limited. We have undergone “ownership changes” as a result of shifts in stock ownership in the past, which
significantly limited our ability to use net operating loss carryforwards and other pre-change tax attributes. Any additional ownership change within the
definition of Section 382 would further limit our ability to use net operating loss carryforwards and other tax attributes. This change may require us to pay
federal income taxes in future years despite generating a loss for federal income tax purposes in prior years.
Risks Related to Our Business and Industry
Our future success is in large part dependent upon our ability to successfully develop our nanomedicine platform and commercialize rhenium (186Re)
obisbemeda and 188RNL-BAM and any failure to do so could significantly harm our business and prospects.
Our ability to successfully develop and commercialize rhenium (186Re) obisbemeda and 188RNL-BAM is subject to a number of risks, including
the following:
•
•
•
we do not have substantive drug development, manufacturing, and commercialization experience, and thus we may be required to hire and
rely on significant numbers of scientific, quality, regulatory and other technical personnel with the experience and expertise necessary to
develop, manufacture, and commercialize our nanomedicine product candidates. We may be unable to identify, hire and retain personnel
with the requisite experience to conduct the operations necessary to obtain regulatory approval and commercialize our RNL product
candidates, in which case our business would be materially harmed;
we intend to find a commercialization partner to share or assume responsibility for marketing, sales, and distribution activities and related
costs and expenses for our RNL product candidates. There can be no assurance that we would obtain sufficient capital to fund the
development, manufacturing, and commercialization of our nanomedicine program ourselves, or if we do obtain such capital, that our
development, manufacturing, and commercialization efforts would be successful; and
to the extent that we incur unanticipated expenses in our business, are unable to timely obtain sufficient additional capital on terms
acceptable to us (or at all) to fund this business, our ability to develop our RNL product candidates could be materially and adversely
impacted.
If we are unable to successfully partner with other companies to commercialize our product candidates, our business could materially suffer.
A key part of our business strategy is to leverage strategic partnerships and collaborations to commercialize our product candidates. We do not
have the financial, human or other resources necessary to develop, commercialize, launch or sell our therapeutic offerings in all of the geographies that we
are targeting, and thus it is important that we identify and partner with third parties who possess the necessary resources to bring our product candidates to
market. We expect that any such partners will provide regulatory and reimbursement/pricing expertise, sales and marketing resources, and other expertise
and resources vital to the success of our product offerings in their territories. We further expect, but cannot guarantee, that any such partnering
arrangements will include upfront cash payments to us in return for the rights to develop, manufacture, and/or sell our product candidates in specified
territories, as well as downstream revenue in the form of milestone payments and royalties. If we are unable to successfully partner with other companies to
commercialize our product candidates, our business could materially suffer.
Our success depends in substantial part on our ability to obtain regulatory approvals for our RNL product candidates. However, we cannot be certain
that we will receive regulatory approval for these product candidates or our other product candidates.
We have a limited number of product candidates in development, and our business depends substantially on their successful development and
commercialization. Our product candidates will require development, regulatory review and approval in multiple jurisdictions, substantial investment,
access to sufficient commercial manufacturing capacity and significant marketing efforts before we can generate any revenue from sales of our product
candidates. The research, testing, manufacturing, labeling, approval, sale, marketing and distribution of products are subject to extensive regulation by the
FDA and other regulatory authorities in the United States and other countries, whose regulations differ from country to country.
We are not permitted to market our product candidates in the United States until we receive approval from the FDA, or in any foreign countries
until we receive the requisite approval from the regulatory authorities of such countries (including centralized marketing authorization from EMA), and we
may never receive such regulatory approvals. Obtaining regulatory approval for a product candidate is a lengthy, expensive and uncertain process, and may
not be obtained. Any failure to obtain regulatory approval of any of our product candidates would limit our ability to generate future revenue (and any
failure to obtain such approval for all of the indications
28
and labeling claims we deem desirable could reduce our potential revenue), would potentially harm the development prospects of our product candidates
and would have a material and adverse impact on our business.
Even if we successfully obtain regulatory approvals to market our product candidates, our revenue will be dependent, in part, on our ability to
commercialize such products as well as the size of the markets in the territories for which we gain regulatory approval. If the markets for our product
candidates are not as significant as we estimate, our business and prospects will be harmed.
If a product candidate is not approved in a timely fashion on commercially viable terms, or if development of any product candidate is terminated
due to difficulties or delays encountered in the regulatory approval process, it could have a material adverse effect on our business, and we may become
more dependent on the development of other proprietary products and/or our ability to successfully acquire other products and technologies. There can be
no assurance that any product candidate will receive regulatory approval in a timely manner, or at all.
If we or any party to a key collaboration, licensing, development, acquisition or similar arrangement fails to perform material obligations, or commit a
breach, under such arrangement, or any arrangement is terminated for any reason, there could be an adverse effect on our business.
We are currently party to certain licensing, collaboration and acquisition agreements under which we may make or receive future payments in the
form of milestone payments, maintenance fees, royalties and/or minimum product purchases. Our collaborators may not devote the attention and resources
to such efforts to be successful. The termination of a key collaboration agreement by one of our collaborators could materially impact our ability to enter
into additional collaboration agreements with new collaborators on favorable terms.
On March 29, 2020, we entered into an exclusive license agreement with NanoTx for the global rights to develop and commercialize NanoTx’s
glioblastoma treatment, rhenium (186Re) obisbemeda. Under the license agreement with NanoTx, we are required to use commercial reasonable efforts to
develop the rhenium (186Re) obisbemeda product candidate acquired under the license agreement. Further, we are subject to future milestone, earn-out and
other payments to NanoTx all of which are tied to our commercialization and sale activities for product candidates. If we are unsuccessful in our efforts to
develop these assets, or if NanoTx and we were to enter into a dispute over the terms of our agreement, then our business could be seriously harmed.
On December 31, 2021, we entered into an exclusive license agreement with UT Health Science Center at San Antonio for the global rights to
develop and commercialize Rhenium-188 NanoLiposome biodegradable alginate microspheres (188RNL-BAM). Under the license agreement with UT
Health Science at San Antonio, we are required to use commercial reasonable efforts to develop the 188RNL-BAM product candidate acquired under the
license agreement. Further, we are subject to future milestone, earn-out and other payments to UT Heath Science Center San Antonio all of which are tied
to our commercialization and sale activities for product candidates. If we are unsuccessful in our efforts to develop these assets, or if UT Heath Science
Center San Antonio and we were to enter into a dispute over the terms of our agreement, then our business could be seriously harmed.
If we breach any of the agreements under which we license the use, development and commercialization rights to our product candidates or
technology from third parties, we could lose license rights that are important to our business. Licensing of intellectual property is of critical importance to
our business and involves complex legal, business and scientific issues. Disputes may arise between us and our licensors regarding intellectual property
subject to a license agreement, including:
•
•
•
•
•
•
the scope of rights granted under the license agreement and other interpretation-related issues;
whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the
licensing agreement;
our right to sublicense patents and other intellectual property rights to third parties under collaborative development relationships;
our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our
product candidates, and what activities satisfy those diligence obligations;
the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our
partners; and
whether and the extent to which inventors are able to contest the assignment of their rights to our licensors.
If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on
acceptable terms or at all, we may be unable to successfully develop and commercialize the affected product candidates. In addition, if disputes arise as to
ownership of licensed intellectual property, our ability to pursue or enforce the licensed patent rights
29
may be jeopardized. If we or our licensors fail to adequately protect this intellectual property, our ability to commercialize our products could suffer.
Our current business strategy is high-risk and may not be successful.
Our current business strategy is to aggressively develop our nanomedicine platforms, while simultaneously controlling expenses, which is a
high-risk strategy for a number of reasons including the following:
•
•
•
•
•
•
we do not have prior experience with obtaining regulatory, reimbursement, or other approvals for product candidates such as rhenium
(186Re) obisbemeda and 188RNL-BAM;
our nanomedicine product candidates, if commercialized, will compete against established competitive drugs that are marketed and sold by
large companies with significant human, technical and financial resources;
we are not experienced in acquiring and integrating new assets;
there is an intense and rapidly evolving competitive landscape for our nanomedicine product candidates, including chemotherapies, targeted
therapies and immuno-oncology therapies, and as such key assumptions regarding market entry, pricing, and revenue/unit share may not be
realized;
our product candidates may never become commercially viable; and
we may not be able to prevent other companies from depriving us of market share and profit margins by selling products based on our
intellectual property and developments.
Reliance on government funding for our programs may impose requirements that limit our ability to take certain actions, and subject it to potential
financial penalties, which could materially and adversely affect its business, financial condition and results of operations.
A significant portion of our funding will come from grants received from CPRIT. The CPRIT Grant includes provisions that reflect the
government’s substantial rights and remedies, many of which are not typically found in commercial contracts, including powers of the government to
potentially require repayment of all or a portion of the grant award proceeds, in certain cases with interest, in the event we violate certain covenants
pertaining to various matters that include any potential relocation outside of the State of Texas. After the CPRIT Grant ends, we are not permitted to retain
any unused grant award proceeds without CPRIT’s approval, but our obligation to pay CPRIT sales-based royalty, if and when commercialization is
achieved, and other obligations, including our obligation to repay the disbursed grant proceeds under certain circumstances, to maintain certain records and
documentation, to notify CPRIT of certain unexpected adverse events and our obligation to use reasonable efforts to ensure that any new or expanded
preclinical testing, clinical trials, commercialization or manufacturing related to any aspect to our CPRIT project take place in Texas, survive the
termination of the agreement.
Our award from CPRIT requires us to pay CPRIT a portion of our revenues from sales of certain products by us, or received from our licensees
or sublicensees, at tiered percentages of revenue in the low- to mid-single digits until the aggregate amount of such payments equals 400% of the grant
award proceeds, and thereafter at a rate of 0.5% for as long as we maintain government exclusivity, subject to our right, under certain circumstances, to
make a one-time payment in a specified amount to CPRIT to terminate such payment obligations. In addition, the grant contract also contains a provision
that provides for repayment to CPRIT of some amount not to exceed the full amount of the grant proceeds under certain specified circumstances involving
relocation of our principal place of business outside Texas.
The CPRIT Grant requires us, as a Texas-based company, to meet certain criteria, including among other things, that we maintain our
headquarters in Texas and use certain vendors, consultants and employees that are located in Texas. If we fail to maintain compliance with any such
requirements that may apply to us now or in the future, we may be subject to potential liability and to termination of our contracts, and potentially full
repayment of the CPRIT Grant.
30
If our competitors market or develop products that are marketed more effectively, approved more quickly than our product candidates, or demonstrated
to be safer or more effective than our product candidates, our commercial opportunities could be reduced or eliminated.
The life science industry is characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary
therapeutics. We face competition from a number of sources, some of which may target the same indications as our products or product candidates,
including small and large, domestic and multinational, medical device, biotechnology and pharmaceutical companies, academic institutions, government
agencies, and private and public research institutions.
Competitors may have greater experience in developing drugs, conducting clinical trials, obtaining regulatory clearances or approvals,
manufacturing and commercialization. It is possible that competitors may obtain patent protection, approval, or clearance from the FDA or achieve
commercialization earlier than we can, any of which could have a substantial negative effect on our business. Many of our potential competitors have
substantially greater:
•
•
•
•
•
•
•
capital resources;
research and development resources and experience, including personnel and experience;
product development, clinical trial and regulatory resources and experience;
sales and marketing resources and experience;
manufacturing and distribution resources and experience;
name, brand and product recognition; and
resources, experience and expertise in prosecution and enforcement of intellectual property rights.
We expect that product candidates in our pipeline, if approved, to compete on the basis of, among other things, product efficacy and safety, time
to market, price, coverage, and reimbursement by third-party payers, extent of adverse side effects, and convenience of treatment procedures. One or more
of our competitors may develop other products that compete with ours, obtain necessary approvals for such products from the FDA, EMA, Ministry of
Health, Labour and Welfare or other agencies, if required, more rapidly than we do or develop alternative products or therapies that are safer, more
effective and/or more cost effective than any products developed by us. The competition that we encounter with respect to any of our product candidates
that receive the requisite regulatory approval and classification and are marketed may have an effect on our product prices, market share, and results of
operations. We may not be able to differentiate any products that we are able to market from those of our competitors, successfully develop or introduce
new products that are less costly or offer better results than those of our competitors, or offer purchasers of our products payment and other commercial
terms as favorable as those offered by our competitors.
As a result of these factors, our competitors may obtain regulatory approval of their products more quickly than we are able to or may obtain
patent protection or other intellectual property rights that limit or block us from developing or commercializing our product candidates. Our competitors
may also develop products that are more effective, more useful, better tolerated, subject to fewer or less severe side effects, more widely prescribed or
accepted, or less costly than ours and may also be more successful than we are in manufacturing and marketing their products. If we are unable to compete
effectively with the marketed therapeutics of our competitors or if such competitors are successful in developing products that compete with any of our
product candidates that are approved, our business, results of operations, financial condition, and prospects may be materially adversely affected.
Product development involves a lengthy and expensive process, with an uncertain outcome. We may incur additional costs or experience delays in
completing, or ultimately be unable to complete, the development and commercialization of our product candidates.
Clinical testing of our product candidates is a long, expensive and uncertain process, and the failure or delay of a clinical trial can occur at any
stage. Many factors, currently known and unknown, can adversely affect clinical trials and the ability to evaluate a product candidate’s efficacy. During the
course of treatment, patients can die or suffer other adverse events for reasons that may or may not be related to the proposed product being tested. Even if
initial results of preclinical and nonclinical studies or clinical trial results are promising, we may obtain different results in subsequent trials or studies that
fail to show the desired levels of safety and efficacy, or we may not obtain applicable regulatory approval for a variety of other reasons.
Further, with respect to the conduct and results of clinical trials generally, in the United States, Europe, Japan, and other jurisdictions, the
conduct and results of clinical trials can be delayed, limited, suspended, or otherwise adversely affected for many reasons, including, among others:
•
•
delay or failure in reaching agreement with the FDA or other regulatory authorities outside of the United States on acceptable clinical trial
design, or in obtaining authorization to commence a trial;
delay or failure in reaching agreement on acceptable terms with prospective clinical research organizations (“CRO”), and clinical trial sites;
31
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
delay or failure in obtaining approval of an IRB or ethics committees before a clinical trial can be initiated at a prospective trial site;
withdrawal of clinical trial sites from our clinical trials, including as a result of changing standards of care or the ineligibility of a site to
participate;
clinical results may not meet prescribed endpoints for the studies, produce negative or inconclusive results, or otherwise not provide
sufficient data to support the efficacy of our product candidates;
clinical and nonclinical test results may reveal side effects, adverse events or unexpected safety issues associated with the use of our product
candidates;
emerging of dosing issues;
lack of adequate funding to continue the clinical trial, including the incurrence of unforeseen costs due to enrollment delays, requirements
to conduct additional trials and studies, and increased expenses associated with the services of our CROs, and other third parties;
inability to design appropriate clinical trial protocols;
slower than expected rates of subject recruitment and enrollment rates in clinical trials;
clinical sites or investigators may deviate from trial protocol or fail to conduct the trial in accordance with applicable regulatory
requirements, or drop out of a trial;
regulatory review may not find a product safe or effective enough to merit either continued testing or final approval;
regulatory authorities may require that we change our studies or conduct additional studies which may significantly delay or make
continued pursuit of approval commercially unattractive;
a regulatory agency may reject our trial data or disagree with our interpretations of either clinical trial data or applicable regulations;
the cost of clinical trials required for product approval may be greater than what we originally anticipate, and we may decide to not pursue
regulatory approval for such a product;
changes in the standard of care of the indication being studied;
a regulatory agency may identify problems or other deficiencies in our existing manufacturing processes or facilities or the existing
processes or facilities of our collaborators, our contract manufacturers, or our raw material suppliers;
a regulatory agency may change its formal or informal approval requirements and policies, act contrary to previous guidance, adopt new
regulations, or raise new issues or concerns late in the approval process; and
a regulatory agency may ask us to put a clinical study on hold pending additional safety data (and there can be no assurance that we will be
able to satisfy the regulator agencies’ requests in a timely manner, which can lead to significant uncertainty in the completion of a clinical
study).
We also face clinical trial-related risks with regard to our reliance on other third parties in the performance of many of the clinical trial functions,
including CROs that help execute our clinical trials, the hospitals and clinics at which our trials are conducted, the clinical investigators at the trial sites,
and other third-party service providers. Failure of any third-party service provider to adhere to applicable trial protocols, laws and regulations in the
conduct of one of our clinical trials could adversely affect the conduct and results of such trial (including possible data integrity issues), which could
seriously harm our business.
We, the FDA, other regulatory authorities outside the United States, or an IRB may suspend a clinical trial at any time for various reasons,
including if it appears that the clinical trial is exposing participants to unacceptable health risks or if the FDA or one or more other regulatory authorities
outside the United States find deficiencies in our IND or similar application outside the United States or the conduct of the trial. If we experience delays in
the completion of, or the termination of, any clinical trial of any of our product candidates, the commercial prospects of such product candidate will be
harmed, and our ability to generate product revenues from such product candidate will be delayed or inhibited. In addition, any delays in completing our
clinical trials will increase our costs, slow down our product candidate development and approval process, and jeopardize our ability to commence product
sales and generate revenues. Any of these occurrences may harm our business, financial condition, results of operations, cash flows and prospects
significantly. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead
to the denial of regulatory approval of our product candidates. Further, regulatory authorities may disagree with our clinical trial design and our
interpretation of data from clinical trials, or may change the requirements for approval even after they have reviewed and commented on the design for our
clinical trials.
Pre-clinical studies and preliminary and interim data from clinical trials of our product candidates are not necessarily predictive of the results or
success of ongoing or future clinical trials of our product candidates.
Pre-clinical studies and any positive preliminary and interim data from our clinical trials of our product candidates may not necessarily be
predictive of the results of ongoing or later clinical trials. A number of companies in the pharmaceutical and biotechnology industries, including us and
many other companies with greater resources and experience than we, have suffered significant setbacks in clinical trials, even after seeing promising
results in prior pre-clinical studies and clinical trials. Even if we are able to complete our planned clinical trials of our product candidates according to our
current development timeline, initial positive
32
results from pre-clinical studies and clinical trials of our product candidates may not be replicated in subsequent clinical trials. The design of our later stage
clinical trials could differ in significant ways (e.g., inclusion and exclusion criteria, endpoints, statistical analysis plan) from our earlier stage clinical trials,
which could cause the outcomes of the later stage trials to differ from those of our earlier stage clinical trials. If we fail to produce positive results in our
planned clinical trials of any of our product candidates, the development timeline and regulatory approval and commercialization prospects for our product
candidates, and, correspondingly, our business and financial prospects, could be materially adversely affected. If we fail to produce positive results in our
planned clinical trials of any of our product candidates, the development timeline and regulatory approval and commercialization prospects for such
product candidates, and, correspondingly, our business and financial prospects, could be materially adversely affected.
Because we have limited resources, we may decide to pursue a particular product candidate and fail to advance product candidates that later
demonstrate a greater chance of clinical and commercial success.
We are an early-stage company with limited resources and revenues. The product candidates we currently have under development will require
significant development, pre-clinical and clinical testing and investment of significant funds before their commercialization. Because of this, we must
make strategic decisions regarding resource allocations and which product candidates to pursue. There can be no assurance that we will be able to develop
all potentially promising product candidates that we may identify. Based on preliminary results, we may choose to advance a particular product candidate
that later fails to be successful, and simultaneously forgo or defer further investment in other product candidates that later are discovered to demonstrate
greater promise in terms of clinical and commercial success. If we make resource allocation decisions that later are shown to be inaccurate, our business
and prospects could be harmed.
Clinical trial results may fail to support approval of our product candidates.
Even if our clinical trials are successfully completed as planned, the results may not support approval of our product candidates under the laws
and regulations of the FDA or other regulatory authorities outside the United States. The clinical trial process may fail to demonstrate that our product
candidates are both safe and/or effective for their intended uses. Pre-clinical and clinical data and analyses are often able to be interpreted in different
ways. Even if we view our results favorably, if a regulatory authority has a different view, we may still fail to obtain regulatory approval of our product
candidates. This, in turn, would significantly adversely affect our business prospects.
If third parties we engage are not able to successfully perform, we may not be able to successfully complete clinical development, obtain regulatory
approval or commercialize our product candidates and our business could be substantially harmed.
We rely on third parties in the performance of many of the clinical trial functions, including CROs, which help execute our clinical trials, the
hospitals and clinics at which our trials are conducted, the clinical investigators at the trial sites, and other third-party service providers. Failure of any
third-party service provider to adhere to applicable trial protocols, laws and regulations in the conduct of one of our clinical trials could adversely affect the
conduct and results of such trial (including possible data integrity issues), which could seriously harm our business. As a result, results from our clinical
trials may be delayed, which in turn would have a material adverse impact on our clinical trial plans and timelines and impair our ability to successfully
complete clinical development, obtain regulatory approval, or commercialize our product candidates. This in turn would substantially harm our business
and operations.
We also rely on third-party expertise to support us in this area. We have entered into contracts with third-party manufacturers to manufacture,
supply, store and distribute supplies of our product candidates for our clinical trials. If any of our product candidates receives FDA approval, we expect to
rely on third-party contractors to manufacture our drugs. We have no current plans to build internal manufacturing capacity for any product candidate, and
we have no long-term supply arrangements.
Our reliance on third-party manufacturers exposes us to potential risks, such as the following:
•
•
•
•
we may be unable to contract with third-party manufacturers on acceptable terms, or at all, because the number of potential manufacturers is
limited. Potential manufacturers of any product candidate that is approved will be subject to FDA compliance inspections and any new
manufacturer would have to be qualified to produce our products;
our third-party manufacturers might be unable to formulate and manufacture our drugs in the volume and of the quality required to meet our
clinical and commercial needs, if any;
our third-party manufacturers may not perform as agreed or may not remain in the contract manufacturing business for the time required to
supply our clinical trials through completion or to successfully produce, store and distribute our commercial products, if approved;
drug manufacturers are subject to ongoing periodic unannounced inspection by the FDA and other government agencies to ensure compliance
with cGMP and other government regulations and corresponding foreign standards. We do not have control over third-party manufacturers’
compliance with these regulations and standards, but we may ultimately be responsible for any of their failures;
33
•
•
if any third-party manufacturer makes improvements in the manufacturing process for our products, we may not own, or may have to share, the
intellectual property rights to such improvements; and
a third-party manufacturer may gain knowledge from working with us that could be used to supply one of our competitors with a product that
competes with ours.
Each of these risks could delay or have other adverse impacts on our clinical trials and the approval and commercialization of our product
candidates, potentially resulting in higher costs, reduced revenues or both.
We may have difficulty enrolling, or fail to enroll patients, in our clinical trials, which could delay or prevent clinical trials of our drug candidates.
Identifying and enrolling patients to participate in clinical trials of our product candidates is essential to our success. The timing of our clinical
trials depends in part on the rate at which we can recruit patients to participate in clinical trials of our product candidates, and we may experience delays in
our clinical trials if we encounter difficulties in enrollment. The eligibility criteria of our planned clinical trials may further limit the available eligible trial
participants as we require that patients have specific characteristics that we can measure or meet the criteria to assure their conditions are appropriate for
inclusion in our clinical trials. We may not be able to identify, recruit and enroll a sufficient number of patients to complete our clinical trials in a timely
manner because of the perceived risks and benefits of the drug candidate under study, the availability and efficacy of competing therapies and clinical trials,
and the willingness of physicians to participate in our planned clinical trials. If patients are unwilling to participate in our clinical trials for any reason, the
timeline for conducting trials and obtaining regulatory approval of our drug candidates may be delayed.
If we experience delays in the completion of, or termination of, any clinical trials of our drug candidates, the commercial prospects of our
product candidates could be harmed, and our ability to generate product revenue from any of these product candidates could be delayed or prevented. In
addition, any delays in completing our clinical trials would likely increase our overall costs, impair product candidate development and jeopardize our
ability to obtain regulatory approval relative to our current plans. Any of these occurrences may materially and adversely harm our business, financial
condition, and prospects.
If a particular product candidate causes significant adverse events, then we may be unable to receive regulatory approval or market acceptance for
such product candidate.
We may experience numerous unforeseen events during, or as a result of, the testing process that could delay or prevent commercialization of
any of our product candidates, including the occurrence of significant adverse events in clinical trials. Such significant adverse events could lead to clinical
trial challenges, such as difficulties in patient recruitment, retention, and adherence, potential product liability claims, and possible trial termination by us,
regulatory authorities, and/or an IRB or ethics committees. These types of clinical trial challenges could delay or prevent regulatory approval of our
product candidate. Significant adverse events may also lead regulatory authorities to require additional warnings on the label for such product, require us
to conduct additional costly post-marketing studies, require us to develop a REMS, among other possible requirements. If the product candidate has
already been approved, such approval may be withdrawn. Any delay in, denial, or withdrawal of marketing approval for one of our product candidates will
adversely affect our financial position. Even if our product candidates receive marketing approval, undesirable side effects may limit the product’s
commercial viability. Patients may not wish to use our product, physicians may not prescribe our product, and our reputation may suffer. Any of these
events may significantly harm our business and financial prospects.
If our product candidates and technologies receive regulatory approval but do not achieve broad market acceptance, especially by physicians, the
revenue that we generate will be limited.
The commercial success of any of our approved products or technologies will depend upon the acceptance of these products and technologies by
physicians, patients and the medical community. The degree of market acceptance of these products and technologies will depend on a number of factors,
including, among others:
•
•
•
•
•
•
•
•
•
acceptance by physicians and patients of the product as a safe and effective treatment;
any negative publicity or political action related to our or our competitors’ products or technologies;
the relative convenience and ease of administration;
the prevalence and severity of adverse side effects;
demonstration to authorities of the pharmacoeconomic benefits;
demonstration to authorities of the improvement in burden of illness;
limitations or warnings contained in a product’s approved labeling;
payers’ level of restrictions and/or barriers to coverage;
the clinical indications for which a product is approved;
34
•
•
•
availability and perceived advantages of alternative treatments;
the effectiveness of our or future collaborators’ sales, marketing and distribution strategies; and
pricing and cost effectiveness.
We expect physicians’ inertia and skepticism to also be a significant barrier as we attempt to gain market penetration with our future products.
We believe we will continue to need to finance lengthy time-consuming clinical studies to provide evidence of the medical benefit of our products and
resulting therapies in order to overcome this inertia and skepticism.
Overall, our efforts to educate the medical community on the benefits of any of our products or technologies for which we obtain marketing
approval from the FDA or other regulatory authorities and gain broad market acceptance may require significant resources and may never be successful. If
our products and technologies do not achieve an adequate level of acceptance by physicians, pharmacists and patients, we may not generate sufficient
revenue from these products to become or remain profitable.
All potential applications of our product candidates are investigational, which subjects us to development and marketing risks.
Our product candidates are at various stages of development. Successful development and market acceptance of our products is subject to
developmental risks, including risk of negative clinical data from current and anticipated trials, failure of inventive imagination, ineffectiveness, lack of
safety, unreliability, manufacturing hurdles, failure to receive necessary regulatory clearances or approvals, high commercial cost, preclusion or
obsolescence resulting from third parties’ proprietary rights or superior or equivalent products, competition from copycat products and general economic
conditions affecting purchasing patterns. There can be no assurance that we or our partners will successfully develop and commercialize our product
candidates, or that our competitors will not develop competing technologies that are superior or less expensive. Failure to successfully develop and market
our product candidates would have a substantial negative effect on our results of operations and financial condition. If we are unable to establish or sustain
coverage and adequate reimbursement for any future product candidates from third-party payors, the adoption of those products and sales revenue will be
adversely affected, which, in turn, could adversely affect the ability to market or sell those product candidates, if approved.
We and our product candidates are subject to extensive regulation, and the requirements to obtain regulatory approvals in the United States and other
jurisdictions can be costly, time-consuming and unpredictable. If we or our partners are unable to obtain timely regulatory approval for our product
candidates, our business may be substantially harmed.
The worldwide regulatory process for our nanomedicine drug candidates can be lengthy and expensive, with no guarantee of approval.
Before any new drugs may be introduced to the U.S. market, the manufacturer generally must obtain FDA approval through either an ANDA
process for generic drugs off patent that allow for bioequivalence to an existing RLD or the lengthier NDA process, which typically requires multiple
successful and successive clinical trials to generate clinical data supportive of safety and efficacy along with extensive pharmacodynamic and
pharmacokinetic preclinical testing to demonstrate safety. Our RNL product candidates are subject to the FDA’s 505(b)(1) NDA process. NDA drugs can
take significant time due to the preclinical and clinical trial requirements.
There are numerous risks arising out of the regulation of our nanomedicine product candidates include the following:
•
•
•
•
•
we can provide no assurances that our current and future oncology drugs will meet all of the stringent government regulation in the United
States under the Federal Food, Drug and Cosmetic Act, and/or in international markets such as Europe, by the EMA under its Medicinal
Products Directive;
our nanomedicine product candidates, if approved, will still be subject to post-market reporting requirements for instances where the drug
may have caused or contributed to the death or serious injury, or serious adverse events;
there are no assurances that our product candidates will not have safety or effectiveness problems occurring after the drugs reach the
market;
there are no assurances that regulatory authorities will not take steps to prevent or limit further marketing of the drug due to safety concerns;
and
it is possible that the new legislation in our priority markets will yield additional regulatory requirements for therapeutic drugs for our
nanomedicine product candidates.
We will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant expense, and if we or
collaborators fail to comply with such requirements, regulatory agencies may take action against us or them, which could significantly harm our
business.
Approved drug products are subject to ongoing regulatory requirements and oversight, including requirements related to manufacturing, quality
control, conduct of post-marketing studies, labeling, packaging, storage, distribution, safety surveillance, import, export, advertising, promotion,
recordkeeping and reporting. Regulatory authorities subject a marketed product, its manufacturer, and the manufacturing facilities to continual review and
periodic inspections. We, our collaborators, and our and their respective contractors, suppliers and vendors, will be subject to ongoing regulatory
requirements, including complying with regulations and laws regarding advertising, promotion and sales of products (including applicable anti-kickback,
fraud and abuse and other health care laws and regulations), required submissions of safety and other post-market information and reports, registration
requirements, Clinical Good
35
Manufacturing Practices ("cGMP") regulations (including requirements relating to quality control and quality assurance, as well as the corresponding
maintenance of records and documentation), and the requirements regarding the distribution of samples to physicians and recordkeeping requirements.
Regulatory agencies may change existing requirements or adopt new requirements or policies. We, our collaborators, and our and their respective
contractors, suppliers, and vendors, may be slow to adapt or may not be able to adapt to these changes or new requirements.
Failure to comply with regulatory requirements may result in any of the following:
•
•
•
•
•
•
•
•
•
•
•
•
restrictions on the marketing of our product candidates or manufacturing processes;
warning letters or untitled letters;
withdrawal of the products from the market;
voluntary or mandatory recall;
fines;
suspension or withdrawal of regulatory approvals;
suspension or termination of any of our ongoing clinical trials;
refusal to permit the import or export of our product candidates;
refusal to approve pending applications or supplements to approved applications that we submit;
product seizure;
injunctions; or
imposition of civil or criminal penalties.
Changing, new and/or emerging government regulations, including healthcare legislative reform measures, may adversely affect us.
Our nanoparticle and microparticle technologies and pipeline oncology products are being developed under existing government criteria, which
are subject to change in the future. Clinical and/or pre-clinical criteria and cGMP manufacturing requirements may change and additional regulatory
burdens may be imposed. Any regulatory review committees and advisory groups and any contemplated new guidelines may lengthen the regulatory
review process, require us to perform additional studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay
or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. As we advance our
product candidates, we may be required to consult with these regulatory and advisory groups and comply with applicable guidelines. If we fail to do so, we
may be required to delay or discontinue development of our product candidates. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory
approval necessary to bring a product candidate to market could decrease our ability to generate sufficient revenue to maintain our business. Divergence in
regulatory criteria for different regulatory agencies in international jurisdictions could result in the repeat of clinical studies and/or preclinical studies to
satisfy local territory requirements, resulting in the repeating of studies and/or delays in the regulatory process. Some territories may require clinical data
in their indigenous population, resulting in the repeat of clinical studies in whole or in part. Some territories may object to the formulation ingredients in the
final finished product and may require reformulation to modify or remove objectionable components; resulting in delays in regulatory approvals. Such
objectionable reformulations include, but are not limited to, human or animal components, Bovine Spongiform Encephalopathy and/or Transmissible
Spongiform Encephalopathy risks, banned packaging components, prohibited chemicals, and banned substances. There can be no assurances that the FDA
or foreign regulatory authorities will accept our pre-clinical and/or clinical data.
Anticipated or unanticipated changes in the way or manner in which the FDA or other regulators regulate products or classes and groups of
products can delay, further burden, or alleviate regulatory pathways that were once available to other products. There are no guarantees that such changes in
the FDA’s or other regulators’ approach to the regulatory process will not deleteriously affect some or all of our product candidates or product applications.
In the United States and in some other jurisdictions, there have been a number of legislative and regulatory changes and proposed changes
regarding the health care system that could prevent or delay marketing approval of our drug candidates, restrict or regulate post-approval activities, or
affect our ability to profitably sell any drug candidates for which we obtain marketing approval, if any. Further, any increased scrutiny of the FDA’s
approval process for drugs and biological products may significantly delay or prevent marketing approval, as well as subject us to more stringent product
labeling and post-marketing testing and other requirements. There also are a number of state and local legislative and regulatory efforts related to drug
pricing, including drug price transparency laws that apply to pharmaceutical manufacturers, which may have an impact on our business.
In addition, the Drug Supply Chain Security Act enacted in 2013 imposes new obligations on manufacturers of pharmaceutical products related
to product tracking and tracing, and that law is expected to be fully implemented over a ten-year period. In December 2019, the Further Consolidated
Appropriations Act for 2020 was signed into law (P.L. 116-94) that includes a piece of bipartisan legislation called the Creating and Restoring Equal
Access to Equivalent Samples Act of 2019 or the “CREATES Act.” The CREATES Act aims to address the concern articulated by both the FDA and others
in the industry that some brand manufacturers have improperly restricted the distribution of their products, including by invoking the existence of a REMS
for certain products, to deny generic and biosimilar product developers access to samples of brand products. The CREATES Act establishes a private cause
of action that permits a generic or biosimilar product developer to sue the brand manufacturer to compel it to furnish the necessary samples on
“commercially
36
reasonable, market-based terms.” Whether and how generic and biosimilar product developments will use this new pathway, as well as the likely outcome
of any legal challenges to provisions of the CREATES Act, remain highly uncertain and its potential effects on our future commercial products are
unknown. Other legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for
pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether FDA regulations, guidance or
interpretations will be changed, or what the impact of such changes on the marketing approvals, if any, of our drug candidates, may be or whether such
changes will have any other impacts on our business. In addition, increased scrutiny by the U.S. Congress of the FDA’s approval process may significantly
delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing conditions and other requirements.
In the European Union, similar political, economic and regulatory developments may affect our ability to profitably commercialize our product
candidates. In addition to continuing pressure on prices and cost containment measures, legislative developments at the European Union or EU member
state level may result in significant additional requirements or obstacles that may increase our operating costs.
We expect that other legislative or healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria,
lower reimbursement, and additional downward pressure on the price that we will receive for any approved product. Any reduction in payments from
Medicare or other government-funded programs may result in a similar reduction in payments from private payors. The implementation of cost
containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product
candidates.
Adequate coverage and reimbursement from third party payors may not be available for our products and we may be unable to successfully contract for
coverage from pharmacy benefit managers and other organizations; conversely, to secure coverage from these organizations, we may be required to
pay rebates or other discounts or other restrictions to reimbursement, either of which could diminish our sales or adversely affect our ability to sell our
products profitably.
In both U.S. and non-U.S. markets, our ability to successfully commercialize and achieve market acceptance of our products depends in
significant part on adequate financial coverage and reimbursement from third party payors, including governmental payors (such as the Medicare and
Medicaid programs in the U.S.), managed care organizations and private health insurers. Without third party payor reimbursement, patients may not be
able to obtain or afford prescribed medications. In addition, reimbursement guidelines and incentives provided to prescribing physicians by third party
payors may have a significant impact on the prescribing physicians’ willingness and ability to prescribe our products. The demand for, and the profitability
of, our products could be materially harmed if the state Medicaid programs, Medicare program, other healthcare programs in the U.S. or elsewhere, or third
party commercial payors in the U.S. or elsewhere deny reimbursement for our products, limit the indications for which our products will be reimbursed, or
provide reimbursement only on unfavorable terms.
As part of the overall trend toward cost containment, third party payors often require prior authorization for, and require reauthorization for
continuation of, prescription products or impose step edits, which require prior use of another medication, usually a generic or preferred brand, prior to
approving coverage for a new or more expensive product. Such restrictive conditions for reimbursement and an increase in reimbursement-related
activities can extend the time required to fill prescriptions and may discourage patients from seeking treatment. We cannot predict actions that third party
payors may take, or whether they will limit the access and level of reimbursement for our products or refuse to provide any approvals or coverage. From
time to time, third party payors have refused to provide reimbursement for our products, and others may do so in the future.
Third party payors increasingly examine the cost-effectiveness of pharmaceutical products, in addition to their safety and efficacy, when making
coverage and reimbursement decisions. We may need to conduct expensive pharmacoeconomic and/or clinical studies in order to demonstrate the cost-
effectiveness of our products. If our competitors offer their products at prices that provide purportedly lower treatment costs than our products, or
otherwise suggest that their products are safer, more effective or more cost-effective than our products, this may result in a greater level of access for their
products relative to our products, which would reduce our sales and harm our results of operations. In some cases, for example, third party payors try to
encourage the use of less expensive generic products through their prescription benefit coverage and reimbursement and co-pay policies. Because some of
our products compete in a market with both branded and generic products, obtaining and maintaining access and reimbursement coverage for our products
may be more challenging than for products that are new chemical entities for which no therapeutic alternatives exist.
Some intellectual property that we have in-licensed has been discovered through government funded programs and thus may be subject to federal
regulations such as "march-in" rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations
may limit our exclusive rights and limit our ability to contract with non-U.S. manufacturers.
Some of the intellectual property rights we have licensed are generated through the use of U.S. government funding and are therefore subject to
certain federal regulations. As a result, the U.S. government may have certain rights to intellectual property embodied in our current or future product
candidates pursuant to the Bayh-Dole Act of 1980, or Bayh-Dole Act, and implementing regulations. These U.S. government rights in certain inventions
developed under a government-funded program include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any
governmental purpose. In addition, the U.S. government has the
37
right to require us or our licensors to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party if it
determines that: (i) adequate steps have not been taken to commercialize the invention; (ii) government action is necessary to meet public health or safety
needs; or (iii) government action is necessary to meet requirements for public use under federal regulations (also referred to as "march-in rights"). The U.S.
government also has the right to take title to these inventions if we, or the applicable licensor, fail to disclose the invention to the government and fail to file
an application to register the intellectual property within specified time limits. These time limits have recently been changed by regulation and may change
in the future. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which
may require us or the applicable licensor to expend substantial resources. In addition, the U.S. government requires that any products embodying the
subject invention or produced through the use of the subject invention be manufactured substantially in the United States. The manufacturing preference
requirement can be waived if the owner of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on
similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic
manufacture is not commercially feasible. This preference for U.S. manufacturers may limit our ability to contract with non-U.S. product manufacturers for
products covered by such intellectual property. To the extent any of our current or future intellectual property is generated through the use of U.S.
government funding, the provisions of the Bayh-Dole Act may similarly apply.
Orphan drug designation may not ensure that we will enjoy market exclusivity in a particular market, and if we fail to obtain or maintain orphan drug
designation or other regulatory exclusivity for some of our product candidates, our competitive position would be harmed.
A product candidate that receives orphan drug designation can benefit from potential commercial benefits following approval. Under the U.S.
Orphan Drug Act, the FDA may designate a product candidate as an orphan drug if it is intended to treat a rare disease or condition, defined as affecting a
patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable
expectation that the cost of developing the drug will be recovered from sales in the United States. In the European Union, the EMA’s Committee for
Orphan Medicinal Products, grants orphan drug designation to promote the development of products that are intended for the diagnosis, prevention or
treatment of a life-threatening or chronically debilitating condition affecting not more than 10,000 persons in the European Union. Currently, this
designation provides market exclusivity in the U.S. and the European Union for seven years and ten years, respectively, if a product is the first such product
approved for such orphan indication. This market exclusivity does not, however, pertain to indications other than those for which the drug was specifically
designated in the approval, nor does it prevent other types of drugs from receiving orphan designations or approvals in these same indications. Further,
even after an orphan drug is approved, the FDA can subsequently approve a drug with similar chemical structure for the same condition if the FDA
concludes that the new drug is clinically superior to the orphan product or a market shortage occurs. In the European Union, orphan exclusivity may be
reduced to six years if the drug no longer satisfies the original designation criteria or can be lost altogether if the marketing authorization holder consents to
a second orphan drug application or cannot supply enough drug, or when a second applicant demonstrates its drug is “clinically superior” to the original
orphan drug. In September 2020, the FDA granted both Orphan Drug designation and Fast Track designation to rhenium (186Re) obisbemeda for the
treatment of patients with GBM. In November 2021, the FDA granted Fast Track designation to rhenium (186Re) obisbemeda for the treatment of patients
with LM.
If we experience an interruption in supply from a material sole source supplier, our business may be harmed
We acquire some of our components and other raw materials from sole source suppliers. If there is an interruption in supply of our raw materials
from a sole source supplier, for any reason, there can be no assurance that we will be able to obtain adequate quantities of the raw materials within a
reasonable time or at commercially reasonable prices. Interruptions in supplies due to pricing, timing, availability, or other issues with our sole source
suppliers could have a negative impact on our ability to manufacture products and product candidates, which in turn could adversely affect the development
and commercialization of our nanomedicine product candidates and cause us to potentially breach our supply or other obligations under our agreements
with certain other counterparties.
We are dependent on sole source suppliers to manufacture the active pharmaceutical ingredients ("API") and certain other components of our
nanomedicine product candidates. There is no assurance that these sole source suppliers will enter into supply agreements with us to provide contractual
assurance to us around supply and pricing. Regardless of whether a sole source supplier enters into a written supply arrangement with us, such supplier
could still delay, suspend, or terminate supply of raw materials to us for a number of reasons, including manufacturing or quality issues, payment disputes
with us, bankruptcy or insolvency, or other occurrences.
If a sole source supplier ceases supply of raw materials necessary, there is no guarantee that we will find an alternative supplier for the necessary
raw materials on terms acceptable to us, or at all. Further the qualification process for a new vendor could take months or years, and any such day in
qualification could significantly harm our business.
We may engage in strategic transactions that could impact our liquidity, increase our expenses, and present significant distractions to our management.
From time to time, we may consider strategic transactions, such as acquisitions of companies, asset purchases and out-licensing or in-licensing of
products, product candidates or technologies. Growth of the nanomedicine business will require significant
38
management time and attention. Further, the future growth of our business will depend in part on our ability to in-license or otherwise acquire the rights to
additional product candidates or technologies. We cannot assure you that we will be able to in-license or acquire the rights to any product candidates or
technologies from third parties on acceptable terms or at all.
Additional potential transactions that we may consider include a variety of different business arrangements, including spin-offs, strategic
partnerships, joint ventures, restructurings, divestitures, business combinations and investments. Any such transaction may require us to incur non-
recurring or other charges, may increase our near and long-term expenditures and may pose significant integration challenges or disrupt our management or
business, which could adversely affect our operations and financial results. For example, these transactions may entail numerous operational and financial
risks, including:
•
•
•
•
•
•
•
•
•
exposure to unknown liabilities;
disruption of our business and diversion of our management’s time and attention in order to develop acquired products, product candidates
or technologies;
incurrence of substantial debt or dilutive issuances of equity securities to pay for acquisitions;
higher than expected acquisition and integration costs;
write-downs of assets or goodwill or impairment charges;
increased amortization expenses;
difficulty and cost in combining the operations and personnel of any acquired businesses with our operations and personnel;
impairment of relationships with key suppliers or customers of any acquired businesses due to changes in management and ownership; and
inability to retain key employees of any acquired businesses.
The in-licensing and acquisition of these technologies is a competitive area, and a number of more established companies are also pursuing
strategies to license or acquire product candidates or technologies that we may consider attractive. In addition, companies that perceive us to be a
competitor may be unwilling to license rights to us. Furthermore, we may be unable to identify suitable product candidates or technologies within our area
of focus. If we are unable to successfully obtain rights to suitable product candidates or technologies undertake or to successfully complete any additional
transactions of the nature described above, our business, financial condition and prospects could suffer. In addition, even if we are able to successfully
complete any additional transactions of the nature described above, any additional transactions that we do complete could have a material adverse effect on
our business, results of operations, financial condition, and prospects.
We must maintain quality controls and compliance with manufacturing standards.
The manufacture of our product candidates is, and the manufacture of any future drug and/or cell-related therapeutic products would be, subject
to periodic inspection by regulatory authorities and distribution partners. The manufacture of drug and device products for human use is subject to
regulation and inspection from time to time by the FDA for compliance with the FDA’s cGMP, Quality System Regulations (“QSRs”), as well as equivalent
requirements and inspections by state and non-U.S. regulatory authorities. There can be no assurance that the FDA or other authorities will not, during the
course of an inspection of existing or new facilities, identify what they consider to be deficiencies in our compliance with QSRs or other requirements and
request, or seek remedial action.
Failure to comply with such regulations or a potential delay in attaining compliance may adversely affect our manufacturing activities and could
result in, among other things, injunctions, civil penalties, FDA refusal to grant pre- market approvals or clearances of future or pending product
submissions, fines, recalls or seizures of products, total or partial suspensions of production and criminal prosecution. There can be no assurance that after
such occurrences that we will be able to obtain additional necessary regulatory approvals or clearances on a timely basis, if at all. Delays in receipt of or
failure to receive such approvals or clearances, or the loss of previously received approvals or clearances could have a substantial negative effect on our
results of operations and financial condition.
If we are unable to identify, hire and/or retain key personnel, we may not be able to sustain or grow our business.
We maintain a very small executive team. Our ability to operate successfully and manage our potential future growth depends significantly upon
our ability to attract, retain, and motivate highly skilled and qualified research, technical, clinical, regulatory, sales, marketing, managerial and financial
personnel. We compete for talent with numerous companies, as well as universities and non-profit research organizations. In the future, we may hire a
significant number of scientists, quality and regulatory personnel, and other technical staff with the requisite expertise to support and expand our
nanomedicine business. The manufacturing of our oncology drug assets is a highly complex process that requires significant experience and know-how. If
we are unable to attract personnel with the necessary skills and experience to reestablish and expand our nanomedicine business, which is currently
conducted out of our San Antonio, Texas facility, our business could suffer.
39
Our future success also depends on the personal efforts and abilities of the principal members of our senior management and scientific staff to
provide strategic direction, manage our operations, and maintain a cohesive and stable environment. In particular, we are highly dependent on our executive
officers, especially Marc Hedrick, M.D., our Chief Executive Officer. Given his leadership, extensive technical, scientific, and financial expertise and
management and operational experience, if we were unable to retain the services of Dr. Hedrick for any reason, it would materially and adversely impact
our business and operations. Further, the loss of services of Dr. Hedrick or any other executive officer could result in product development delays or the
failure of our collaborations with current and future collaborators, which, in turn, may hurt our ability to develop and commercialize products and generate
revenue. We do not maintain key man life insurance on the lives of any of the members of our senior management. The loss of key personnel for any
reason or our inability to hire, retain, and motivate additional qualified personnel in the future could prevent us from sustaining or growing our business.
The loss of services of any of our personnel, including Dr. Hedrick, particularly for an extended period, would likely result in product development delays
or the failure of our collaborations with current and future collaborators, which, in turn, may impede or delay our ability to develop and commercialize
products and generate revenue. In addition, it could also result in difficulty to obtain additional funding for our development of products and our future
operations.
We face potential product liability exposure, and if successful claims are brought against us, we may incur substantial liability if our insurance
coverage for those claims is inadequate.
The clinical use of our product candidates exposes us to the risk of product liability claims. This risk exists even if a product or product candidate
is approved for commercial sale by applicable regulatory authorities and manufactured in facilities regulated by such authorities. Our product candidates
are designed to affect important bodily functions and processes. Any side effects, manufacturing defects, misuse, or abuse associated with our product
candidates could result in injury to a patient or even death. For example, rhenium (186Re) obisbemeda and 188RNL-BAM are cytotoxic, or toxic to living
cells, and, if incorrectly or defectively manufactured or labeled, or incorrectly dosed or otherwise used in a manner not contemplated by its label, could
result in patient harm and even death. In addition, a liability claim may be brought against us even if our product candidates merely appear to have caused
an injury.
Product liability claims may be brought against us by consumers, health care providers, pharmaceutical companies or others selling or otherwise
coming into contact with our products or product candidates, if approved, among others. If we cannot successfully defend ourselves against product
liability claims, we will incur substantial liabilities. In addition, regardless of merit or eventual outcome, product liability claims may result in:
•
•
•
•
•
•
•
•
•
the inability to commercialize our product candidates;
decreased demand for our product candidates, if approved;
impairment of our business reputation;
product recall or withdrawal from the market;
withdrawal of clinical trial participants;
costs of related litigation;
distraction of management’s attention from our primary business;
substantial monetary awards to patients or other claimants; or
loss of revenue.
We have obtained product liability insurance coverage for clinical trials with a $10 million per occurrence and annual aggregate coverage limit.
Our insurance coverage may not be sufficient to cover all of our product liability related expenses or losses and may not cover us for any expenses or losses
we may suffer. Moreover, insurance coverage is becoming increasingly expensive, and, in the future, we may not be able to maintain insurance coverage at
a reasonable cost, in sufficient amounts or upon adequate terms to protect us against losses due to product liability. If we determine that it is prudent to
increase our product liability coverage, we may be unable to obtain this increased product liability insurance on commercially reasonable terms or at all.
Large judgments have been awarded in class action or individual lawsuits based on drugs that had unanticipated side effects. A successful product liability
claim or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could decrease our
cash and have a material adverse effect on our business, results of operations, financial condition and prospects.
A failure to adequately protect private health information could result in severe harm to our reputation and subject us to significant liabilities, each of
which could have a material adverse effect on our business.
Throughout the clinical trial process, we may obtain the private health information of our trial subjects. There are a number of state, federal and
international laws protecting the privacy and security of health information and personal data. The Healthcare Information Portability and Accountability
Act (“HIPAA") imposes privacy, security, breach reporting obligations, and mandatory contractual terms on covered entity health care providers, health
plans, and health care clearinghouses, as well as their "business associates" – certain persons or covered entities that create, receive, maintain, or transmit
protected health information in connection with providing a specified service or performing a function on behalf of a covered entity. We could potentially
be subject to criminal penalties if we, our affiliates, or our agents knowingly use or disclose individually identifiable health information maintained by a
40
HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA. Most states have laws requiring notification of affected individuals and
state regulators (breach notification laws) in the event of a breach of personal information, which is a broader class of information than the health
information protected by HIPAA. Many state laws impose significant data security requirements, such as encryption or mandatory contractual terms to
ensure ongoing protection of personal information. Additionally, in California, the California Consumer Privacy Act (“CCPA”) establishes certain
requirements for data use and sharing transparency and creates new data privacy rights for California residents. The CCPA and its implementing
regulations have already been amended multiple times since their enactment. In November 2020, California voters approved the California Privacy Rights
Act (“CPRA”) ballot initiative which introduced significant amendments to the CCPA and established and funded a dedicated California privacy regulator,
the California Privacy Protection Agency (“CPPA”). The amendments introduced by the CPRA went into effect on January 1, 2023. Failure to comply
with the CCPA may result in, among other things, significant civil penalties and injunctive relief, or statutory or actual damages. In addition, California
residents have the right to bring a private right of action in connection with certain types of incidents. These claims may result in significant liability and
damages. Activities outside of the U.S. implicate local and national data protection standards, impose additional compliance requirements and generate
additional risks of enforcement for non-compliance. The European Union’s General Data Protection Regulation (“GDPR”), which imposes fines of up to
EUR 20 million or 4% of the annual global revenue of a noncompliant company, whichever is greater, Canada’s Personal Information Protection and
Electronic Documents Act and other data protection, privacy and similar national, state/provincial and local laws may also restrict the access, use and
disclosure of patient health information abroad. We may be required to expend significant capital and other resources to ensure ongoing compliance with
applicable privacy and data security laws, to protect against security breaches and hackers, or to alleviate problems caused by such breaches. Compliance
with these laws is difficult, constantly evolving, time consuming, and requires a flexible privacy framework and substantial resources. Compliance efforts
will likely be an increasing and substantial cost in the future.
We and our collaborators must comply with environmental laws and regulations, including those pertaining to use of hazardous and biological
materials in our business, and failure to comply with these laws and regulations could expose us to significant liabilities.
We and our collaborators are subject to various federal, state, and local environmental laws, rules and regulations, including those relating to
discharge of materials into the air, water and ground, those relating to manufacturing, storage, use, transportation and disposal of hazardous and biological
materials, and those relating to the health and safety of employees with respect to laboratory activities required for the development of our products and
activities. In particular, our nanomedicine products and processes involve the controlled storage, use and disposal of certain cytotoxic, or toxic to living
cells, materials. Even if we and these suppliers and collaborators comply with the standards prescribed by law and regulation, the risk of accidental
contamination or injury from hazardous materials, or other violations of applicable environmental laws, rules or regulations cannot be completely
eliminated. In the event of any violation of such laws, rules or regulations, we could be held liable for any damages that result, and any liability could
exceed the limits or fall outside the coverage of any insurance we may obtain and could exceed our financial resources. We may not be able to maintain
insurance on acceptable terms, or at all. We may incur significant costs in complying with environmental laws, rules and regulations.
Risks Relating to Our Intellectual Property
Our success depends in part on our ability to protect our intellectual property.
Our success depends in part on our ability to obtain and maintain patent, trademark, and trade secret protection of our platform technology and
current product candidates, including but not limited to our nanomedicine product candidates, including rhenium (186Re) obisbemeda and 188RNL-BAM,
as well as successfully defending our intellectual property against third-party challenges. Our ability to stop unauthorized third parties from making, using,
selling, offering to sell, or importing our platform technology and/or our product candidates is dependent upon the extent to which we have rights under
valid and enforceable patents or trade secrets that cover these activities.
The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately
protect our rights or permit us to gain or keep our competitive advantage. For example:
•
•
•
•
•
•
•
•
we, NanoTx, or UT Health Science Center at San Antonio, as the case may be, might not have been the first to file patent applications for
the covered inventions;
it is possible that our pending patent applications will not result in issued patents;
it is possible that there are dominating patents to our product candidates of which we are not aware;
it is possible that there are prior public disclosures that could invalidate our patents, of which we are not aware;
it is possible that others may circumvent our patents;
it is possible that there are unpublished applications or patent applications maintained in secrecy that may later issue with claims covering
our product candidates or technology similar to ours;
the claims of our patents or patent applications, if and when issued, may not cover our system or products, or our system or product
candidates;
our owned or in-licensed issued patents may not provide us with any competitive advantages, or may be narrowed in scope, be held invalid
or unenforceable as a result of legal administrative challenges by third parties;
41
•
•
•
•
•
others may be able to make or use compounds that are the same or similar to the rhenium (186Re) obisbemeda or 188RNL-BAM product
candidates but that are not covered by the claims of our patents;
we may not be able to detect infringement against our patents, which may be especially difficult for manufacturing processes or formulation
patents, such as the patents/applications related to rhenium (186Re) obisbemeda or 188 RNL-BAM;
the active pharmaceutical ingredient ("API") used in rhenium (186Re) obisbemeda, 186-Re, is routinely produced in nuclear reactors or at a
particle accelerator and is commercially available as 186-Re Sulfide for isotropic radiation synovectomy of medium sized joints and in
developing countries as 186-Re-HEDP for bone pain palliation;
we may not develop additional proprietary technologies for which we can obtain patent protection; or
the patents of others may have an adverse effect on our business.
The patent positions of pharmaceutical, biopharmaceutical and medical device companies can be highly uncertain and involve complex legal and
factual questions for which important legal principles remain unresolved. No consistent policy regarding the breadth of claims allowed in patents in these
fields has emerged to date in the United States. There have been recent changes regarding how patent laws are interpreted, and both the USPTO and
Congress have recently made significant changes to the patent system. There have been three U.S. Supreme Court decisions that now show a trend of the
Supreme Court which is distinctly negative on patents. The trend of these decisions along with resulting changes in patentability requirements being
implemented by the USPTO could make it increasingly difficult for us to obtain and maintain patents on our product candidates. We cannot accurately
predict future changes in the interpretation of patent laws or changes to patent laws which might be enacted into law. Those changes may materially affect
our patents, our ability to obtain patents and/or the patents and applications of our collaborators and licensors. The patent situation in these fields outside
the United States is even more uncertain. Changes in either the patent laws or in interpretations of patent laws in the United States and other countries may
diminish the value of our intellectual property or narrow the scope of our patent protection. Accordingly, we cannot predict the breadth of claims that may
be allowed or enforced in the patents we own or to which we have a license or third-party patents.
Intellectual property law outside the United States is uncertain and in many countries is currently undergoing review and revisions. The laws of
some countries do not protect our patent and other intellectual property rights to the same extent as United States laws. Third parties may attempt to oppose
the issuance of patents to us in foreign countries by initiating opposition proceedings. Opposition proceedings against any of our patent filings in a foreign
country could have an adverse effect on our corresponding patents that are issued or pending in the United States. It may be necessary or useful for us to
participate in proceedings to determine the validity of our patents or our competitors’ patents that have been issued in countries other than the United
States. This could result in substantial costs, divert our efforts and attention from other aspects of our business, and could have a material adverse effect on
our results of operations and financial condition.
Failure to obtain or maintain patent protection or protect trade secrets, for any reason (or third-party claims against our patents, trade secrets, or
proprietary rights, or our involvement in disputes over our patents, trade secrets, or proprietary rights, including involvement in litigation), could have a
substantial negative effect on our results of operations and financial condition.
We may not be able to protect our trade secrets.
We may rely on trade secrets to protect our technology, especially with respect to the nanomedicine products, as well as in areas where we do not
believe patent protection is appropriate or obtainable. Trade secrets are difficult to protect, and we have limited control over the protection of trade secrets
used by our collaborators and suppliers. Although we use reasonable efforts to protect our trade secrets, our employees, consultants, contractors, outside
scientific collaborators, and other advisors may unintentionally or willfully disclose our information to competitors. Enforcing a claim that a third party
illegally obtained and is using any of our trade secrets is expensive and time consuming, and the outcome is unpredictable. In addition, state laws in the
Unites States vary, and their courts as well as courts outside the United States are sometimes less willing to protect trade secrets. Moreover, our competitors
may independently develop equivalent knowledge, methods, and know-how. If our confidential or proprietary information is divulged to or acquired by
third parties, including our competitors, our competitive position in the marketplace will be harmed and our ability to successfully penetrate our target
markets could be severely compromised.
We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.
As is common in the device, biotechnology and pharmaceutical industries, we employ individuals who were previously employed at other
device, biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although no claims against us are currently
pending, we may be subject to claims that these employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary
information of their former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these
claims, litigation could result in substantial costs and be a distraction to management, which would adversely affect our financial condition.
42
We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights, and we may be
unable to protect our rights to our product candidates and technology.
Litigation may be necessary to enforce or confirm the ownership of any patents issued or licensed to us, or to determine the scope and validity of
third-party proprietary rights, which would result in substantial costs to us and diversion of effort on our part. If our competitors claim technology also
claimed by us and prepare and file patent applications in the United States, we may have to participate in interference proceedings declared by the USPTO
or a foreign patent office to determine priority of invention, which could result in substantial costs to and diversion of effort, even if the eventual outcome
is favorable to us. Any such litigation or interference proceeding, regardless of outcome, could be expensive and time-consuming.
Successful challenges to our patents through oppositions, reexamination proceedings or interference proceedings could result in a loss of patent
rights in the relevant jurisdiction. If we are unsuccessful in actions we bring against the patents of other parties, and it is determined that we infringe the
patents of third-parties, we may be subject to litigation, prevented from commercializing potential products in the relevant jurisdiction and/or may be
required to obtain licenses to those patents or develop or obtain alternative technologies, any of which could harm our business. Furthermore, if such
challenges to our patent rights are not resolved in our favor, we could be delayed or prevented from entering into new collaborations or from
commercializing certain products, which could adversely affect our business and results of operations.
Competitors or third parties may infringe on or upon our patents. We may be required to file patent infringement claims, which can be expensive
and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours is not valid or is unenforceable or that the third
party’s technology does not in fact infringe upon our patents. An adverse determination of any litigation or defense proceedings could put one or more of
our patents at risk of being invalidated or interpreted narrowly and could put our related pending patent applications at risk of not issuing.
Litigation may fail and, even if successful, may result in substantial costs and be a distraction to our management. We may not be able to prevent
misappropriation of our proprietary rights, particularly in countries outside the United States where patent rights may be more difficult to enforce. Further,
because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential or
sensitive information could be compromised by disclosure in the event of litigation. In addition, during the course of litigation there could be public
announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to
be negative, it could have a substantial adverse effect on the price of our common stock.
Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have
substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse
effect on our ability to raise the funds necessary to continue our operations or otherwise have a material adverse effect on our business, results of
operations, financial condition, and prospects.
If we are sued for infringing intellectual property rights of third parties, it will be costly and time consuming, and an unfavorable outcome in that
litigation would have a material adverse effect on our business.
Our commercial success will also depend, in part, on our ability to avoid infringing on patents issued by others. There may be issued patents of
third parties of which we are currently unaware, that are infringed or are alleged to be infringed by our product candidate or proprietary technologies.
Because some patent applications in the United States may be maintained in secrecy until the patents are issued, patent applications in the United States and
many foreign jurisdictions are typically not published until eighteen months after filing, and publications in the scientific literature often lag behind actual
discoveries, we cannot be certain that others have not filed patent applications for technology covered by our owned and in-licensed issued patents or our
pending applications, or that we or, if applicable, a licensor were the first to invent the technology. Our competitors may have filed, and may in the future
file, patent applications covering our product candidates or technology similar to ours. Any such patent application may have priority over our patent
applications or patents, which could further require us to obtain rights to issued patents covering such technologies.
We may be exposed to, or threatened with, future litigation by third parties having patent or other intellectual property rights alleging that our
product candidates and/or proprietary technologies infringe their intellectual property rights. These lawsuits are costly and could adversely affect our results
of operations and divert the attention of managerial and technical personnel. There is a risk that a court would decide that we or our commercialization
partners are infringing the third party’s patents and would order us or our partners to stop the activities covered by the patents. In addition, there is a risk
that a court will order us or our partners to pay the other party damages for having violated the other party’s patents.
If a third-party’s patent were found to cover our product candidates, proprietary technologies or their uses, we could be enjoined by a court and
required to pay damages and could be unable to commercialize our product candidates or use our proprietary technologies unless we or they obtained a
license to the patent. A license may not be available to us on acceptable terms, if at all. In addition, during litigation, the patent holder could obtain a
preliminary injunction or other equitable relief which could prohibit us from making, using or selling our product candidates, technologies or methods
pending a trial on the merits, which could be years away.
43
Risks Relating to the Securities Markets and an Investment in our Common Stock
Our stockholders may experience substantial dilution in the value of their investment if we issue additional shares of our capital stock, including in
connection with the sale or issuance of our common stock to Lincoln Park and the sale of the shares of common stock acquired by Lincoln Park and
the sale of our common stock by Canaccord.
Our charter allows us to issue up to 100,000,000 shares of our common stock and to issue and designate the rights of, without stockholder
approval, up to 5,000,000 shares of preferred stock. To raise additional capital, we may in the future sell additional shares of our common stock or other
securities convertible into or exchangeable for our common stock at prices that are lower than the prices paid by existing stockholders, and investors
purchasing shares or other securities in the future could have rights superior to existing stockholders, which could result in substantial dilution to the
interests of existing stockholders.
On August 2, 2022, we entered into the 2022 Purchase Agreement with Lincoln Park, pursuant to which Lincoln Park committed to purchase up
to $50.0 million (the “Commitment Amount”) of our common stock, subject to certain limitations. As consideration for Lincoln Park’s irrevocable
commitment to purchase shares of our common stock upon the terms of and subject to satisfaction of the conditions set forth in the 2022 Purchase
Agreement, upon execution of the 2022 Purchase Agreement, we agreed to pay Lincoln Park an initial commitment fee equal to 1.5% of the Commitment
Amount. The initial commitment fee was paid upon execution of the 2022 Purchase Agreement through the issuance of 492,698 shares of common stock
and $0.1 million in cash. An additional commitment fee equal to 2.5% of the remainder of the Commitment Amount will be paid if and when we sell over
$25.0 million of our common stock under the 2022 Purchase Agreement. The additional commitment fee may be paid in cash, common stock, or a
combination of cash and common stock.
The remaining shares of our common stock that may be issued under the 2022 Purchase Agreement may be sold by us to Lincoln Park at our
discretion from time to time over a 36-month period commencing August 17, 2022, subject to satisfaction of certain conditions. The purchase price for the
shares that we may sell to Lincoln Park under the 2022 Purchase Agreement will fluctuate based on the price of our common stock. Depending on market
liquidity at the time, sales of such shares may cause the trading price of our common stock to fall.
If and when we do sell shares to Lincoln Park, after Lincoln Park has acquired the shares, Lincoln Park may resell all or some of those shares at
any time or from time to time in its discretion. Therefore, sales to Lincoln Park by us could result in substantial dilution to the interests of other holders of
our common stock. Additionally, the sale of a substantial number of shares of our common stock to Lincoln Park, or the anticipation of such sales, could
make it more difficult for us to sell equity or equity-related securities in the future at a time and at a price that we might otherwise wish to effect sale.
On September 9, 2022, we entered into the September 2022 Distribution Agreement with Canaccord, pursuant to which we may issue and sell,
from time to time, shares of our common stock having an aggregate offering price of up to $5,000,000, depending on market demand, with Canaccord
acting as an agent for sales. Sales of the Shares may be made by any method permitted by law deemed to be an “at the market offering” as defined in Rule
415(a)(4) of the Securities Act, including, without limitation, sales made directly on or through the Nasdaq. Sales pursuant to the September 2022
Distribution Agreement, if any, could result in substantial dilution to the interest of other holders of our common stock. Depending on market liquidity at
the time, sales of such shares may cause the trading price of our common stock to fall.
Future sales of our common stock may depress our share price.
As of December 31, 2022, we had 33,601,373 shares of our common stock outstanding. Sales of a number of shares of common stock in the
public market could cause the market price of our common stock to decline. We may also sell additional common stock or securities convertible into or
exercisable or exchangeable for common stock in subsequent public or private offerings or other transactions, which may adversely affect the market price
of our common stock.
The market price of our common stock may be volatile and fluctuate significantly, which could result in substantial losses for stockholders.
The market price of our common stock has been, and may continue to be, subject to significant fluctuations. Among the factors that may cause
the market price of our common stock to fluctuate are the risks described in this “Risk Factors” section and other factors, including:
•
•
•
•
fluctuations in our operating results or the operating results of our competitors;
the outcome of clinical trials involving the use of our product candidates, including our sponsored trials;
changes in estimates of our financial results or recommendations by securities analysts;
variance in our financial performance from the expectations of securities analysts;
44
•
•
•
•
•
•
•
•
•
•
•
•
•
changes in the estimates of the future size and growth rate of our markets;
changes in accounting principles or changes in interpretations of existing principles, which could affect our financial results;
conditions and trends in the markets we currently serve or which we intend to target with our product candidates;
changes in general economic, industry and market conditions;
success of competitive products and services;
changes in market valuations or earnings of our competitors;
announcements of significant new products, contracts, acquisitions or strategic alliances by us or our competitors;
our continuing ability to list our securities on an established market or exchange;
the timing and outcome of regulatory reviews and approvals of our product candidates;
the commencement or outcome of litigation involving our company, our general industry or both;
changes in our capital structure, such as future issuances of securities or the incurrence of additional debt;
actual or expected sales of our common stock by the holders of our common stock; and
the trading volume of our common stock.
In addition, the financial markets may experience a loss of investor confidence or otherwise experience continued volatility and deterioration. A
loss of investor confidence may result in extreme price and volume fluctuations in our common stock that are unrelated or disproportionate to the operating
performance of our business, our financial condition or results of operations, which may materially harm the market price of our common stock and result
in substantial losses for stockholders. Further, although our common stock is traded on the Nasdaq, there is currently a limited market for our common
stock and an active market may never develop. An active trading market in our common stock may not develop.
We may be or become the target of securities litigation, which is costly and time-consuming to defend.
In the past, following periods of market volatility in the price of a company’s securities, the reporting of unfavorable news or continued decline
in a company’s stock price, security holders have often instituted class action litigation. The market value of our securities has steadily declined over the
past several years for a variety of reasons discussed elsewhere in this “Risk Factors” section, which heightens our litigation risk. If we face such litigation,
we could incur substantial legal costs and our management’s attention could be diverted from the operation of our business, causing our business to suffer.
Any adverse determination in any such litigation or any amounts paid to settle any such actual or threatened litigation could require that we make
significant payments.
We may issue debt and equity securities or securities convertible into equity securities, any of which may be senior to our common stock as to
distributions and in liquidation, which could negatively affect the value of our common stock.
In the future, we may attempt to increase our capital resources by entering into debt or debt-like financing that is unsecured or secured by up to
all of our assets, or by issuing additional debt or equity securities, which could include issuances of secured or unsecured commercial paper, medium-term
notes, senior notes, subordinated notes, guarantees, preferred stock, hybrid securities, or securities convertible into or exchangeable for equity securities. In
the event of our liquidation, our lenders and holders of our debt and preferred securities would receive distributions of our available assets before
distributions to the holders of our common stock. Because our decision to incur debt and issue securities in future offerings may be influenced by market
conditions and other factors beyond our control, we cannot predict or estimate the amount, timing or nature of our future offerings or debt financings.
Further, market conditions could require us to accept less favorable terms for the issuance of our securities in the future.
Our charter documents contain anti-takeover provisions.
Certain provisions of our amended and restated certificate of incorporation and amended and restated bylaws could discourage, delay or prevent
a merger, acquisition or other change of control that stockholders may consider favorable. These provisions could also prevent or frustrate attempts by our
stockholders to replace or remove members of our Board of Directors. Stockholders who wish to participate in these transactions may not have the
opportunity to do so. These provisions:
•
•
authorize our Board of Directors to issue without stockholder approval up to 5,000,000 shares of preferred stock, the rights of which will be
determined at the discretion of the Board of Directors;
require that stockholder actions must be effected at a duly called stockholder meeting and cannot be taken by written consent;
45
•
•
establish advance notice requirements for stockholder nominations to our Board of Directors or for stockholder proposals that can be acted
on at stockholder meetings; and
limit who may call stockholder meetings.
We are governed by the provisions of Section 203 of the Delaware General Corporation Law, which may, unless certain criteria are met, prohibit
large stockholders, in particular those owning 15% or more of the voting rights on our common stock, from merging or combining with us for a prescribed
period of time.
We presently do not intend to pay cash dividends on our common stock.
We have never paid cash dividends in the past, and we currently anticipate that no cash dividends will be paid on the common stock in the
foreseeable future. Furthermore, our Loan and Security Agreement with Oxford currently prohibits our issuance of cash dividends. This could make an
investment in our common stock inappropriate for some investors, and may serve to narrow our potential sources of additional capital. While our dividend
policy will be based on the operating results and capital needs of the business, it is anticipated that all earnings, if any, will be retained to finance the future
expansion of our business.
If securities and/or industry analysts fail to continue publishing research about our business, if they change their recommendations adversely, or if our
results of operations do not meet their expectations, our stock price and trading volume could decline.
The trading market for our common stock may be influenced by the research and reports that industry or securities analysts publish about us or
our business. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, we could lose visibility in the
financial markets, which in turn could cause our stock price or trading volume to decline. In addition, it is likely that in some future period our operating
results will be below the expectations of securities analysts or investors. If one or more of the analysts who cover us downgrade our stock, or if our results
of operations do not meet their expectations, our stock price could decline.
General Risk Factors
Increased information technology security threats and more sophisticated and targeted computer crime could pose a risk to our systems, networks, and
products.
Increased global information technology security threats and more sophisticated and targeted computer crime pose a risk to the security of our
systems and networks and the confidentiality, availability and integrity of our data and communications. While we attempt to mitigate these risks by
employing a number of measures, including employee refreshers, monitoring of our networks and systems, and maintenance of backup and protective
systems, our systems, networks and products remain potentially vulnerable to advanced persistent threats. Depending on their nature and scope, such
threats could potentially lead to the compromising of confidential information and communications, improper use of our systems and networks,
manipulation and destruction of data, defective products, production downtimes and operational disruptions, which in turn could adversely affect our
reputation, competitiveness and results of operations.
Item 1B. Unresolved Staff Comments
Not applicable.
Item 2. Properties
We have one lease agreement for our San Antonio, Texas locations. The lease for this property will expire in February 2025. We also lease
certain office space in Austin, Texas under a month-to-month operating lease agreement. We also have a lease agreement for office space in
Charlottesville, Virginia. We pay an aggregate of approximately $16,000 in rent per month for these properties.
Item 3. Legal Proceedings
On June 22, 2021, we were named as a defendant in an action brought by Lorem Vascular, Pte. Ltd. (“Lorem”) in the District Court for the
District of Delaware. The complaint alleged false representations were made to Lorem regarding the manufacturing facility in the United Kingdom (the
“UK Facility”) that Lorem purchased from us under the Asset and Equity Purchase Agreement, dated March 29, 2019, between us and Lorem (the “Lorem
Agreement”). Lorem also claimed that false representations were made regarding the UK Facility’s certification to sell and distribute devices in the
European Union and export such devices to China. In connection with these allegations, Lorem claimed entitlement to at least $6,000,000 in compensatory
damages and operational costs and expenses (collectively,
46
the “Lorem Claim”). On December 9, 2022, we entered into a settlement agreement (the “Settlement Agreement”) with Lorem to settle the Lorem Claim.
Under the terms of the Settlement Agreement, we made a payment to Lorem, and Lorem moved to dismiss the lawsuit with prejudice. The Settlement
Agreement released us from all claims made by Lorem. The parties to the Settlement Agreement recognized that it did not constitute an admission of
liability, wrongdoing, or any matter of fact or law. As of December 31, 2022, we accrued the settlement amount, as well as the accounts that we have
confirmed to be recoverable under our insurance claims on the matter. The net amount of $1.4 million that was not recoverable under our insurance has
been reflected as an expense in the year ended December 31, 2022. The full settlement amount was paid in January 2023. All legal costs incurred related to
the Lorem Claim were expensed. The Settlement was conditioned on the customary terms contained in the Settlement Agreement and was approved by the
Court and the case was dismissed on January 17, 2023.
Refer to Note 7 of the Financial Statements included in this Form 10-K.
Item 4. Mine Safety Disclosures
Not applicable.
47
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
PART II
Market Prices
Market Information
Our common stock is traded on the Nasdaq Capital Market under the symbol “PSTV”. As of February 17, 2023, we had approximately 16 record
holders of our common stock. Because many of our shares are held by brokers and other institutions on behalf of stockholders, we are unable to estimate
the total number of individual stockholders represented by these record holders.
Equity Compensation Plan Information
The following table gives information as of December 31, 2022 about shares of our common stock that may be issued upon the exercise of
outstanding options, and shares remaining available for issuance under all of our equity compensation plans:
Plan Category
Equity compensation plans not
approved by security
holders (1)
Equity compensation plans
approved by security
holders (2)
Total
Number of securities to be issued
upon exercise of outstanding
options and rights
(a)
Weighted-average exercise price
of outstanding options and rights
(b)
Number of securities remaining
available for future issuance under
equity compensation
plans (excluding securities reflected
in column(a))
(c)
160,095 $
13.42
90,389
1,014,921 $
1,175,016 $
3.14
4.54
2,635,717
2,726,106
(1)
(2)
Represents (i) options outstanding that were issued under the 2004 Stock Option and Stock Purchase Plan which expired in August 2004 and (ii)
the 2015 New Employee Incentive Plan.
See Notes to the Financial Statements included elsewhere herein for a description of our 2020 Stock Incentive Plan.
Material Features of the Amended and Restated 2015 New Employment Incentive Plan and the 2020 Stock Incentive Plan
We adopted the 2015 Plan on December 29, 2015 pursuant to Rule 5653(c)(4) of the Nasdaq. The 2015 Plan was subsequently amended by the
Board in May 2016 and January 2020.
Awards granted under the 2015 Plan were intended to constitute “employment inducement awards” under Nasdaq Listing Rule 5635(c)(4) and,
therefore, the 2015 Plan was intended to be exempt from the Nasdaq Listing Rules regarding stockholder approval of stock option and stock purchase
plans. The 2015 Plan provides for the grant of restricted stock unit awards, restricted stock awards, performance awards, unrestricted securities, stock-
equivalent units, stock appreciation units, securities or debentures convertible into common stock or other forms. These awards may be granted to
individuals who were then new employees, or were commencing employment with us or one of our subsidiaries following a bona fide period of non-
employment with us, and for whom such awards were granted as a material inducement to commencing employment with us or one of our subsidiaries.
The 2015 Plan is administered by the Compensation Committee. The plan administrator has discretion to take action under the 2015 Plan, such
as determining the purchase price, performance measures, any repurchase rights, as well as make adjustment to the terms of any Award to reflect, or related
to, such changes in our capital structure or distributions as we deem appropriate, including modification of performance goals, performance award
formulas, and performance periods. As of December 31, 2022, there were 90,389 shares of common stock remaining and available for issuance under the
2015 Plan.
On June 16, 2020, our stockholders approved our 2020 Stock Incentive Plan (the “2020 Plan”), which replaced the Company’s 2014 Equity
Incentive Plan. The 2020 Plan, as amended, provides for the issuance of up to 3,550,000 shares of common stock, plus the number of shares available for
issuance is increased to the extent that awards granted under the 2020 Plan and the 2014 Equity Incentive Plan are forfeited or expire (except as otherwise
provided in the 2020 Plan).
48
The 2020 Plan provides for the direct award or sale of shares of common stock (including restricted stock), the award of stock units and stock
appreciation rights, and the grant of both incentive stock options to purchase common stock intended to qualify for preferential tax treatment under Section
422 of the Code and nonstatutory stock options to purchase common stock that do not qualify for such treatment under the Code. All employees (including
officers) and directors of the Company or any subsidiary and any consultant who performs services for us or a subsidiary are eligible to purchase shares of
common stock and to receive awards of shares or grants of nonstatutory stock options, stock units and stock appreciation rights. Only employees are
eligible to receive grants of incentive stock options.
The 2020 Plan is administered by the Compensation Committee. Subject to the limitations set forth in the 2020 Plan, the Compensation
Committee has the authority to determine, among other things, to whom awards will be granted, the number of shares subject to awards, the term during
which an option, stock unit or stock appreciation right may be exercised and the rate at which the awards may vest or be earned, including any performance
criteria to which they may be subject. The Compensation Committee also has the authority to determine the consideration and methodology of payment for
awards.
Share Repurchase Program
On August 15, 2022, we announced that our Board of Directors had approved a share repurchase program pursuant to which we were authorized
to repurchase up to $2.0 million of our outstanding common stock. The timing and amount of any shares repurchased will be determined based on our
evaluation of market conditions and other factors. Repurchases may be made from time to time on the open market over the course of 12 months. We are
not obligated to acquire any shares and the program may be discontinued or suspended at any time. Through the date of filing of this Form 10-K, we have
not repurchased any of its common stock under this share repurchase program.
Item 6. [Reserved]
49
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Our Management’s Discussion and Analysis of Financial Condition and Results of Operations includes the following sections:
Overview that discusses our business and some of the relevant trends.
Results of Operations that includes a detailed discussion of our revenue and expenses.
Liquidity and Capital Resources which discusses key aspects of our statements of cash flows, changes in our financial position and our
financial commitments.
•
•
•
Overview
Plus Therapeutics, Inc. is a U.S. pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central
nervous system ("CNS") cancers. Our novel radioactive drug formulations and therapeutic candidates are designed to deliver safe and effective doses of
radiation to tumors. To achieve this, we have developed innovative approaches to drug formulation, including encapsulating radionuclides such as Rhenium
isotopes with nanoliposomes and microspheres. Our formulations are intended to achieve elevated patient absorbed radiation doses and extend retention
times such that the clearance of the isotope occurs after significant and essentially complete radiation decay, which will contribute and provide less normal
tissue/organ exposure and improved safety margins.
Traditional approaches to radiation therapy for cancer, such as external beam radiation, have many disadvantages including continuous treatment
for four to six weeks (which is onerous for patients), that the radiation damages healthy cells and tissue, and that the amount of radiation delivered is very
limited and, therefore, is frequently inadequate to fully destroy the cancer.
Our targeted radiotherapeutic platform and unique investigational drugs have the potential to overcome these disadvantages by directing higher,
more powerful radiation doses at the tumor—and only the tumor—potentially in a single treatment. By minimizing radiation exposure to healthy tissues
while simultaneously maximizing locoregional delivery and, thereby, efficacy, we hope to reduce the radiation toxicity for patients, improving their quality
of life and life expectancy. Our radiotherapeutic platform, combined with advances in surgery, nuclear medicine, interventional radiology, and radiation
oncology, affords us the opportunity to target a broad variety of cancer types.
Our lead radiotherapeutic candidate, rhenium (186Re) obisbemeda (formerly, “186RNL”), is designed specifically to CNS cancers including
recurrent glioblastoma ("GBM"), leptomeningeal metastases ("LM"), and pediatric brain cancers ("PBC") by direct localized delivery utilizing approved
standard-of-care tissue access such as with convection-enhanced delivery (“CED”) and intraventricular brain(Ommaya reservoir) catheters. Our recently
acquired radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (“188RNL-BAM”) is designed to treat many solid
organ cancers including primary and secondary liver cancers by intra-arterial injection.
Our headquarters and manufacturing facilities are in Texas and are in proximity to world-class cancer institutions and researchers. Our dedicated
team of engineers, physicians, scientists, and other professionals are committed to advancing our targeted radiotherapeutic technology for the benefit of
cancer patients and healthcare providers worldwide and our current pipeline is focused on treating rare and difficult-to-treat cancers with significant unmet
medical needs.
In addition to its headquarters in Austin, we have an established, GMP-validated research and development and manufacturing facility in San
Antonio, Texas, tailored to produce cGMP rhenium (186Re) obisbemeda. We have built a robust supply chain through strategic partnerships that enable the
development, manufacturing and future potential commercialization of our products. Our current supply chain and key partners are positioned to supply
cGMP rhenium (186Re) obisbemeda for ongoing and planned Phase 2 and Phase 3 clinical trials in patients with GBM, LM and PBC..
Pipeline
Our most advanced investigational drug, rhenium (186Re) obisbemeda, is a patented radiotherapy potentially useful for patients with CNS and
other cancers. Preclinical study data describing the use of rhenium (186Re) obisbemeda for several cancer targets have been published in peer-reviewed
journals and reported at a variety of medical society peer-reviewed meetings. Besides GBM, LM and PBC, rhenium (186Re) obisbemeda has been reported
to have potential applications for head and neck cancer, ovarian cancer, breast cancer and peritoneal metastases.
The Rhenium (186Re) Obisbemeda technology was part of a licensed radiotherapeutic portfolio that we acquired from NanoTx, Corp.
(“NanoTx”) on May 7, 2020. The licensed radiotherapeutic has been evaluated in preclinical studies for several cancer targets and we have an active $3.0
million award from U.S. National Institutes of Health/National Cancer Institute which is expected to provide financial support for the continued clinical
development of rhenium (186Re) obisbemeda for recurrent GBM through the completion of
50
a Phase 2 clinical trial, including enrollment of up to 55 patients. As of February 23, 2023, 26 patients have been treated in the Phase 1 clinical trial and the
Phase 2 clinical trial has been initiated with the first patient treated. In addition, we anticipate obtaining FDA IND approval for the ReSPECT-PBC clinical
trial for PBC in early 2023.
On August 29, 2022, we announced feedback from a Type C meeting with the FDA regarding Chemistry, Manufacturing and Controls (“CMC”)
practices. The meeting focused on our Current Good Manufacturing Practice (“cGMP”) clinical and commercial manufacturing process for our lead
investigational targeted radiotherapeutic, BMEDA-chelated Rhenium (186Re) Obisbemeda, for recurrent GBM.
The FDA indicated agreement with our proposed application of cGMP guidance for radiotherapeutics, small molecule drug products and
liposome drug products for our novel rhenium (186Re) obisbemeda in support of ongoing and future GBM clinical trials, manufacturing scale up, and
commercialization. Alignment with the FDA includes support of our proposed controls and release strategy for new drug substance and new drug product.
Because this product is identical for recurrent GBM and LM adult development and pediatric brain tumors, we believe this FDA alignment and feedback
will apply to rhenium (186Re) obisbemeda used in other clinical development programs, including LM and PBC.
Rhenium (186Re) obisbemeda versus External Beam Radiation Therapy for Recurrent GBM
Rhenium (186Re) obisbemeda is a novel injectable radiotherapy designed to deliver targeted, high dose radiation directly into GBM tumors in a
safe, effective, and convenient manner that may ultimately prolong patient survival. rhenium (186Re) obisbemeda is composed of the radionuclide Rhenium-
186 and a nanoliposomal carrier, and is infused in a highly targeted, controlled fashion, directly into the tumor via precision brain mapping and CED
catheters. Potential benefits of rhenium (186Re) obisbemeda compared to standard external beam radiotherapy or EBRT include:
•
•
•
•
•
The rhenium (186Re) obisbemeda radiation dose delivered to patients may be up to 20 times greater than what is possible with commonly
used external beam radiation therapy (“EBRT”), which, unlike EBRT and proton beam devices, spares normal tissue and the brain from
radiation exposure.
Rhenium (186Re) obisbemeda can be visualized in real-time during administration, possibly giving clinicians better control of radiation
dosing, distribution and retention.
Rhenium (186Re) obisbemeda potentially more effectively treats a bulk tumor and microscopic disease that has already invaded healthy
tissue.
Rhenium (186Re) obisbemeda is infused directly into the targeted tumor by CED catheter insertion using MRI guided software to avoid
critical patient neurological structures and neural pathways and also bypasses the blood brain barrier, which delivers the therapeutic product
where it is needed. Importantly, it reduces radiation exposure to healthy cells, in contrast to EBRT which passes through normal tissue to
reach the tumor, continuing its path through the tumor, hence being less targeted and selective.
Rhenium (186Re) obisbemeda is given during a single, short, in-patient hospital visit, and is available in all hospitals with nuclear medicine
and neurosurgery, while EBRT requires out-patient visits five days a week for approximately four to six weeks.
ReSPECT-GBM Trial for Recurrent GBM
Recurrent GBM is the most common, complex, and aggressive primary brain cancer in adults. In the U.S., there are more than 13,000 GBM
cases diagnosed and approximately 10,000 patients succumb to the disease each year. The average length of overall survival ("OS") for GBM patients is
eight months, with a one-year survival rate of 40.8% and a five-year survival rate of only 6.8% and these estimates varies and are lower in some
publications. GBM routinely presents with headaches, seizures, vision changes and other significant neurological complications, with a significant
compromise in quality of life. Despite the best available medical treatments, the disease remains incurable. Even after efforts to manage the presenting
signs and symptoms and completely resect the initial brain tumor, some microscopic disease almost always remains and tumor regrowth occurs within
months. Approximately 90% or more of patients with primary GBM experience tumor recurrence. Complete surgical removal of GBM is usually not
possible and GBM is often resistant or quickly develops resistance to most available current and investigational therapies. Even today, the treatment of
GBM remains a significant challenge and it has been nearly a decade since the FDA approved a new therapy for this disease, and these more recent
approvals have not improved GBM patients OS over past decades, and a significant unmet medical need persists.
For recurrent GBM, there are few currently approved treatments, which in the aggregate, provide only marginal survival benefit. Furthermore,
these therapies are associated with significant side effects, which limit dosing and prolonged use.
While EBRT has been shown to be safe and has temporary efficacy in many malignancies including GBM, typically at absorbed, fractionated
radiation dose of ~30 Gray in GBM, this maximum possible administered dose is always limited by toxicity to the normal tissues surrounding the
malignancy and because EBRT requires fractionation to manage toxicity and maximum EBRT limits are typically reached before long-term efficacy
reached. Because of this limitation EBRT cannot provide a cure or long term control of
51
GBM and GBM always recurs within months after EBRT. In contrast, locally delivered and targeted radiopharmaceuticals that precisely deliver radiation in
the form of beta particles such as Iodine-131 for thyroid cancer, are known to be safe and effective and minimize exposure to normal cells and tissues
especially with optimal targeting and avoidance of normal tissue. The locally delivered rhenium (186Re) obisbemeda is designed for and provides patient
tolerability and safety. Though no head-to-head trial with chemo, immune, EBRT or systemic radiopharmaceutical products have been conducted, patient
tolerability and safety considerations have been reported as expected.
Interim results from our ongoing Phase 1/2a ReSPECT-GBM trial (ClinicalTrials.gov NCT01906385) show that the beta particle energy from our
lead investigational drug rhenium (186Re) obisbemeda has provided preliminary positive data and utility in treating GBM and potential other malignancies.
More specifically, the preliminary data from our Phase 1/2a ReSPECT-GBM trial suggests that radiation, in the form of high energy beta particles or
electrons, can be effective against GBM. Thus far, we have been able to deliver up to 740 Gy of absorbed radiation to tumor tissue in humans, without
significant or dose limiting toxicities and with what we believe has the capability to go higher if required. In comparison, current EBRT protocols for
recurrent GBM typically recommend a total maximum radiation dose of about ~30-35 Gray.
In September 2020, the FDA granted both Orphan Drug designation and Fast Track designations to rhenium (186Re) obisbemeda for the treatment
of patients with GBM. In November 2021, the FDA granted Fast Track designation for rhenium (186Re) obisbemeda for the treatment of LM.
Rhenium (186Re) obisbemeda is under clinical investigation in a multicenter, sequential cohort, open-label, volume and dose escalation study of the
safety, tolerability, and distribution of rhenium (186Re) obisbemeda given by CED catheters to patients with recurrent or progressive malignant glioma
after standard surgical, radiation, and/or chemotherapy treatment (NCT01906385). The study uses a standard, modified 3x3 Fibonacci dose escalation,
followed by a planned Phase 2 expansion trial at the maximum tolerated dose (“MTD”) / maximum feasible dose (“MFD”) or non-dose limiting toxicity
(“DLT”) if MTD is not reached, to determine efficacy. The trial is funded through Phase 2 in large part by a NIH/NCI grant. These investigations have not
reached DLT or MTD/MFD and the study is in its eighth dosing administration cohort. Due to the observation of a preliminary efficacy signal, we have
initiated in parallel a Phase 2, non-DLT dose trial pursuant to the currently funded NIH/NCI Grant. This trial will begin at the current non-DLT rhenium
(186Re) obisbemeda dose and will expand exploring higher radiation doses in larger volumes to treat larger tumors. Additionally, two or more rhenium
(186Re) obisbemeda administrations, if indicated, will be evaluated, and reviewed with the FDA, as well as expanded safety, imaging and efficacy data to
support a planned future registrational trial. This in turn will provide a path to a registration trial.
On September 6, 2022, we announced a summary of our Type C clinical meeting with the FDA that focused on the ReSPECT-GBM trial. The
FDA agreed with us that the ReSPECT-GBM clinical trial should proceed to the planned Phase 2. The key focus areas of clinical investigation of the Phase
2 trial will be 1) further dose exploration, including both increased dosing and multiple doses, and 2) collecting additional safety and efficacy data to
inform the design of a future registrational trial. Because no DLT administered doses were observed, the FDA and we also agreed to continue to dose
cohort eight. There was further agreement with the FDA that in a planned future registrational trial, overall survival should be used as the primary endpoint.
We agreed with the FDA to hold future meeting(s) to consider the use of external data to augment the use of a control arm in the registrational trial.
At the European Society for Medical Oncology Congress, held September 9 to 13, 2022, we presented updated data from the ReSPECT-GBM
trial, which evaluated 23 adult patients with recurrent GBM across eight cohorts of increasing dose and treated over a seven-year period. Key findings
include:
•
•
•
•
No DLTs have been observed and the procedure was very well tolerated with a strong safety profile. Minimal systemic radiation has been
observed and the majority of adverse events have been mild or moderate and considered causally unrelated to rhenium (186Re) obisbemeda.
Improved median overall survival (“OS”) rates correlated with the absorbed radiation tumor dose. When patients were stratified based on
receipt of either a therapeutic or a subtherapeutic absorbed dose of radiation to the tumor, a statistically significant improvement in survival
was observed. Specifically, patients receiving a therapeutic absorbed radiation dose (>100 Gray) had a median OS of 22.9 months (95% CI of
8.8-42.3) compared to those receiving a subtherapeutic absorbed radiation dose (<100 Gray) whose median OS was 5.6 months (95% CI of
1.6-9.4). Currently, three patients remain alive, all in the therapeutic group.
Feasibility to deliver up to at least 20 times more radiation to the tumor than the standard of care, EBRT. A maximum of 32.2 mCi in 12.3
mL of volume has been delivered in and near the tumors, and a maximum average absorbed dose of radiation of 740 Gray was successfully
administered in a single procedure.
Average absorbed radiation dose to the tumor increased in latter dosing cohorts with greater administered doses of rhenium (186Re)
obisbemeda β-particle radiation, larger drug CED infusate volumes, more catheters used (up to four versus one),
52
and higher convection flow rates. In cohorts five and later, 82% of patients received a therapeutic radiation dose of >100Gray.
•
Single-photon emission computerized tomography and (SPECT)/CT scanning were used during treatment to compute tumor coverage and
dosimetry. Post treatment imaging analyses, including MRI, relative cerebral blood volume (rCBV) analysis and treatment response
assessment maps (TRAMs) correlated with a positive tumor response and confirmed the presence of pseudoprogression in patients with
positive tumor responses.
At the Society for Neuro-Oncology Annual Meeting in November 2022, we presented patient data, which at that time included the results for 24
patients treated in the ReSPECT-GBM trial. As of the date of this report, rhenium (186Re) obisbemeda given by CED in recurrent GBM patients was
observed in the trial to be feasible and well tolerated. Across all subjects in the first eight cohorts (n=24), the median absorbed dose to the tumor volume
increased as cohorts evaluated progressed, with patients receiving >100Gy absorbed dose showing significant survival benefit versus patients receiving
<100Gy absorbed dose. Importantly, in a subset of patients where tumor coverage was greater than or equal to 75%, the median absorbed dose was 405 Gy
(range 146-593). By contrast, given the protocol dose escalation design where early cohorts often had much lower doses, the absorbed doses were adequate
for small tumors even with low doses. Small, absorbed doses to specific organs and whole body, are typically well-tolerated. Based on observed and
reported patient protocol activity and all available adverse event (AE) data, rhenium (186Re) obisbemeda has been well-tolerated with AEs related to CED
insertion that were limited and fully recovered. No AEs with an outcome of death, study discontinuation or study drug-related serious AEs have been
reported. All AEs have been mild or moderate (Grade 1 or 2) in intensity, except for one case of Grade 3 vasogenic edema, which was considered by the
investigator to be unrelated to the study drug. AEs considered by the investigator to be at least possibly related to rhenium (186Re) obisbemeda have
included Grade 1 to 2 skin and soft tissue infection, intermittent cephalgia, neck and jaw pain, nausea with or without vomiting, constipation, increased
lethargy, difficulty walking (gait disturbance), worsening double vision, and dysuria. Scalp discomfort and tenderness related to the surgical procedure has
also been reported.
In the 24 subjects with recurrent GBM receiving a single administration of rhenium (186Re) obisbemeda, the median OS for all 24 patients as of
November 2022 was 8.8 months, with four patients alive. In a subset of 13 patients receiving a presumed therapeutic absorbed radiation dose to the tumor
(>100 Gy), the mean OS was 22.9 months, respectively, with seven of 13 patients alive. In contrast, in nine patients receiving a presumed sub-therapeutic
absorbed radiation dose to the tumor (<100 Gy), the mean and median OS was 23.9 and 22.3 weeks, respectively. A Kaplan-Meier curve comparing
patients with presumed therapeutic (>100 Gy) versus sub-therapeutic (<100 Gy) radiation dose to the tumor showed a statistically significant difference
between the groups (p=.0003). It is hypothesized that targeted infusion of rhenium (186Re) obisbemeda into the tumor by CED, which exposure and
potential toxicity and concentrates radiation to the tumor and surrounding region of interest. On January 18, 2023, we announced that the first patient has
been dosed in the ReSPECT-GBM Phase 2b dose expansion clinical trial evaluating rhenium obisbemeda for the treatment of recurrent GBM. The Phase 2b
trial is expected to enroll up to 31 total patients with small- to medium-sized tumors in approximately 24 months.
ReSPECT-LM Clinical Trial for Leptomeningeal Metastases (LM)
LM is a rare complication of cancer in which the disease spreads to the membranes (meninges) surrounding the brain and spinal cord. The
incidence of LM is growing and occurs in approximately 5%, or more, of people with late-stage cancer, or 110,000 people in the U.S. each year. It is highly
lethal with an average one-year survival of just 7%. All solid cancers have the potential to spread to the central nervous system and leptomeninges resulting
in LM.
The ReSPECT-LM Phase 1 clinical trial (ClinicalTrials.gov NCT05034497) is predicated in part upon preclinical studies in which tolerance to
doses of rhenium (186Re) obisbemeda as high as 1,075 Gy was shown in animal models with LM without significant observed toxicity. Furthermore,
treatment led to a marked reduction in tumor burden in both C6 and MDA-231 LM models.
Upon receiving acceptance of our Investigational New Drug application and Fast Track designation by the FDA for rhenium (186Re)
obisbemeda for the treatment of LM, we initiated the trial and began screening patients for the ReSPECT-LM Phase 1 clinical trial in Q4 2021.
The ReSPECT-LM is a multi-center, sequential cohort, open-label, dose escalation study evaluating the safety, tolerability, and efficacy of a
single-dose application of rhenium (186Re) obisbemeda administered through intrathecal infusion to the ventricle of patients with LM after standard
surgical, radiation, and/or chemotherapy treatment. The primary endpoint of the study is the incidence and severity of adverse events and dose limiting
toxicities.
On March 31, 2022, we entered into a Sales Order (the “Sales Order”) with Medidata Solutions, Inc. (“Medidata”), pursuant to which Medidata
built a Synthetic Control Arm® (SCA) platform that facilitates the use of historical clinical data to incorporate into our Phase 2 clinical trial of rhenium
(186Re) obisbemeda in GBM. The Sales Order had a term of six (6) months. Work under this Sales Order has been completed.
53
On September 19, 2022, we entered into a Cancer Research Grant Contract (the “CPRIT Contract”), effective as of August 31, 2022, with
CPRIT, pursuant to which CPRIT will provide us a grant of up to $17.6 million (the “CPRIT Grant”) over a three-year period to fund the continued
development of rhenium (186Re) obisbemeda for the treatment of patients with LM through Phase 2 of the ReSPECT LM clinical trial. The CPRIT Grant is
subject to customary CPRIT funding conditions, including, but not limited to, a matching fund requirement (one dollar from us for every two dollars
awarded by CPRIT), revenue sharing obligations upon commercialization of rhenium (186Re) obisbemeda based on specific dollar thresholds until CPRIT
receives the aggregate amount of 400% of the proceeds awarded under the CPRIT Grant, and certain reporting requirements.
Interim results showed that treatment with rhenium (186Re) obisbemeda decreased CSF tumor cell count/ml and was well tolerated by all four
LM patients. rhenium (186Re) obisbemeda was administered through a standard intraventricular catheter (Ommaya Reservoir), redistributed throughout the
CSF, and was retained in the leptomeninges at least through day seven. All four patients have shown prompt and durable rhenium (186Re) obisbemeda
distribution throughout the subarachnoid space. A single dose of rhenium (186Re) obisbemeda at 6.6 millicurie ("mCi") in 5.0 mL, in Cohort 1, achieved
absorbed doses of 18.7 to 29.0 Gy to the ventricles and cranial subarachnoid spaces, respectively. Cohort 2 is in progress with a 13.2 mCi administered
dose in 5ml and was also well tolerated. All four patients experienced a decreased CSF cell count ranging from 46% to 92%. Three patients remain alive, as
the first patient in Cohort 1 has died, due to primary tumor progression. A single dose of rhenium (186Re) obisbemeda was well-tolerated with limited AEs
and no patients had definite treatment related AEs. Additionally, there were no AEs greater than Grade 1 that were even possibly related to treatment.
Cohort 2 was completed on January 26, 2023 and Cohort 3 is expected to enroll in late February/early March 2023 after a protocol defined follow-up 28-
day period. Besides continued dose escalation, repeated dosing will be explored.
ReSPECT-PBC Clinical Trial for Pediatric Brain Cancer
In August 2021, we announced plans for treating pediatric brain cancer at the 2021 American Association of Neurological Surgeons (AANS)
Annual Scientific Meeting. In July 2021, we reported that we had received FDA feedback pertaining to a pre-IND meeting briefing package in which the
FDA stated that we are not required to perform any additional preclinical or toxicology studies.
It is estimated that in 2022 there were approximately 25,050 new brain and other central nervous system cases diagnosed (1.3% of all cancers)
and 18,280 deaths (3.0% of all cancer related deaths). The average annual age adjusted mortality rate (“AAAMR”) for children aged 0-14 for malignant
brain (and other CNS) tumors is 0.71/100,000, making it the most common cause of death and cancer death in this age group. The 2021 World Health
Organization Classification of CNS Tumors (“WHO CNS5”) classifies gliomas, glioneuronal tumors, and neuronal tumors into six different families: (1)
adult-type diffuse gliomas; (2) pediatric-type diffuse low-grade gliomas; (3) pediatric-type diffuse high-grade gliomas (“HGG”); (4) circumscribed
astrocytic gliomas; (5) glioneuronal and neuronal tumors; and (6) ependymomas.
Since the initial FDA feedback and receiving important adult GBM data and experience with rhenium (186Re) obisbemeda and follow-up
communications with the FDA, we plan to submit a pediatric brain tumor IND to investigate the use of rhenium (186Re) obisbemeda in two pediatric brain
cancers in early 2023.
Pediatric high-grade gliomas can be found almost anywhere within the CNS; however, they are most commonly found within the supratentorium.
The highest incidence of supratentorial, high-grade gliomas in pediatrics appears to occur in children aged 15 to 19 years, with a median age of
approximately nine years. Overall, pediatric high grade glioma confers a three-year progression free survival (“PFS”) of 11 ± 3% and three-year overall
survival (“OS”) of 22% ±5%. One-year PFS is as low as 40% in recent trials. Ependymomas are slow-growing central nervous system tumors that involve
the ventricular system. Diagnosis is based on MRI and biopsy and survival rate depends on tumor grade and how much of the tumor can be removed.
Grade II pathology was associated with significantly improved OS compared to Grade III (anaplastic) pathology (five-year OS = 71 ± 5% vs. 57 ± 10%; p
= 0.026). Gross total resection compared to subtotal resection was associated with significantly improved OS (five-year OS = 75 ± 5% vs. 54 ± 8%; p =
0.002).
Overall, pediatric HGG and ependymoma are extremely difficult-to-treat pediatric brain tumors, frequently aggressive, and in recurrent settings,
carry an extremely poor prognosis.
Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere Technology
In January 2022, we announced that we licensed Biodegradable Alginate Microsphere (“BAM”) patents and technology from The University of
Texas Health Science Center at San Antonio (“UT Health Science Center at San Antonio”) to expand our tumor targeting capabilities and precision
radiotherapeutics pipeline. We intend to combine our Rhenium NanoLiposome technology with the BAM technology to create a novel radioembolization
technology. Initially, we intend to utilize the Rhenium-188 isotope, 188RNL-BAM for the intra-arterial embolization and local delivery of a high dose of
targeted radiation for a variety of solid organ cancers such as hepatocellular cancer, hepatic metastases, pancreatic cancer and many others.
54
Preclinical data from an ex vivo embolization experiment in which Technetium99m-BAM was intra-arterially delivered to a bovine kidney
perfusion model was presented at the recent 2021 Society of Interventional Radiology (“SIR”) Annual Scientific Meeting. The study concluded that the
technology required for radiolabeling BAM could successfully deliver, embolize and retain radiation in the target organ. 188RNL-BAM is a preclinical
investigational drug we intend to further develop and move into clinical trials. Specifically, in 2022 we transferred the 188RNL-BAM technology from UT
Health Science Center at San Antonio, and began planning to develop the drug product and complete early preclinical studies to support a future FDA IND
submission. Our intended initial clinical target is liver cancer which is the sixth most common and third deadliest cancer worldwide. It is a rare disease with
increasing U.S. annual incidence (42,000) and deaths (30,000).
Recent Developments
Grant Agreement with CPRIT
On September 19, 2022, we entered into a Cancer Research Grant Contract (the “CPRIT Contract”), effective as of August 31, 2022, with
CPRIT, pursuant to which CPRIT will provide us a grant of up to $17.6 million (the “CPRIT Grant”) over a three-year period to fund the continued
development of rhenium (186Re) obisbemeda for the treatment of patients with LM. The CPRIT Grant is subject to customary CPRIT funding conditions,
including, but not limited to, a matching fund requirement (one dollar from Plus Therapeutics for every two dollars awarded by CPRIT), revenue sharing
obligations upon commercialization of rhenium (186Re) obisbemeda based on specific dollar thresholds until CPRIT receives the aggregate amount of 400%
of the proceeds awarded under the CPRIT Grant, and certain reporting requirements.
Services Agreement and Statement of Work with Biocept
On June 22, 2022, we announced a multi-year laboratory services agreement with Biocept, Inc. (“Biocept”) to employ their cerebrospinal fluid
(“CSF”) assay, CNSide, in Plus Therapeutics’ ReSPECT-LM Phase 1/2a dose-escalation trial of Rhenium-186 NanoLiposome for the treatment of patients
with (“LM”).
Services Agreement and Sales Order with Medidata
On March 31, 2022, we entered into a Sales Order (the “Sales Order”) with Medidata Solutions, Inc. (“Medidata”), pursuant to which Medidata
will build a Synthetic Control Arm® (SCA) platform that facilitates the use of historical clinical data to incorporate into our Phase 2 clinical trial of
rhenium (186Re) obisbemeda in GBM. The Sales Order had a term of six (6) months. Work under this Sales Order has been completed.
UT Health Science Center San Antonio (UTHSCSA) License Agreement
On December 31, 2021, we entered into an exclusive license agreement with UT Health Science Center at San Antonio for the global rights to
develop and commercialize 188RNL-BAM. Under the license agreement with UT Health Science Center at San Antonio, we are required to use commercial
reasonable efforts to develop the 188RNL-BAM product candidate acquired under the license agreement. Further, we are subject to future milestone, earn-
out and other payments to UT Health Science Center at San Antonio all of which are tied to our commercialization and sale activities for product
candidates.
Recent Financings
Refer to the “Liquidly and Capital Resources” section below for information on our recent financings.
Results of Operations
Grant Revenue
We recognized $0.2 million of grant revenue during the year ended December 31, 2022, which represents CPRIT's share of the costs incurred for
our rhenium (186Re) obisbemeda development for the treatment of patients with LM.
Research and development expenses
Research and development expenses include costs associated with the design, development, testing, and enhancement of our product candidates,
payment of regulatory fees, laboratory supplies, pre-clinical studies, and clinical studies.
The following table summarizes the components of our research and development expenses for the years ended December 31, 2022 and 2021 (in
thousands):
Research and development
Share-based compensation
Total research and development expenses
55
Years ended December 31,
2021
2022
$
$
9,611 $
87
9,698 $
5,248
75
5,323
The increase in research and development expenses of $4.4 million for the year ended December 31, 2022 as compared to the same period in
2021 was due primarily to an increase of $1.6 million in development costs relating to the development of cGMP rhenium (186Re) obisbemeda drug, an
increase of $1.6 million in other expenses which includes the development of the SCA, an increase of $0.8 million related to personnel related expenses, an
increase of $0.3 million in licensing payments under the NanoTx agreement for grant revenue received (Note 7), and an increase of $0.1 million in
depreciation expenses.
We expect aggregate research and development expenditures to remain consistent during 2023 as compared to the year ended December 31,
2022, due to an increase in licensing payments offset by reduced research and development spend.
General and administrative expenses
General and administrative expenses include costs for administrative personnel, legal and other professional expenses, and general corporate
expenses. The following table summarizes the general and administrative expenses for the years ended December 31, 2022 and 2021 (in thousands):
General and administrative
Share-based compensation
Total general and administrative expenses
Years ended December 31,
2021
2022
$
$
9,719 $
519
10,238 $
6,322
531
6,853
General and administrative expenses increased by $3.4 million during the year ended December 31, 2022, as compared to the same period in
2021, primarily due to $1.4 million settlement cost for Lorem claim (Note 6 of the financial statements), an increase of $1.5 million in legal fees and other
professional expenses due to increased costs related to Lorem litigation, an increase of $0.2 million of personnel expenses and an increase of $0.3 million
in travel and other expenses.
We expect general and administrative expenditures to remain generally consistent in 2023 as compared with the year ended December 31, 2022,
exclusive of the impact of the one-time legal settlement costs and settlement related legal expenses in 2022.
Share-based compensation expenses
Share-based compensation expenses include charges related to options and restricted stock awards issued to employees, directors and non-
employees. We measure share-based compensation expenses based on the grant-date fair value of any awards granted to our employees. Such expense is
recognized over the requisite service period.
The following table summarizes the components of our share-based compensation expenses for the years ended December 31, 2022 and 2021 (in
thousands):
Research and development
General and administrative
Total share-based compensation
Years ended December 31,
2021
2022
$
$
87 $
519
606 $
75
531
606
Our share-based compensation expenses, which are impacted by grants of share-based options, vesting schedule of such grants, as well as grant-
date fair value of share-based awards, remained consistent from 2021 to 2022.
Other Income (Expense)
The following table summarizes interest income, interest expense, and other income and expense for the years ended December 31, 2022 and
2021 (in thousands):
Interest income
Interest expense
Change in fair value of liability instruments
Total
56
Years ended December 31,
2021
2022
147 $
(711 )
1
(563 ) $
19
(932 )
6
(907 )
$
$
The decrease in interest expense for the year ended December 31, 2022 as compared to the same period in 2021 was primarily due to the
repayments of debt principal of $1.6 million in 2022 and $0.3 million in 2021, respectively.
We expect interest expense in 2023 to decrease as compared with 2022 due to scheduled debt principal repayments which began on November 1,
2021.
Liquidity and Capital Resources
Short-term and long-term liquidity
The following is a summary of our key liquidity measures at December 31, 2022 and 2021 (in thousands):
Cash and cash equivalents
Current assets
Current liabilities
Working capital
As of December 31,
2022
2021
18,120 $
18,400
21,817 $
11,852
9,965 $
19,724
5,870
13,854
$
$
$
For the periods presented, operating losses have been funded primarily from outside sources of invested capital in our common stock. We believe
that our cash and cash equivalents of $18.1 million at December 31, 2022 will enable us to fund our current and planned operations for at least the next
twelve months and beyond from the date our financial statements were issued.
We have had, and we will continue to have, an ongoing need to raise additional cash from outside sources to fund our future clinical development
programs and other operations. Our inability to raise additional cash would have a material and adverse impact on operations and would cause us to default
on our loan.
On September 19, 2022, we entered into the CPRIT Contract, pursuant to which CPRIT will provide us with the CPRIT Grant of $17.6 million
subject to the terms of the CPRIT Contract, to fund approximately two-thirds of the continued development of rhenium (186Re) obisbemeda for the
treatment of patients with LM.
On September 9, 2022, we entered into an Equity Distribution Agreement (the “September 2022 Distribution Agreement”) with Canaccord
Genuity LLC ("Canaccord”), pursuant to which we may issue and sell, from time to time, shares of our common stock having an aggregate offering price
of up to $5,000,000, depending on market demand, with Canaccord acting as an agent for sales. Sales of our common stock may be made by any method
permitted by law deemed to be an “at the market offering” as defined in Rule 415(a)(4) of the Securities Act of 1933, as amended (the “Securities Act”),
including, without limitation, sales made directly on or through the NASDAQ Capital Market. Canaccord will use its commercially reasonable efforts to
sell common stock that we requested to be sold on our behalf, consistent with Canaccord's normal trading and sales practices, under the terms and subject
to the conditions set forth in the September 2022 Distribution Agreement. We will pay Canaccord a commission of up to 3.0% of the gross sale of shares of
common stock. We have no obligation to sell any of our common stock. We may instruct Canaccord not to sell any common stock if the sales cannot be
effected at or above the price designated by us from time to time and we may at any time suspend sales pursuant to the September 2022 Distribution
Agreement. During the period from September 9, 2022 to December 31, 2022, we issued 1,031,371 shares under the September 2022 Distribution
Agreement for net proceeds of approximately $0.6 million. From January 1, 2023 to the date of filing of this Form 10-K, we issued 1,812,785 shares under
the September 2022 Distribution Agreement for net proceeds of approximately $0.7 million.
On August 2, 2022, we entered into a purchase agreement (the “2022 Purchase Agreement”) and registration rights agreement pursuant to which
Lincoln Park committed to purchase up to $50.0 million shares of our common stock. Under the terms and subject to the conditions of the 2022 Purchase
Agreement, we have the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase up to $50.0 million shares of our
common stock, provided that we cannot sell more than 57.5 million shares pursuant to the 2022 Purchase Agreement. Sales of common stock by us are
subject to certain limitations, and can occur from time to time, at our sole discretion, over the 36-month period commencing on August 17, 2022, subject to
the satisfaction of certain conditions. Actual sales of shares of common stock to Lincoln Park under the 2022 Purchase Agreement depend on a variety of
factors to be determined by us from time to time, including, among others, market conditions, the trading price of the common stock and determinations by
us as to the appropriate sources of funding for us and our operations. As consideration for Lincoln Park’s irrevocable commitment to purchase shares of our
common stock upon the terms of and subject to satisfaction of the conditions set forth in the Purchase Agreement, we paid $0.1 million in cash as an Initial
Commitment Fee and issued 492,698 Commitment Shares to Lincoln Park in consideration for its commitment to purchase shares of our common stock at
our direction under the Purchase Agreement.
57
On August 17, 2022, a registration statement was declared effective covering the resale of up to 9,500,000 shares of our common stock
comprised of (i) the 492,698 Commitment Shares, and (ii) up to 9,007,302 shares that we have reserved for issuance and sale to Lincoln Park under the
Purchase Agreement. An additional commitment fee equal to 2.5% of the remainder of the $50 million will be paid if and when we sell over $25.0 million
of our common stock under the 2022 Purchase Agreement. The additional commitment fee may be paid in cash, common stock, or a combination thereof.
We cannot sell more shares under the 2022 Purchase Agreement without registering additional shares.
During the period from August 17, 2022 to December 31, 2022, we issued 4,000,000 shares under the 2022 Purchase Agreement for net proceeds
of approximately $3.2 million. From January 1, 2023 to the date of filing of this Form 10-K, we did not issue any shares under the 2022 Purchase
Agreement.
On January 14, 2022, we entered into an Equity Distribution Agreement (the “January 2022 Distribution Agreement”) with Canaccord, pursuant
to which we could issue and sell, from time to time, shares of our common stock in “at the market” offerings, having an aggregate offering price of up to
$5,000,000, depending on market demand, with Canaccord acting as an agent for sales. During the year ended December 31, 2022, we issued 6,902,279
shares under the January 2022 Distribution Agreement for net proceeds of approximately $4.8 million. The January 2022 Distribution Agreement was
terminated after all available registered shares were fully utilized.
On October 23, 2020, we entered into an Equity Distribution Agreement (the “2020 Distribution Agreement”) with Canaccord, pursuant to which
we could issue and sell, from time to time, shares of our common stock in “at the market” offerings, having an aggregate offering price of up to
$10,000,000, depending on market demand, with Canaccord acting as an agent for sales. During 2021, we issued 2,179,193 shares under the 2020
Distribution Agreement for net proceeds of $6.3 million. The 2020 Distribution Agreement has been terminated.
On September 30, 2020, we entered into the 2020 Purchase Agreement and a registration rights agreement with Lincoln Park, pursuant to which
Lincoln Park committed to purchase up to $25.0 million of our common stock. During 2021, we issued 5,685,186 shares of our common stock under the
2020 Purchase Agreement for total proceeds of $12.5 million. During the year ended December 31, 2022, we issued 5,665,000 shares of common stock for
net proceeds of approximately $7.0 million under the 2020 Purchase Agreement. The 2020 Purchase Agreement has been terminated.
We continue to seek additional capital through strategic transactions and other financing alternatives. Without additional capital, current working
capital and cash generated from grants will not provide adequate funding for research and product development activities at their current levels. If sufficient
capital is not raised in the future, we eventually may need to significantly reduce or curtail our research and development and other operations, and this
would negatively affect our ability to achieve corporate growth goals. There may be continued market volatility due to the pandemic, downturn in the
global economy, or other events, which could cause our stock price to decline. This in turn would likely negatively impact our ability to raise funds through
equity-related financings.
Should we be unable in the future to raise additional cash from outside sources or if we are unable to do so in a timely manner or on
commercially reasonable terms, it would have a material adverse impact on our operations.
Cash (used in) provided by operating, investing and financing activities for the years ended December 31, 2022 and 2021 is summarized as
follows (in thousands):
Net cash used in operating activities
Net cash used in investing activities
Net cash provided by financing activities
Net increase (decrease) in cash and cash equivalents
Years Ended December 31,
2021
2022
(12,972 ) $
(759 )
13,451
(280 ) $
(10,280 )
(82 )
20,416
10,054
$
$
Material Cash Obligations
On September 19, 2022, we entered into the CPRIT Contract, effective as of August 31, 2022, pursuant to which we will continue the
development of rhenium (186Re) obisbemeda for the treatment of patients with LM, with CPRIT providing matching funds for approximately two-thirds of
the total development costs, subject to various funding conditions. The CPRIT contract is effective for three years, unless otherwise terminated per terms of
the contract. CPRIT may require us to repay some or all of the disbursed CPRIT grant proceeds (with interest not to exceed 5% annually) in the event of
the early termination of the CPRIT Contract.
We are also obligated to make ongoing payments against the remaining principal and interest payments of approximately $6.0 million in total
under the Term Loan with Oxford through the maturity date of June 1, 2024 (See Note 5 of the accompanying financial
58
statements for more information). In addition, as described in more detail in Note 7 of the accompanying financial statements, we are obligated to make
operating lease payments for our office and laboratory space and we may be required to make payments under certain of our other contractual agreements.
Operating activities
Net cash used in operating activities for the year ended December 31, 2022 was $13.0 million compared to $10.3 million in the same period of
2021. Overall, our operational cash use increased during the year ended December 31, 2022 as compared to the same period in 2021, due primarily to
increased expenditures for our research and development activities.
Investing activities
Net cash used in investing activities for year ended December 31, 2022 was primarily related to cash payments of $0.5 million made for
purchases of fixed assets and intangible assets, and $0.3 million paid for in-process research and development. Net cash used in investing activities for the
year ended December 31, 2021 was related to purchases of fixed assets of $0.1 million, offset by proceeds of $0.1 million from sale of property and
equipment.
On August 15, 2022, we announced that our Board of Directors had approved a share repurchase program pursuant to which we were authorized
to repurchase up to $2.0 million of our outstanding common stock. The timing and amount of any shares repurchased will be determined based on our
evaluation of market conditions and other factors. Repurchases may be made from time to time on the open market over the course of 12 months. We are
not obligated to acquire any shares and the program may be discontinued or suspended at any time. Through the date of filing of this Form 10-K, we have
not repurchased any of its common stock under this share repurchase program.
Financing Activities
Net cash provided by financing activities for year ended December 31, 2022 was primarily related to sales of common stock of $15.1 million, net
of offering cost through the Purchase Agreements with Lincoln Park and the Distribution Agreements with Canaccord, offset by principal repayment of the
Oxford term loan of $1.6 million.
Net cash provided by financing activities for year ended December 31, 2021 was primarily related to sales of common stock of $18.7 million, net
of offering cost through the 2020 Purchase Agreement with Lincoln Park and the Distribution Agreement with Canaccord, as well as $2.0 million from
exercise of warrants, offset by principal repayment of the Oxford term loan of $0.3 million.
Critical Accounting Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires us to make
estimates and assumptions that affect the reported amounts of our assets, liabilities, revenue, and expenses, and that affect our recognition and disclosure of
contingent assets and liabilities. On an on-going basis, we evaluate our estimates and judgments, including those related to impairment assessment of our
grants and awards, indefinite lived intangible assets, and share-based compensation. We base our estimates on historical experience, known trends and
events, and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about
the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different
assumptions or conditions.
Grants and Awards
We determined that grants and awards are out of the scope of ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”) because the
funding entities do not meet the definition of a “customer”, as defined by ASC 606, as there is no transfer of control of goods or services. With respect to
each grant or award, we determine if it has a collaboration in accordance with ASC Topic 808, Collaborative Arrangements (“ASC 808”). To the extent the
grant or award is within the scope of ASC 808, we recognize the award upon achievement of certain milestones as credits to research and development
expenses. For grant and awards outside the scope of ASC 808, we apply ASC 606 or International Accounting Standards No. 20, Accounting for
Government Grants and Disclosure of Government Assistance, by analogy, and revenue is recognized when we incur expenses related to the grants for the
amount we are entitled to under the provisions of the contract.
We also consider the guidance in ASC Topic 730, Research and Development (“ASC 730”), which requires an assessment, at the inception of the
grant or award, of whether the agreement is a liability. If we are obligated to repay funds received regardless of the outcome of the related research and
development activities, then we are required to estimate and recognize that liability. Alternatively, if we are not required to repay the funds, then payments
received are recorded as revenue or contra-expense as the expenses are incurred.
59
Deferred grant or award liability represents award funds received or receivable for which the allowable expenses have not yet been incurred as of
the balance sheet date.
Impairment of Goodwill
We perform our goodwill impairment analysis at the reporting unit level. For the years ended December 31, 2022 and 2021, our company has
one reporting unit. We perform our annual impairment analysis by either doing a qualitative assessment of a reporting unit’s fair value from the last
quantitative assessment to determine if there is potential impairment, or comparing a reporting unit’s estimated fair value to its carrying amount. If a
quantitative assessment is performed the evaluation includes management estimates of cash flow projections based on internal future projections and/or use
of a market approach by looking at market values of comparable companies. Our market capitalization is also considered as a part of this analysis.
In accordance with our accounting policy, we completed the annual evaluation for impairment of goodwill as of December 31, 2022 using the
qualitative method and determined that no impairment existed.
Share-based Compensation
Compensation expense related to stock options granted is measured at the grant date based on the estimated fair value of the award and is
recognized on an accelerated attribution method over the requisite service period. We determine the estimated fair value of each stock option on the date of
grant using the Black-Scholes valuation model which uses assumptions regarding a number of complex and subjective variables. The risk-free interest rate
is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. Expected volatility is based
on an analysis of the historical volatility of our common stock. The expected term represents the period that we expect our stock options to be outstanding.
The expected term assumption is estimated using the simplified method set forth in the U.S. Securities and Exchange Commission’s (the “SEC”) Staff
Accounting Bulletin 110, which is the mid-point between the option vesting date and the expiration date. We have never declared or paid dividends on our
common stock and have no plans to do so in the foreseeable future. Changes in these assumptions may lead to variability with respect to the amount of
stock compensation expense we recognize related to stock options.
Item 7A. Quantitative and Qualitative Disclosures About Market Risk
Not applicable.
60
Item 8. Financial Statements and Supplementary Data
Report of BDO USA, LLP, Independent Registered Public Accounting Firm (BDO USA, LLP; Austin, TX; PCAOB ID#243)
Balance Sheets as of December 31, 2022 and 2021
Statements of Operations and Comprehensive Loss for the years ended December 31, 2022 and 2021
Statements of Stockholders’ Equity for the years ended December 31, 2022 and 2021
Statements of Cash Flows for the years ended December 31, 2022 and 2021
Notes to Financial Statements
61
Page
62
63
64
65
66
67
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
Report of Independent Registered Public Accounting Firm
Shareholders and Board of Directors
Plus Therapeutics, Inc.
Austin, Texas
Opinion on the Financial Statements
We have audited the accompanying balance sheets of Plus Therapeutics, Inc. (the “Company”) as of December 31, 2022 and 2021, the related statements of
operations and comprehensive loss, stockholders’ equity, and cash flows for the years then ended and the related notes (collectively referred to as the
“financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December
31, 2022 and 2021, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted
in the United States of America.
Basis for Opinion
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial
statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States)
(“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules
and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable
assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor
were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of
internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over
financial reporting. Accordingly, we express no such opinion.
Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and
performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in
the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as
evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matters
Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated
to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially
challenging, subjective, or complex judgments. We determined that there are no critical audit matters.
/s/ BDO USA, LLP
We have served as the Company’s auditor since 2016.
Austin, Texas
February 23, 2023
62
PLUS THERAPEUTICS, INC.
BALANCE SHEETS
(in thousands, except share and par value data)
As of December 31,
2022
2021
Assets
Current assets:
Cash and cash equivalents
Other current assets
Total current assets
Property and equipment, net
Operating lease right-use-of assets
Goodwill
Intangible assets, net
Other assets
Total assets
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable and accrued expenses
Operating lease liability
Term loan obligation, current
Total current liabilities
Noncurrent operating lease liability
Term loan obligation
Deferred grant liability
Warrant liability
Total liabilities
Commitments and contingencies (Note 6)
Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; 1,952
shares issued and outstanding as of December 31, 2022 and 2021
Common stock, $0.001 par value; 100,000,000 shares authorized; 33,601,373 and 15,510,025 shares
issued and outstanding as of December 31, 2022 and 2021, respectively
Additional paid-in capital
Accumulated deficit
Total stockholders’ equity
Total liabilities and stockholders’ equity
$
$
$
$
18,120 $
3,697
21,817
1,324
248
372
94
12
23,867 $
10,134 $
110
1,608
11,852
141
3,786
1,643
—
17,422
18,400
1,324
19,724
1,477
341
372
51
16
21,981
4,151
111
1,608
5,870
269
5,005
—
1
11,145
—
—
34
473,596
(467,185 )
6,445
23,867 $
16
457,730
(446,910 )
10,836
21,981
See Accompanying Notes to these Financial Statements
63
PLUS THERAPEUTICS, INC.
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(in thousands, except share and per share data)
Grant revenue
Operating expenses:
Research and development
In process research and development acquired
General and administrative
Loss on disposal of property and equipment
Total operating expenses
Operating loss
Other income (expense):
Interest income
Interest expense
Change in fair value of liability instruments
Total other expense
Net loss
Net loss per share, basic and diluted
Basic and diluted weighted average shares used in calculating net loss per share
attributable to common stockholders
For the Years Ended December 31,
2021
2022
$
224 $
—
9,698
—
10,238
—
19,936
(19,712 )
147
(711 )
1
(563 )
(20,275 ) $
5,323
250
6,853
66
12,492
(12,492 )
19
(932 )
6
(907 )
(13,399 )
(0.77 ) $
(1.11 )
26,255,256
12,089,186
$
$
See Accompanying Notes to these Financial Statements
64
PLUS THERAPEUTICS, INC.
STATEMENTS OF STOCKHOLDERS’ EQUITY
FOR THE YEARS ENDED December 31, 2022 and 2021
(in thousands, except share data)
Balance at December 31, 2020
Share-based compensation
Sale of common stock, net
Issuance of common stock for exercise of warrants
Conversion of Series B convertible preferred stock into common
stock
Net loss
Balance at December 31, 2021
Share-based compensation
Sale of common stock, net
Net loss
Balance at December 31, 2022
Convertible
preferred stock
Shares
Amount
$
1,954
—
—
—
(2 )
—
1,952
—
—
—
1,952
$
—
—
—
—
—
—
—
—
—
—
—
Shares
6,749,02
8
—
7,864,37
9
896,500
118
—
15,510,0
25
—
18,091,3
48
—
33,601,3
73
Common stock
Amount
Additional
paid-in
capital
Accumulated
deficit
Total
stockholders’
equity
$
$
7
—
436,535
606
$
(433,511 ) $
—
8
1
—
—
16
—
18
—
18,573
2,016
—
—
457,730
606
15,260
—
—
—
—
(13,399 )
(446,910 )
—
—
(20,275 )
3,031
606
18,581
2,017
—
(13,399 )
10,836
606
15,278
(20,275 )
$
34
$
473,596
$
(467,185 ) $
6,445
See Accompanying Notes to these Financial Statements
65
PLUS THERAPEUTICS, INC.
STATEMENTS OF CASH FLOWS
(in thousands)
Cash flows used in operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Amortization of deferred financing costs and debt discount
In process research and development acquired
Change in fair value of liability instruments
Loss on disposal of property and equipment
Share-based compensation expense
Amortization of operating lease right-of-use assets
Increases (decreases) in cash caused by changes in operating assets and liabilities:
Other current assets
Accounts payable and accrued expenses
Change in operating lease liabilities
Other long-term liabilities
Net cash used in operating activities
Cash flows used in investing activities:
Purchases of property and equipment and intangible assets
In process research and development acquired
Proceeds from sale of property and equipment
Net cash used in investing activities
Cash flows from financing activities:
Principal payments of long-term obligations
Payment of finance lease liability
Proceeds from exercise of warrants
Proceeds from sale of common stock
Net cash provided by financing activities
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Supplemental disclosure of cash flows information:
Cash paid during period for:
Interest
Supplemental schedule of non-cash investing and financing activities:
Unpaid offering cost
For the Years Ended December 31,
2021
2022
$
(20,275 ) $
(13,399 )
619
389
—
(1 )
—
606
93
(2,369 )
6,452
(129 )
1,643
(12,972 )
(509 )
(250 )
—
(759 )
(1,608 )
—
—
15,059
13,451
(280 )
18,400
18,120 $
327 $
—
$
395
546
250
(6 )
66
606
24
(496 )
1,734
—
—
(10,280 )
(144 )
—
62
(82 )
(268 )
(8 )
2,017
18,675
20,416
10,054
8,346
18,400
388
219
$
$
$
See Accompanying Notes to these Financial Statements
66
PLUS THERAPEUTICS, INC.
NOTES TO FINANCIAL STATEMENTS
December 31, 2022
1.
Organization and Operations
The Company
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the development, manufacture and commercialization of complex and
innovative treatments for patients battling cancer and other life-threatening diseases.
Certain Risks and Uncertainties
The Company’s prospects are subject to the risks and uncertainties frequently encountered by companies in the early stages of development and
commercialization, especially those companies in rapidly evolving and technologically advanced industries such as the biotech/medical device field.
The Company’s future viability largely depends on its ability to complete development of new products and receive regulatory approvals for those
products. No assurance can be given that the Company’s new products will be successfully developed, regulatory approvals will be granted, or
acceptance of these products will be achieved.
Liquidity
The Company incurred net losses of $20.3 million for the year ended December 31, 2022, and as of December 31, 2022, the Company had an
accumulated deficit of $467.2 million and cash and cash equivalents of $18.1 million. Additionally, the Company used net cash of $13.0 million to
fund its operating activities for the year ended December 31, 2022. The Company expects that its research and development expenditures will
increase in absolute dollars in 2023 and beyond.
As disclosed in more detail in Note 12, the Company has entered into various financing agreements and raised capital by issuing its common stock.
The Company believes its current cash and cash equivalents will be sufficient to fund its operations for at least the next 12 months from the date
these financial statements are issued.
The Company continues to seek additional capital through strategic transactions and from other financing alternatives. If sufficient capital is not
raised in the future, the Company may eventually need to significantly reduce or curtail its research and development and other operations, and this
would negatively affect its ability to achieve corporate growth goals.
On May 24, 2022, the Company received notice from The Nasdaq Stock Market LLC (“Nasdaq”) that, because the closing bid price for the
Company’s common stock had fallen below $1.00 per share for 30 consecutive business days, the Company no longer complied with the minimum
bid price requirement pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Requirement”).
Nasdaq’s notice had no immediate effect on the listing or trading of the Company’s common stock. On November 22, 2022, the Company received a
second letter from Nasdaq advising that the Company had been granted an additional 180 calendar days, or to May 22, 2023, to regain compliance
with the Minimum Bid Requirement, in accordance with Nasdaq Listing Rule 5810(c)(3)(A).
The Company intends to continue to actively monitor the closing bid price of its common stock and will evaluate available options to regain
compliance with the Minimum Bid Requirement. Specifically, the Company has confirmed to Nasdaq that, if necessary, it will implement a reverse
stock split of its outstanding common stock (if approved by the Company’s stockholders) to attempt to regain compliance. If the Company does not
regain compliance within the additional compliance period, Nasdaq will provide notice that the Company’s common stock will be subject to
delisting. The Company would then be entitled to appeal that determination to a Nasdaq hearings panel. There can be no assurance that the
Company will regain compliance with the Minimum Bid Requirement during the 180-day additional compliance period or maintain compliance
with the other Nasdaq listing requirements.
67
2.
Summary of Significant Accounting Policies
Use of Estimates
The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates
and assumptions affecting the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial
statements, and the reported amounts of revenue and expenses during the reporting period. The most significant estimates and critical accounting
policies involve grant revenue recognition, reviewing assets for impairment, and determining the assumptions used in measuring share-based
compensation expense.
Actual results could differ from these estimates. Management’s estimates and assumptions are reviewed regularly, and the effects of revisions are
reflected in the financial statements in the periods they are determined to be necessary.
Cash and cash equivalents
The Company considers all highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents.
Cash and cash equivalents include cash in readily available checking and savings accounts. The Company held no investments as of December 31,
2022 and 2021. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has
not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the
depository institution in which those deposits are held.
Financial Instruments
Financial instruments include cash equivalents, other current assets, accounts payable, accrued expenses, other liabilities and long-term debt. The
carrying values of cash equivalents, other current assets, accounts payable, accrued expenses, other liabilities generally approximate fair value due
to the short-term nature of these instruments. Based on level 3 inputs and the borrowing rates currently available for loans with similar terms, the
Company believes the fair value of the long-term debt is materially consistent with its carrying value.
Property and Equipment
Property and equipment are stated at cost, net of accumulated depreciation. Depreciation expense, which includes the amortization of capitalized
leasehold improvements, is provided for on a straight-line basis over the estimated useful lives of the assets, or the life of the lease, whichever is
shorter, and range from three to five years. When assets are sold or otherwise disposed of, the cost and related accumulated depreciation are
removed from the accounts and the resulting gain or loss, if any, is included in operations. Maintenance and repairs are charged to operations as
incurred.
Impairment
The Company assesses its property and equipment for potential impairment when there is a change in circumstances that indicates carrying values of
assets may not be recoverable. Such long-lived assets are deemed to be impaired when the undiscounted cash flows expected to be generated by the
asset (or asset group) are less than the asset’s carrying amount. Any required impairment loss would be measured as the amount by which the asset’s
carrying value exceeds its fair value and would be recorded as a reduction in the carrying value of the related asset and a charge to operating
expense. The Company recognized no impairment losses during any of the periods presented in these financial statements.
Goodwill
The Company’s goodwill represents the excess of the cost over the fair value of net assets acquired from its business combinations. The
determination of the value of goodwill arising from business combinations requires extensive use of accounting estimates and judgments to allocate
the purchase price to the fair value of the net tangible and intangible assets acquired.
68
Goodwill is not amortized; however, it is assessed for impairment using fair value measurement techniques on an annual basis or more frequently if
facts and circumstance warrant such a review. Goodwill is considered to be impaired if the Company determines that the carrying value of the
reporting unit exceeds its fair value.
The Company performs its impairment test annually during the fourth quarter by comparing the Company’s estimated fair value, calculated from the
Company’s market capitalization, to its carrying amount. The Company’s annual evaluation for impairment of goodwill consists of one reporting
unit. The Company completed its most recent annual evaluation for impairment as of December 31, 2022 and determined that no impairment
existed.
Warrant Liability
Warrants are accounted for in accordance with the applicable authoritative accounting guidance as either liabilities or as equity instruments
depending on the specific terms of the agreements. Liability-classified instruments are recorded at fair value at each reporting period with any
change in fair value recognized as a component of change in fair value of warrant liabilities in the statements of operations and comprehensive loss.
Grant Receivable and Revenue Recognition
In applying the provisions of Accounting Standards Codification ("ASC") Topic 606, Revenue from Contracts with Customers (“ASC 606”), the
Company has determined that government grants are out of the scope of ASC 606 because the funding entities do not meet the definition of a
“customer”, as defined by ASC 606, as there is not considered to be a transfer of control of goods or services. With respect to the grant, the
Company determines if it has a collaboration in accordance with ASC Topic 808, Collaborative Arrangements (“ASC 808”). For grants outside the
scope of ASC 808, the Company applies ASC 606 or International Accounting Standards No. 20, Accounting for Government Grants and
Disclosure of Government Assistance, by analogy, and revenue is recognized when the Company incurs expenses related to the grant for the amount
the Company is entitled to under the provisions of the contract.
The Company also considers the guidance in ASC Topic 730, Research and Development (“ASC 730”), which requires an assessment, at the
inception of the grant, of whether the agreement is a liability. If the Company is obligated to repay funds received regardless of the outcome of the
related research and development activities, then the Company is required to estimate and recognize that liability. Alternatively, if the Company is
not required to repay the funds, then payments received are recorded as revenue or contra-expense as the expenses are incurred.
Deferred grant liability represents grant funds received or receivable for which the allowable expenses have not yet been incurred as of the balance
sheet date.
Research and Development
Research and development expenditures, which are charged to operations in the period incurred, include costs associated with the design,
development, testing and enhancement of the Company’s products, regulatory fees, the purchase of laboratory supplies, and pre-clinical and clinical
studies as well as salaries and benefits for our research and development employees.
Acquired In-Process Research and Development (IPR&D)
Acquired IPR&D represents the value assigned to research and development assets that have not reached technological feasibility. Upon the
acquisition of IPR&D, the Company completes an assessment of whether the acquisition constitutes the purchase of a single asset or group of assets.
The Company considers multiple factors in this assessment, including the nature of the technology acquired, the presence or absence of separate
cash flows, the development process and stage of completion, quantitative significance, and the Company's rationale for entering into the
transaction.
Deferred Financing Costs and Other Debt-Related Costs
Deferred financing costs are capitalized, recorded as an offset to debt balances and amortized to interest expense over the term of the associated debt
instrument using the effective interest method. If the maturity of the debt is accelerated because of default or early debt repayment, then the
amortization would be accelerated.
69
Income Taxes
Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax
consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax
bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to
taxable income (loss) in the years in which those temporary differences are expected to be recovered or settled. Due to our history of losses, a full
valuation allowance has been recognized against our deferred tax assets.
The Company’s policy is to recognize interest and penalties related to income tax matters in income tax expense. For the years ended December 31,
2022 and 2021, the Company has not recorded any interest or penalties related to income tax matters. The Company does not foresee any material
changes to unrecognized tax benefits within the next twelve months.
Share-Based Compensation
The Company recognizes the fair value of all share-based payment awards in our statements of operations over the requisite vesting period of each
award, which approximates the period during which the employee and non-employee director is required to provide service in exchange for the
award. The Company estimates the fair value of these options using the Black-Scholes option pricing model using assumptions for expected
volatility, expected term, and risk-free interest rate. Expected volatility is based primarily on historical volatility and is computed using daily pricing
observations for recent periods that correspond to the expected term of the options. The expected term is calculated based on historical data for and
applied to all employee awards as a single group as the Company does not expect (nor does historical data suggest) substantially different exercise
or post-vesting termination behavior amongst our employee population. The risk-free interest rate is the interest rate for treasury instruments with
maturities that approximate the expected term.
Segment Information
For the years ended December 31, 2022 and 2021, the Company is managed as a single operating segment, and therefore reports its results in one
operating segment.
Loss Per Share
Basic per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common
shares outstanding during the period. Diluted per share data is computed by dividing net income or loss applicable to common stockholders by the
weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares
that would have been outstanding as calculated using the treasury stock method. Potential common shares were related entirely to outstanding but
unexercised options, warrants and convertible preferred stocks for all periods presented.
The Company excluded all potentially dilutive securities from the calculation of diluted loss per share attributable to common stockholders for the
years ended December 31, 2022 and 2021, as their inclusion would be antidilutive.
Concentration Risk
Although the Company’s contracts with its vendors are not exclusive, the Company currently uses sole source providers for core materials used in
its clinical trials.
Recently Issued Accounting Pronouncements
In June 2016, the FASB issued ASU 2016-13, Financial Instruments -- Credit Losses (Topic 326), Measurement of Credit Losses on Financial
Instruments. The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to
estimate credit losses for most financial assets and certain other instruments that aren’t measured at fair value through net income. For available-for-
sale debt securities, entities will be required to recognize an allowance for credit losses rather than a reduction in carrying value of the asset. Entities
will no longer be permitted to consider the length of time that fair value has been less than amortized cost when evaluating when credit losses should
be recognized. This new guidance is effective in the first quarter of 2023 for calendar-year SEC filers that are smaller reporting companies as of the
one-time determination date. Early adoption is permitted. The Company will adopt the new guidance for the quarter beginning on January 1, 2023,
and it does not expect that adoption of this standard will have a material impact on its financial statements and related disclosures.
3.
Fair Value Measurements
Fair value measurements are market-based measurements, not entity-specific measurements. Therefore, fair value measurements are determined
based on the assumptions that market participants would use in pricing the asset or liability. The Company follows
70
a three-level hierarchy to prioritize the inputs used in the valuation techniques to derive fair values. The basis for fair value measurements for each
level within the hierarchy is described below:
•
•
•
Level 1: Quoted prices in active markets for identical assets or liabilities.
Level 2: Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar instruments in markets that are
not active; and model-derived valuations in which all significant inputs are observable in active markets.
Level 3: Valuations derived from valuation techniques in which one or more significant inputs are unobservable in active markets.
Certain warrants issued in an underwritten public offering in September 2019 (“Series U Warrants”) are classified as liability instruments. The
Company estimated the fair value of the Series U Warrants with the Black Scholes model. Because some of the inputs to the Company’s valuation
model are either not observable or are not derived principally from or corroborated by observable market data by correlation or other means, the
warrant liability is classified as Level 3 in the fair value hierarchy.
Liability-classified Series U Warrants are marked to market as of each balance sheet date until they are exercised or upon expiration, with the
changes in fair value recorded as non-operating income or loss in the statements of operations. As of December 31, 2022 and 2021, the fair value of
the Series U Warrants was immaterial, and the change in the fair value of liability classified Series U Warrants during year ended December 31,
2022 and 2021 was immaterial.
Nonfinancial Assets and Liabilities
The Company applies fair value techniques on a non-recurring basis, if and when necessary, associated with: (1) valuing potential impairment losses
related to goodwill which are accounted for pursuant to the authoritative guidance for intangibles—goodwill and other; and (2) valuing potential
impairment losses related to long-lived assets which are accounted for pursuant to the authoritative guidance for property, plant and equipment.
4. Loss per Share
The following were excluded from the diluted loss per share calculation for the periods presented because their effect would be anti-dilutive:
Outstanding stock options
Preferred stock
Outstanding warrants
Total
For the Year Ended December 31,
2022
2021
1,175,016
422,867
2,141,378
3,739,261
1,170,890
422,867
2,141,378
3,735,135
5. Composition of Certain Financial Statement Captions
Other Current Assets
As of December 31, 2022 and 2021, other current assets were comprised of the following (in thousands):
Prepaid services
Prepaid insurance
Other
December 31,
2022
2021
$
$
2,999 $
698
—
3,697 $
622
695
7
1,324
71
Property and Equipment, net
As of December 31, 2022 and 2021, property and equipment, net, were comprised of the following (in thousands):
Office and computer equipment
Leasehold improvements
Less accumulated depreciation
December 31,
2022
2021
1,474 $
1,810
3,284
(1,960 )
1,324 $
1,231
1,661
2,892
(1,415 )
1,477
$
$
Depreciation expense totaled $0.5 million and $0.4 million for the year ended December 31, 2022 and 2021, respectively.
Intangible Assets, net
As of December 31, 2022, intangible assets included the net book value of costs incurred for software upgrades. Amortization
expenses totaled $0.1 million and $32 thousand for the year ended December 31, 2022 and 2021, respectively.
Accounts Payable and Accrued Expenses
As of December 31, 2022 and 2021, accounts payable and accrued expenses were comprised of the following (in thousands):
Accounts payable
Accrued payroll and bonus
Accrued professional fees
Accrued vacation and compensation
Accrued R&D studies
Other current liabilities
6. Commitments and Contingencies
Leases
December 31,
2022
2021
$
$
8,364 $
989
147
325
309
—
10,134 $
2,611
781
189
252
196
122
4,151
At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an
identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of
time. If both criteria are met, the Company calculates the associated lease liability and corresponding right-of-use asset upon lease commencement
using a discount rate based on the rate implicit in the lease or an incremental borrowing rate commensurate with the term of the lease. Lease
renewable options are included in the estimation of lease term when it is reasonably certain that the Company will exercise such options.
The Company records lease liabilities within current liabilities or long-term liabilities based upon the length of time associated with the lease
payments. The Company records its operating lease right-of-use assets as long-term assets. Right-of-use assets for finance leases are recorded within
property and equipment, net in the balance sheets. Leases with an initial term of 12 months or less are not recorded on the balance sheets. Instead,
the Company recognizes lease expense for these leases on a straight-line basis over the lease term in the statements of operations.
The Company leases laboratory, office and storage facilities in San Antonio, Texas, under operating lease agreements that expire in 2025. The
Company also leases certain office space in Austin, Texas under a month-to-month operating lease agreement and certain office space in
Charlottesville, Virginia (the “Charlottesville Lease”). The Charlottesville Lease has a term of 12 months and the Company has the ability to renew
for three additional one-year periods. The Charlottesville Lease is currently set to expire on March 31, 2023. The Company measured the operating
lease right-of-use asset and related lease liability related to the Charlottesville Lease as of the lease commencement date of April 1, 2021. In
addition, the Company has entered into leases for certain equipment under various operating and finance leases. During 2021, contractual terms of
all finance leases had expired and the Company did not have any right-of-use assets or lease liabilities relating to finance leases as of December 31,
2022 or 2021. The Company’s existing operating lease agreements generally provide for periodic rent increases, and renewal and termination
options. The Company’s lease agreements do not contain any material variable lease payments, residual value guarantees or material restrictive
covenants.
72
Certain leases require the Company to pay taxes, insurance, and maintenance. Payments for the transfer of goods or services such as common area
maintenance and utilities represent non-lease components. The Company elected the package of practical expedients and therefore does not separate
non-lease components from lease components.
The Company’s operating lease liabilities and corresponding right-of-use assets are included in the balance sheets. As of December 31, 2022, the
weighted average discount rate used to measure operating lease liabilities and the operating leases remaining term were 9% and 2.03 years,
respectively.
The table below summarizes the Company’s lease costs from its statements of operations, and cash payments from its statements of cash flows.
Lease expense:
Operating lease expense
Finance lease expense:
Depreciation of right-of-use assets
Total lease expense
Cash payment information:
Operating cash used for operating leases
Financing cash used for financing leases
Total cash paid for amounts included in the
measurement of lease liabilities
$
$
$
$
Year Ended December 31,
2022
159 $
—
159 $
159 $
—
159 $
2021
211
7
218
206
8
214
Total rent expenses for each of the years ended December 31, 2022 and 2021 was $0.2 million, which includes leases in the table above, month-to-
month operating leases, and common area maintenance charges.
The Company’s future minimum annual lease payments under operating and finance leases at December 31, 2022 are as follows (in thousands):
2023
2024
2025
Total minimum lease payments
Less: amount representing interest
Present value of obligations under leases
Less: current portion
Noncurrent lease obligations
Services Agreement and Sales Order with Medidata
Operating Leases
137
113
18
268
(17 )
251
(110 )
141
$
$
On March 31, 2022, the Company and Medidata Solutions, Inc. (“Medidata”) entered into a Sales Order (the “Sales Order”), pursuant to which
Medidata will build a Synthetic Control Arm® (SCA) platform that facilitates the use of historical clinical data to incorporate into the Company’s
Phase 2 clinical trial of rhenium (186Re) obisbemeda in recurrent glioblastoma (“GBM”). The Sales Order is governed under the terms of a services
agreement (the “Services Agreement”), dated November 5, 2021. The Sales Order had a term of six (6) months, and work under the Sales Order has
been completed. Costs related to the Sales Order of $1.5 million were expensed in the statement of operations for the year ended December 31,
2022.
Piramal Master Services Agreement
On January 8, 2021, the Company entered into a Master Services Agreement (the “MSA”) with Piramal Pharma Solutions, Inc. (“Piramal”), for
Piramal to perform certain services related to the development, manufacture, and supply of the Company’s rhenium (186Re) obisbemeda-Liposome
Intermediate Drug Product. The MSA includes the transfer of analytical methods, development of microbiological methods, process transfer and
optimization, intermediate drug product manufacturing, and stability studies for the Company, which has been initiated at Piramal’s facility located
in Lexington, Kentucky.
73
The MSA has a term of five years and will automatically renew for successive one-year terms unless either party notifies the other no later than six
months prior to the original term or any additional terms of its intention to not renew the MSA. The Company has the right to terminate the MSA
for convenience upon thirty days’ prior written notice. Either party may terminate the MSA upon an uncured material breach by the other party or
upon the bankruptcy or insolvency of the other party.
Other Commitments and Contingencies
The Company has entered into agreements with various research organizations for pre-clinical and clinical development studies, which have
provisions for cancellation. Under the terms of these agreements, the vendors provide a variety of services including conducting research, recruiting
and enrolling patients, monitoring studies and data analysis. Payments under these agreements typically include fees for services and reimbursement
of expenses. The timing of payments due under these agreements is estimated based on current study progress. As of December 31, 2022, the
Company did not have any clinical research study obligations.
Legal proceedings
On June 22, 2021, the Company was named as a defendant in an action brought by Lorem Vascular, Pte. Ltd. (“Lorem”) in the District Court for the
District of Delaware. The complaint alleged false representations were made to Lorem regarding the manufacturing facility in the United Kingdom
(the “UK Facility”) that Lorem purchased from the Company under the Asset and Equity Purchase Agreement, dated March 29, 2019, between the
Company and Lorem (the “Lorem Agreement”). Lorem also claimed that false representations were made regarding the UK Facility’s certification
to sell and distribute devices in the European Union and export such devices to China. In connection with these allegations, Lorem claimed
entitlement to at least $6,000,000 in compensatory damages and operational costs and expenses (collectively, the “Lorem Claim”). On December 9,
2022, the Company entered into a settlement agreement (the “Settlement Agreement”) with Lorem to settle the Lorem Claim. Under the terms of the
Settlement Agreement, the Company made a payment to Lorem, and Lorem moved to dismiss the lawsuit with prejudice. The Settlement Agreement
released us from all claims made by Lorem. The parties to the Settlement Agreement recognized that it did not constitute an admission of liability,
wrongdoing, or any matter of fact or law. The Settlement was conditioned on the customary terms contained in the Settlement Agreement and was
approved by the Court and the case was dismissed on January 17, 2023. As of December 31, 2022, the Company accrued the settlement amount, as
well as the accounts that the Company has confirmed to be recoverable under its insurance claims on the matter. The net amount of $1.4 million that
was not recoverable under the Company's insurance has been reflected as an expense in the year ended December 31, 2022. The full settlement
amount was paid in January 2023. All legal costs related to the Lorem Claim were expensed as incurred.
The Company is subject to various claims and contingencies related to legal proceedings. Due to their nature, such legal proceedings involve
inherent uncertainties including, but not limited to, court rulings, negotiations between affected parties and governmental actions. Management
assesses the probability of loss for such contingencies and accrues a liability and/or discloses the relevant circumstances, as appropriate.
7. License Agreements
UT Health Science Center at San Antonio (“UTHSA”) License Agreement
On December 31, 2021, the Company entered into a Patent and Know-How License Agreement (the “UTHSA License Agreement”) with The
University of Texas Health Science Center at San Antonio, pursuant to which UTHSA granted the Company an irrevocable, perpetual, exclusive,
fully paid-up license, with the right to sublicense and to make, develop, commercialize and otherwise exploit certain patents, know-how and
technology related to the development of biodegradable alginate microspheres (BAM) containing nanoliposomes loaded with imaging and/or
therapeutic payloads.
Pursuant to the UTHSA License Agreement, the Company was required to make an upfront payment, which was recorded as in-process research
and development acquired in the statement of operations for the year ended December 31, 2021. The upfront payment of $0.3 million was paid in
cash in January 2022.
NanoTx License Agreement
On March 29, 2020, the Company and NanoTx, Corp. (“NanoTx”) entered into a Patent and Know-How License Agreement (the “NanoTx License
Agreement”), pursuant to which NanoTx granted the Company an irrevocable, perpetual, exclusive, fully paid-up license, with the right to
sublicense and to make, develop, commercialize and otherwise exploit certain patents, know-how and technology related to the development of
radiolabeled nanoliposomes.
The transaction terms included an upfront payment of $0.4 million in cash and $0.3 million in the Company's voting stock. The transaction terms
also included success-based milestone and royalty payments contingent on key clinical, regulatory and sales milestones, as well as the requirement
to pay 15% of any non-dilutive monetary awards or grants received from external agencies
74
to support product development of the nanoliposome encapsulated BMEDA-chelated radioisotope, which includes grants from the Cancer
Prevention & Research Institute of Texas ("CPRIT"). As of December 31, 2022, the Company accrued $0.3 million of payments due to NanoTx as a
result of the CPRIT grant received (Note 9).
8.
Term Loan Obligations
On May 29, 2015, the Company entered into the Loan and Security Agreement (the “Loan and Security Agreement”), pursuant to which Oxford
Finance, LLC (“Oxford”) funded an aggregate principal amount of $17.7 million (the “Term Loan”), subject to the terms and conditions set forth in
the Loan and Security Agreement. The Term Loan accrues interest at a floating rate of at least 8.95% per annum, comprised of a three-month
LIBOR rate with a floor of 1.00% plus 7.95%. Pursuant to the Loan and Security Agreement, as amended, the Company was required to make
interest only payments through May 1, 2021 and thereafter it is required to make payments of principal and accrued interest in equal monthly
installments sufficient to amortize the Term Loan through June 1, 2024, the maturity date. At maturity of the Term Loan, or earlier repayment in full
following voluntary prepayment or upon acceleration, the Company is required to make a final payment in an aggregate amount equal to
approximately $3.2 million. In connection with the Term Loan, on May 29, 2015, the Company issued to Oxford warrants to purchase an aggregate
of 188 shares of the Company’s common stock at an exercise price of $5,175 per share. These warrants became exercisable as of November 30,
2015 and will expire on May 29, 2025 and, following the authoritative accounting guidance, are equity classified and their respective fair value was
recorded as a discount to the debt.
The Term Loan is collateralized by a security interest in substantially all of the Company’s existing and subsequently acquired assets, including its
intellectual property assets, subject to certain exceptions set forth in the Loan and Security Agreement, as amended. The intellectual property asset
collateral will be released upon the Company achieving a certain liquidity level when the total principal outstanding under the Loan and Security
Agreement is less than $3 million. As of December 31, 2022, there was $2.4 million principal amount outstanding under the Term Loan, excluding
the $3.2 million final payment fee, and the Company was in compliance with all of the debt covenants under the Loan and Security Agreement.
The Company’s interest expense for the years ended December 31, 2022 and 2021 was $0.7 million and $0.9 million, respectively. Interest expense
is calculated using the effective interest method; therefore it is inclusive of non-cash amortization in the amount of $0.4 million and $0.5 million for
the year ended December 31, 2022 and 2021, respectively, related to the amortization of the debt discount, deferred financing costs, and accretion of
final payment.
The Loan and Security Agreement contains customary indemnification obligations and customary events of default, including, among other things,
the Company’s failure to fulfill certain obligations under the Term Loan, as amended, and the occurrence of a material adverse change, which is
defined as a material adverse change in the Company’s business, operations, or condition (financial or otherwise), a material impairment of the
prospect of repayment of any portion of the loan. In the event of default by the Company or a declaration of material adverse change by its lender,
under the Term Loan, the lender would be entitled to exercise its remedies thereunder, including the right to accelerate the debt, upon which the
Company may be required to repay all amounts then outstanding under the Term Loan, which could materially harm the Company’s financial
condition. As of December 31, 2022, the Company has not received any notification or indication from Oxford to invoke the material adverse
change clause.
Additional details relating to the outstanding Term Loan as of December 31, 2022 and 2021 are presented in the following table (in thousands):
Year ended December 31, 2022
Origination Date
May 2015
Year ended December 31, 2021
Origination Date
May 2015
Original
Loan
Amount
Interest
Rate*
Current
Monthly
Payment**
Amended
expiration date
Remaining
Principal
(Face Value)
$
17,700
8.95 % $
134
June 1, 2024 $
2,412
Original
Loan
Amount
Interest
Rate*
Current
Monthly
Payment**
Amended
expiration date
Remaining
Principal
(Face Value)
$
17,700
8.95 % $
134
June 1, 2024 $
4,021
* Three month LIBOR rate with a floor of 1% plus 7.95%
** Monthly payment reflects principal and interest
75
As of December 31, 2022, the future contractual principal and final fee payments on all of our debt obligations are as follows (as thousands):
Years Ending December 31,
2023
2024
Total
Reconciliation of Face Value to Book Value as of December 31, 2022
Total debt obligations, including final payment fee
(Face Value)
Less: Debt discount
Total obligation
Less: Current portion
Term loan obligation -- noncurrent
$
$
$
$
1,608
3,996
5,604
5,604
(210 )
5,394
(1,608 )
3,786
9. Grant Revenue
On September 19, 2022, the Company entered into the CPRIT Contract, effective as of August 31, 2022, with CPRIT, pursuant to which CPRIT will
provide the Company a grant of up to $17.6 million (the “CPRIT Grant”) over a three-year period to fund the continued development of rhenium
(186Re) obisbemeda for the treatment of patients with leptomeningeal metastases (“LM”). The CPRIT Grant is subject to customary CPRIT funding
conditions, including, but not limited to, a matching fund requirement (one dollar for every two dollars awarded by CPRIT), revenue sharing
obligations upon commercialization of rhenium (186Re) obisbemeda based on specific dollar thresholds and tiered low single digit royalty rates until
CPRIT receives the aggregate amount of 400% of the proceeds awarded under the CPRIT Grant, and certain reporting requirements.
The CPRIT Contract will terminate on August 30, 2025, unless terminated earlier by (a) the mutual written consent of all parties to the CPRIT
Contract, (b) CPRIT for an event of default by the Company, (c) CPRIT, if the funds allocated to the CPRIT Grant become legally unavailable
during the term of the CPRIT Contract and CPRIT is unable to obtain additional funds for such purposes, and (d) the Company for convenience.
CPRIT may require the Company to repay some or all of the disbursed CPRIT Grant proceeds (with interest not to exceed 5% annually) in the event
of the early termination of the CPRIT Contract by CPRIT for an event of default by the Company or by the Company for convenience.
The Company will retain ownership over any intellectual property developed under the contract ("Project Result"). With respect to non-commercial
use of any Project Result, the Company agreed to grant to CPRIT a nonexclusive, irrevocable, royalty-free, perpetual, worldwide license with right
to sublicense any necessary additional intellectual property rights to exploit all Project Results by CPRIT, other governmental entities and agencies
of the State of Texas, and private or independent institutions of higher education located in Texas, for education, research and other non-commercial
purposes.
The Company determined that the CPRIT Contract is not in the scope of ASC 808 or ASC 606. Applying ASC 606 by analogy, the Company
recognizes proceeds received under the CPRIT Contract as grant revenue on the statement of operations when related costs are incurred. The
Company recognized $0.2 million in grant revenue from the CPRIT Contract during the year ended December 31, 2022.
10. Income Taxes
Pursuant to the Internal Revenue Code (“IRC”) of 1986, as amended, specifically IRC §382 ("Section 382") and IRC §383, the Company’s ability to
use net operating loss ("NOLs") and R&D tax credit carry forwards (“tax attribute carry forwards”) to offset future taxable income is limited if the
Company experiences a cumulative change in ownership of more than 50% within a three-year testing period. In preparation of the financial
statements as of and for the year ended December 31, 2022, the Company performed an ownership change analysis and concluded that it was
probable that an ownership change within the meaning of IRC §382 occurred prior to December 31, 2020.
As a result, the Company has determined that approximately $346.8 million for federal NOL carryforwards and $173.0 million for state NOL
carryforwards were subject to limitation. Consequently, approximately $84.9 million of deferred tax assets related to NOL carryforwards were
eliminated. In addition, deferred tax assets related to federal and state research and development credits of approximately $6.0 million and $5.5
million were eliminated, resulting in a total reduction of deferred tax assets of $8.4 million, which was completely offset by a corresponding
adjustment to the Company's valuation allowance. The deferred tax assets relating to net operating loss carryforwards and income tax credit
carryforwards and the related valuation allowance as
76
of December 31, 2021 reflected in the table below have been adjusted to give effect to this. These revisions had no impact on the Company’s
balance sheet, statement of operations or statement of cash flows.
The Company's use of federal and state NOLs and research credits could be limited further by the provisions of Section 382 depending upon the
timing and amount of additional equity securities that the Company has issued or will issue. State NOL carryforwards may be similarly limited. If a
change in ownership were to have occurred, NOL and tax credits carryforwards could be eliminated or restricted. If eliminated, the related asset
would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance. Due to the existence of the
valuation allowance, limitations created by ownership changes, if any, will not impact the Company's effective tax rate.
The Company has recorded a full valuation allowance against its net deferred tax assets and due to our net losses for the years ended December 31,
2022 and 2021, there was no provision or benefit for income taxes recorded.
A reconciliation of the total income tax provision tax rate to the statutory federal income tax rates of 21% for the years ended December 31, 2022
and 2021, respectively, is as follows:
Income tax expense (benefit) at federal statutory rate
Change in valuation allowance
Income tax expense (benefit) at state statutory rate
Share based compensation
NOLs expiring and adjustments to NOL
Research credit
Return to provision
Change in state rate
2022
2021
(21.0 )%
22.5 %
(0.2 )%
0.9 %
0.5 %
(2.5 )%
(0.1 )%
(0.1 )%
0.0 %
(21.0 )%
(699.5 )%
(0.6 )%
0.7 %
720.7 %
(0.8 )%
0.5 %
—
(0.0 )%
The tax effects of temporary differences that give rise to significant portions of our deferred tax assets and deferred tax liabilities as of December 31,
2022 and 2021 are as follows (in thousands):
Deferred tax assets:
Accrued expenses
Share based compensation
Net operating loss carryforwards
Income tax credit carryforwards
Property and equipment, principally due to differences in
depreciation
Intangible assets
Other, net
Valuation allowance
Total deferred tax assets, net of allowance
Deferred tax liabilities:
Other
Total deferred tax liability
Net deferred tax assets (liability)
2022
2021
262 $
107
12,605
956
89
2,073
53
16,145
(16,092 )
53
(53 )
(53 )
— $
41
164
10,404
447
19
451
82
11,608
(11,534 )
74
(74 )
(74 )
—
$
$
The Company has established a valuation allowance against its net deferred tax assets due to the uncertainty surrounding the realization of such
assets. The Company periodically evaluates the recoverability of the deferred tax assets. At such time as it is determined that it is more likely than
not that deferred tax assets are realizable, the valuation allowance will be reduced. The Company has recorded a full valuation allowance of $16.1
million as of December 31, 2022 as it does not believe it is more likely than not our net deferred tax assets will be realized. The Company increased
its valuation allowance by approximately $4.6 million during the year ended December 31, 2022.
77
At December 31, 2022, the Company had federal and state tax loss carry forwards of approximately $59.6 million, and $1.8 million, respectively.
The federal net operating loss carry forwards begin to expire in 2037, if unused. The state net operating loss carries over indefinitely. The federal net
operating loss carryover includes $56.2 million of net operating losses generated after 2017. Federal net operating losses generated from 2018
onwards carryover indefinitely and may generally be used to offset up to 80% of future taxable income. At December 31, 2022, the Company had
federal tax credit carry forwards of approximately $1.2 million, before reduction for uncertain tax positions. The federal credits will begin to expire
in 2039, if unused.
The Company follows the provisions of income tax guidance which provides recognition criteria and a related measurement model for uncertain tax
positions taken or expected to be taken in income tax returns. The guidance requires that a position taken or expected to be taken in a tax return be
recognized in the financial statements when it is more likely than not that the position would be sustained upon examination by tax authorities. Tax
positions that meet the more likely than not threshold are then measured using a probability weighted approach recognizing the largest amount of tax
benefit that is greater than 50% likely of being realized upon ultimate settlement. The Company has not recognized any liability for uncertain tax
positions as of December 31, 2022 and 2021.
Following is a tabular reconciliation of the unrecognized tax benefits activity during the years ended December 31, 2022 and 2021 (in thousands):
Unrecognized Tax Benefits – Beginning
Gross decreases – tax positions in prior period
Gross increase – current-period tax positions
Unrecognized Tax Benefits – Ending
2022
2021
81 $
(1 )
129
209 $
2,223
(2,211 )
69
81
$
$
The unrecognized tax benefit amounts are reflected in the determination of the Company’s deferred tax assets. If recognized, none of these amounts
would affect the Company’s effective tax rate, since it would be offset by an equal reduction in the deferred tax asset valuation allowance. The
Company does not foresee material changes to its liability for uncertain tax benefits within the next twelve months.
The Company did not recognize interest related to unrecognized tax benefits in interest expense and penalties in operating expenses for the year
ended December 31, 2022.
The Company files income tax returns with the United States and various state jurisdictions. To its knowledge, the Company is currently not under
examination by the Internal Revenue Service or any other taxing authority.
With few exceptions, the Company’s tax years prior to 2019 are no longer open to examination by the taxing authority. While not open to
examination, the tax attributes generated in tax years 2017 and forward remain subject to adjustment by the taxing authorities if utilized in tax years
which are still open to examination.
11. Employee Benefit Plan
The Company implemented a 401(k) retirement savings and profit sharing plan (the “Plan”) effective January 1, 1999. During 2022, the Company
commenced safe harbor matching contribution for up to 4% of eligible employee contributions. Total matching contribution under the Plan
amounted to approximately $100,000 and $40,000 for the year ended December 31, 2022 and 2021, respectively.
12. Stockholders’ Equity
Preferred Stock
The Company has authorized 5,000,000 shares of preferred stock, par value $0.001 per share. The Company’s Board of Directors is authorized to
designate the terms and conditions of any preferred stock the Company issues without further action by the common stockholders. On September
21, 2021, Series A 3.6% Convertible Preferred Stock was eliminated. There were no shares of Series A 3.6% Convertible Preferred Stock issued
prior to September 21, 2021. There were 1,014 shares of Series B Convertible Preferred Stock and 938 shares of Series C Preferred Stock
outstanding as of each of December 31, 2022 and 2021, respectively.
As of December 31, 2022, there were 938 outstanding shares of Series C Preferred Stock that can be converted into an aggregate of 416,889 shares
of common stock, and 1,014 shares of Series B Convertible Preferred Stock that can be converted into an aggregate of 5,978 shares of common
stock.
Warrants
On September 25, 2019, the Company completed an underwritten public offering. The Company issued 289,000 shares of its common stock, along
with pre-funded warrants to purchase 2,711,000 shares of its common stock and Series U Warrants to
78
purchase 3,450,000 shares of its common stock at $5.00 per share. The Series U Warrants have a term of five years from the issuance date. In
addition, the Company issued warrants to H.C. Wainwright & Co., LLC, as representatives of the underwriters, to purchase 75,000 shares of its
common stock at $6.25 per share with a term of five years from the issuance date, in the form of Series U Warrants (the “Representative Warrants”).
As of December 31, 2022, there were 2,141,000 outstanding Series U Warrants which can be exercised into an aggregate of 2,141,000 shares of
common stock.
Common Stock
Lincoln Park Purchase Agreements
On August 2, 2022, the Company entered into a purchase agreement (the “2022 Purchase Agreement”) and registration rights agreement pursuant to
which Lincoln Park committed to purchase up to $50.0 million of the Company’s common stock. Under the terms and subject to the conditions of
the 2022 Purchase Agreement, the Company has the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase
up to $50.0 million of the Company’s common stock. Such sales of common stock by the Company are subject to certain limitations, and can occur
from time to time, at the Company’s sole discretion, over the 36-month period commencing on August 17, 2022, subject to the satisfaction of certain
conditions. Lincoln Park has no right to require the Company to sell any shares of common stock to Lincoln Park, but Lincoln Park is obligated to
make purchases as the Company directs, subject to certain conditions.
On May 16, 2022, the Company received stockholder approval for purposes of the Nasdaq listing rules to permit issuances of up to 57.5 million
shares of the Company’s common stock (including the issuance of more than 19.99% of the Company’s common stock) to Lincoln Park, and it was
pursuant to that approval that the Company entered into the 2022 Purchase Agreement.
Upon execution of the 2022 Purchase Agreement, the Company paid $0.1 million in cash as the initial commitment fee, and issued 492,698 shares
as the initial commitment shares, to Lincoln Park as consideration for its irrevocable commitment to purchase shares of the Company's common
stock at its direction under the Purchase Agreement. The Company has agreed to pay an additional commitment fee, which it may elect to pay in
cash and/or shares of its common stock, upon receipt of $25.0 million aggregate gross proceeds from sales of common stock to Lincoln Park under
the 2022 Purchase Agreement.
On August 17, 2022, a registration statement was declared effective to cover the resale of up to 9,500,000 shares of the Company's common stock
comprised of (i) the 492,698 initial commitment shares, and (ii) up to 9,007,302 that the Company has reserved for issuance and sale to Lincoln
Park under the Purchase Agreement from time to time from and after the date of this prospectus. The Company cannot sell more shares under the
2022 Purchase Agreement without registering additional shares.
Actual sales of shares of common stock to Lincoln Park under the 2022 Purchase Agreement depend on a variety of factors to be determined by the
Company from time to time, including, among others, market conditions, the trading price of the common stock and determinations by the Company
as to the appropriate sources of funding for the Company and its operations. The net proceeds under the 2022 Purchase Agreement to the Company
depend on the frequency and prices at which the Company sells shares of its stock to Lincoln Park.
During the period from August 17, 2022 to December 31, 2022, the Company issued 4,000,000 shares under the 2022 Purchase Agreement for net
proceeds of approximately $3.2 million. From January 1, 2023 to the date of filing of these financial statements, the Company did not issue any
shares under the 2022 Purchase Agreement.
On September 30, 2020, the Company entered into a purchase agreement (the "2020 Purchase Agreement") and registration rights agreement
pursuant to which Lincoln Park committed to purchase up to $25.0 million of the Company’s common stock. Under the terms and subject to the
conditions of the 2020 Purchase Agreement, the Company had the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park was
obligated to purchase up to $25.0 million of the Company’s common stock. Such sales of common stock by the Company were subject to certain
limitations, and could occur from time to time, at the Company’s sole discretion, over the 36-month period commencing on November 6, 2020,
subject to the satisfaction of certain conditions.
On June 16, 2020, the Company received stockholder approval for purposes of the Nasdaq listing rules to permit issuances of up to 23.8 million
shares of the Company’s common stock (including the issuance of more than 19.99% of the Company’s common stock) to Lincoln Park, and it was
pursuant to that approval that the Company entered into the 2020 Purchase Agreement.
Lincoln Park had no right to require the Company to sell any shares of common stock to Lincoln Park, but Lincoln Park was obligated to make
purchases as the Company directs, subject to certain conditions.
79
During the year ended December 31, 2021, the Company issued 5,685,186 shares of its common stock under the 2020 Purchase Agreement for net
proceeds of approximately $12.5 million. During the year issued December 31, 2022, the Company issued 5,665,000 shares of its common stock
under the 2020 Purchase Agreement for net proceeds of approximately $7.0 million. The Company no longer has any additional shares of common
stock registered to sell under the 2020 Purchase Agreement.
At-the-market Issuances
On September 9, 2022, the Company entered into an Equity Distribution Agreement (the “September 2022 Distribution Agreement”) with
Canaccord Genuity LLC ("Canaccord”), pursuant to which the Company may issue and sell, from time to time, shares of its common stock having
an aggregate offering price of up to $5,000,000, depending on market demand, with Canaccord acting as an agent for sales. Sales of the Company's
common stock may be made by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415(a)(4) of the Securities
Act of 1933, as amended (the “Securities Act”), including, without limitation, sales made directly on or through the NASDAQ Capital Market.
Canaccord will use its commercially reasonable efforts to sell common stock requested by the Company to be sold on its behalf, consistent with
Canaccord's normal trading and sales practices, under the terms and subject to the conditions set forth in the September 2022 Distribution
Agreement. The Company has no obligation to sell any of its common stock. The Company may instruct Canaccord not to sell any common stock if
the sales cannot be effected at or above the price designated by the Company from time to time and the Company may at any time suspend sales
pursuant to the September 2022 Distribution Agreement. During the period from September 9, 2022 to December 31, 2022, the Company issued
1,031,371 shares under the September 2022 Distribution Agreement for net proceeds of approximately $0.6 million. From January1, 2023 to the
date of filing of this Form 10-K, the Company issued 1,812,785 shares under the September 2022 Distribution Agreement for net proceeds of
approximately $0.7 million.
The Company is obligated to pay Canaccord a commission of up to 3.0% of the gross proceeds from the sale of its common stock under the
September 2022 Distribution Agreement. The Company has also agreed to reimburse Canaccord for its reasonable documented out-of-pocket
expenses, including fees and disbursements of its counsel, in the amount of $50,000. In addition, the Company has agreed to provide customary
indemnification rights to Canaccord.
The Offering will terminate upon the earlier of (1) the issuance and sale of all shares of the Company’s common stock subject to the September
2022 Distribution Agreement, or (2) the termination of the Distribution Agreement as permitted therein, including by either party at any time
without liability of any party.
On January 14, 2022, the Company entered into an Equity Distribution Agreement (the “January 2022 Distribution Agreement”) with Canaccord,
pursuant to which the Company could issue and sell, from time to time, shares of its common stock having an aggregate offering price of up to
$5,000,000 shares, with Canaccord acting as an agent for sales. The Company had no obligation to sell any of the Company’s shares and it could
instruct Canaccord not to sell any shares if the sales could not be effected at or above the price designated by the Company from time to time and the
Company could at any time suspend sales pursuant to the January 2022 Distribution Agreement. During the year ended December 31, 2022, the
Company issued 6,902,279 shares under the January 2022 Distribution Agreement for net proceeds of approximately $4.8 million. The January
2022 Distribution Agreement has been terminated after all available registered shares were fully utilized.
Share Repurchase Program
On August 15, 2022, the Company announced that its Board of Directors has approved a share repurchase program pursuant to which the Company
is authorized to repurchase up to $2.0 million of the Company’s outstanding common stock. The timing and amount of any shares repurchased will
be determined based on the Company’s evaluation of market conditions and other factors, including consent of Oxford. Repurchases may be made
from time to time on the open market over the course of 12 months. The Company is not obligated to acquire any shares and the program may be
discontinued or suspended at any time. Through the date of filing of this Form 10-K, the Company has not repurchased any of its common stock
under this share repurchase program.
80
13.
Share-based Compensation
Under the Company’s 2015 New Employee Incentive Plan (the “2015 Plan”), awards may only be granted to employees who were not previously an
employee or director of the Company, or following a bona fide period of non-employment, as a material inducement to entering into employment
with the Company. As of December 31, 2022, there were 90,389 shares of common stock remaining and available for future issuances under the
2015 Plan.
The Company’s 2020 Stock Incentive Plan (the “2020 Plan”), which replaced the Company’s 2014 Equity Incentive Plan, provides for the award or
sale of shares of common stock (including restricted stock), the award of stock units and stock appreciation rights, and the grant of both incentive
stock options to purchase common stock to directors, officers, employees and consultants of the Company. The 2020 Plan, as amended, provides for
the issuance of up to 3,550,000 shares of common stock, plus the number of shares available for issuance is increased to the extent that awards
granted under the 2020 Plan and the Company’s 2014 Equity Incentive Plan are forfeited or expire (except as otherwise provided in the 2020 Plan).
As of December 31, 2022, there were 2,635,717 shares remaining and available for future issuances under the 2020 Plan.
Generally, options issued under the 2020 Plan are subject to a two-year or four-year vesting schedule with 25% of the options vesting on the one
year anniversary of the grant date followed by equal monthly installment vesting, and have a contractual term of 10 years.
A summary of activity for the year ended December 31, 2022 is as follows:
Balance as of December 31, 2021
Granted
Cancelled/forfeited
Balance as of December 31, 2022
Vested and expected to vest at December 31, 2022
Exercisable at December 31, 2022
Weighted
Average
Remainin
g
Contractu
al
Term
(years)
Aggregate
Intrinsic
Value
Weighted
Average
Exercise
Price
5.01
0.53
60.08
4.54
4.57
6.11
9.00
8.00 $
8.00 $
7.84 $
-
-
-
Options
1,170,890 $
13,000 $
(8,874 ) $
1,175,016 $
1,135,664 $
671,892 $
The Company settles exercises of stock options with newly issued shares of its common stock. There were no stock options exercised in 2022 or
2021.
The fair value of each option awarded during the years ended December 31, 2022 and 2021 was estimated on the date of grant using the Black-
Scholes-Merton option valuation model based on the following weighted-average assumptions:
Expected term
Risk-free interest rate
Expected volatility
Dividends
Resulting fair value
December 31,
2022
December 31,
2021
6.0 years
2.83 %
123.4 %
0 %
0.47 $
6.0 years
1.00 %
127.0 %
0 %
2.23
$
The weighted average risk-free interest rate represents the interest rate for treasury constant maturity instruments published by the Federal Reserve
Board. If the term of available treasury constant maturity instruments is not equal to the expected term of an employee option, the Company uses the
weighted average of the two Federal Reserve securities closest to the expected term of the employee option.
The dividend yield has been assumed to be zero as the Company (a) has never declared or paid any dividends and (b) does not currently anticipate
paying any cash dividends on its outstanding shares of common stock in the foreseeable future.
The following table summarizes share-based compensation recognized during the years ended December 31, 2022 and 2021 in the statement of
operations and comprehensive loss:
81
Research and development
General and administrative
Total share-based compensation
Years ended December 31,
2022
2021
$
$
87 $
519
606 $
75
531
606
As of December 31, 2021, the total compensation cost related to non-vested stock options and stock awards not yet recognized for all our plans is
approximately $0.9 million, which is expected to be recognized as a result of vesting under service conditions over a weighted average period of 2.2
years.
82
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
Not applicable.
Item 9A. Controls and Procedures
(a)
Evaluation of Disclosure Controls and Procedures
We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports filed or
furnished pursuant to the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities
and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our
Chief Executive Officer (our principal executive officer) and Chief Financial Officer (our principal accounting officer and principal financial
officer), as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and
procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only
reasonable assurance of achieving the desired control objectives, and management necessarily is required to apply its judgment in evaluating
the cost-benefit relationship of possible controls and procedures.
As required by Rule 13a-15(b) under the Exchange Act, we carried out an evaluation, under the supervision and with the participation of our
management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and
procedures, as such term is defined under Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934, as amended, as of the end
of the period covered by this Annual Report on Form 10-K. Based on the foregoing, our Chief Executive Officer and Chief Financial Officer
concluded that our disclosure controls and procedures as of the end of the period covered by this Annual Report were effective.
(b) Management’s Report on Internal Control Over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over
financial reporting is defined in Rule 13a-15(f) or 15d-15(f) under the Securities Exchange Act of 1934 as a process designed by, or under the
supervision of, our principal executive and principal financial officers and effected by our Board of Directors, management and other
personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:
•
•
•
Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our
assets;
Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance
with generally accepted accounting principles, and that receipts and expenditures are being made only in accordance with authorizations
of management and our Board of Directors; and
Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that
could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any
evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or
that the degree of compliance with the policies or procedures may deteriorate.
Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we
have conducted an evaluation of the effectiveness of our internal control over financial reporting as of the end of the fiscal year covered by
this Annual Report on Form 10-K based on the criteria set forth in Internal Control - Integrated Framework (2013) issued by the Committee
of Sponsoring Organizations of the Treadway Commission (COSO). Based on our evaluation, management concluded that our internal
control over financial reporting was effective as of December 31, 2022 based on the COSO criteria.
This report does not include an attestation report on internal control over financial reporting by the Company’s independent registered public
accounting firm since the Company is a smaller reporting company under the rules of the SEC.
(c)
Changes in Internal Control over Financial Reporting
There have been no changes in our internal control over financial reporting during the quarter ended December 31, 2022 that have materially
affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Item 9B. Other Information
None.
83
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspection
Not Applicable.
PART III
Item 10. Directors, Executive Officers and Corporate Governance.
The information required by this item will be set forth under the captions “Election of Directors – Directors and Nominees,” “Executive
Officers,” “Certain Relationships and Related Transactions – Section 16(a) Beneficial Ownership Reporting Compliance,” “Code of Business Conduct and
Ethics” and “Corporate Governance – Board Committees” in our definitive proxy statement to be filed with the SEC, in connection with our 2022 annual
meeting of stockholders (the “Proxy Statement”), which is expected to be filed not later than 120 days after the end of our fiscal year ended December 31,
2022, and is incorporated in this report by reference.
Item 11. Executive Compensation.
The information required by this item will be set forth under the captions “Executive Compensation”, “Corporate Governance — Compensation
Committee Interlocks and Insider Participation,” “Corporate Governance – Compensation Committee Report” and “Corporate Governance — Non-
Employee Director Compensation” in the Proxy Statement and is incorporated herein by reference.
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.
The information required by this item will be set forth under the caption “Security Ownership of Certain Beneficial Owners and Management”
and “Executive Compensation — Equity Compensation Plan Information” in the Proxy Statement and is incorporated herein by reference.
Item 13. Certain Relationships and Related Transactions, and Director Independence.
The information required by this item will be set forth under the captions “Certain Relationships and Related Person Transactions” and
“Corporate Governance — Board Independence” in the Proxy Statement and is incorporated herein by reference.
Item 14. Principal Accounting Fees and Services.
The information required by this item will be set forth under the caption “Audit Matters — Principal Accounting Fees and Services” in the Proxy
Statement and is incorporated herein by reference.
84
Item 15. Exhibits, Financial Statement Schedules
(a) (1) Financial Statements.
The responses to this portion of Item 15 are set forth under Part II, Item 8 above.
PART IV
(a) (2) Financial Statement Schedules.
None.
(a) (3) Exhibits.
List of Exhibits required by Item 601 of Regulation S-K. See Item 15(b) below.
(b) Exhibits.
The exhibits listed in the accompanying “Exhibit Index” are filed, furnished or incorporated by reference as part of this Annual Report, as
indicated.
Item 16. Form 10-K Summary.
None.
85
EXHIBIT INDEX
PLUS THERAPEUTICS, INC.
Filed with
this Form
10-K
Composite Certificate of Incorporation.
Exhibit Title
Certificate of Amendment to Amended and Restated Certificate of
Incorporation.
Certificate of Amendment to Amended and Restated Certificate of
Incorporation.
Certificate of Amendment to Amended and Restated Certificate of
Incorporation.
Certificate of Amendment to Amended and Restated Certificate of
Incorporation.
Certificate of Designation of Preferences, Rights and Limitations of Series
B Convertible Preferred Stock.
Certificate of Designation of Preferences, Rights and Limitations of Series
C Convertible Preferred Stock.
Amended and Restated Bylaws of Plus Therapeutics, Inc.
Exhibit
Number
3.1
3.2
3.3
3.4
3.5
3.6
3.7
3.8
4.1
Description of Securities.
Form of Common Stock Certificate.
Incorporated by Reference
Form
10-K
8-K
8-K
8-K
8-K
8-K
8-K
8-K
10-K
10-K
File No.
001-34375
Exhibit 3.1
001-34375
Exhibit 3.1
001-34375
Exhibit 3.1
001-34375
Exhibit 3.1
001-34375
Exhibit 3.1
001-34375
Exhibit 3.1
001-34375
Exhibit 3.1
001-34375
Exhibit 3.2
001-34375
Exhibit 4.1
001-34375
Exhibit 4.33
Date Filed
03/11/2016
05/10/2016
05/23/2018
07/29/2019
08/06/2019
11/28/2017
07/25/2018
09/21/2021
03/30/2020
03/09/2018
Form of Series U Warrant.
S-1/A
333-229485
09/16/2019
Form of Warrant Amendment Agreement.
Form of Underwriters’ Warrant Amendment Agreement.
Patent and Know-How License Agreement, dated March 29, 2020, by and
between Plus Therapeutics, Inc. and NanoTx, Corp.
Patent & Technology License Agreement, dated December 31, 2021,
between Plus Therapeutics, Inc. and the University of Texas Health
Science Center at San Antonio.
Distribution Agreement, dated September 9, 2022, by and between Plus
Therapeutics, Inc. and Canaccord Genuity LLC.
Purchase Agreement between Lincoln Park Capital Fund, LLC and Plus
Therapeutics, Inc., dated August 2, 2022.
Registration Rights Agreement between Plus Therapeutics, Inc. and
Lincoln Park Capital Fund, LLC, dated August 2, 2022.
Loan and Security Agreement, dated May 29, 2015, by and between Plus
Therapeutics, Inc. and Oxford Finance, LLC.
First Amendment to Loan and Security Agreement, dated September 20,
2017, by and between Plus Therapeutics, Inc. and Oxford Finance, LLC.
86
8-K
8-K
8-K
Exhibit 4.37
011-34375
Exhibit 4.1
011-34375
Exhibit 4.1
04/23/2020
10/05/2020
011-34375 Exhibit
10.1
3/30/2020
10-K
011-34375
2/24/2022
Exhibit 10.2
8-K
011-34375
09/09/2022
Exhibit 1.1
8-K
011-34375
08/08/2022
8-K
10-Q
S-1/A
Exhibit 10.1
001-34375
Exhibit 10.2
001-34375
Exhibit 10.4
333-219967
Exhibit 10.45
08/08/2022
08/10/2015
10/03/2017
4.2
4.3
4.4
4.5
10.1+
10.2+
10.3
10.4
10.5
10.6
10.7
10.8
10.9
10.10
10.11
10.12
10.13
10.14
10.15+
10.16#
10.17#
10.18#
Second Amendment to Loan and Security Agreement, dated June 19,
2018, by and between Plus Therapeutics, Inc. and Oxford Finance, LLC.
Third Amendment to Loan and Security Agreement, dated August 31,
2018, by and between Plus Therapeutics, Inc. and Oxford Finance, LLC.
Fourth Amendment to Loan and Security Agreement, dated December 31,
2018, by and between Plus Therapeutics, Inc. and Oxford Finance, LLC.
Fifth Amendment to Loan and Security Agreement, dated February 13,
2019, by and between Plus Therapeutics, Inc. and Oxford Finance, LLC.
Sixth Amendment to Loan and Security Agreement, dated March 4, 2019,
by and between Plus Therapeutics, Inc. and Oxford Finance, LLC.
Seventh Amendment to Loan and Security Agreement, dated April 24,
2019, by and between Plus Therapeutics, Inc. and Oxford Finance, LLC.
Eight Amendment to Loan and Security Agreement, dated July 15, 2019,
by and between Plus Therapeutics, Inc. and Oxford Finance, LLC.
Ninth Amendment to Loan and Security Agreement, dated March 29, 2020
by and between Plus Therapeutics, Inc. and Oxford Finance, LLC.
Amended and Restated Employment Agreement between Marc Hedrick
and Plus Therapeutics, Inc.
Amended and Restated Employment Agreement between Andrew Sims
and Plus Therapeutics, Inc.
Employment Agreement, dated December 8, 2021, by and between Plus
Therapeutics, Inc. and Normal LaFrance
10.19#
2015 New Employee Incentive Plan.
10.20#
10.21#
10.22#
10.23#
10.24#
10.25#
10.26+
First Amendment to the Plus Therapeutics, Inc. 2015 New Employee
Incentive Plan, dated Jan. 26, 2017.
Second Amendment to the Plus Therapeutics, Inc. 2015 New Employee
Incentive Plan, dated February 6, 2020.
Form of Notice of Grant of Stock Option under the 2015 New Employee
Incentive Plan.
Form of Stock Option Agreement under the 2015 New Employee Incentive
Plan.
Plus Therapeutics, Inc. 2020 Stock Incentive Plan, as amended and
restated.
Form of Notice of Grant and Stock Option Agreement under the 2020
Stock Incentive Plan.
Master Services Agreement between Piramal Pharma Solutions, Inc. and
Plus Therapeutics, Inc.
10.27#
Form of Indemnification Agreement.
10.28#
Form of Agreement for Acceleration and/or Severance.
87
10-Q
S-1
S-1
10-K
10-K
10-Q
10-Q
8-K
10-Q
10-Q
8-K
8-K
10-K
10-K
S-8
S-8
8-K
10-K
10-K
8-K
10-K
001-34375
Exhibit 10.3
333-227485
Exhibit 10.51
333-229485
Exhibit 10.52
001-34375
Exhibit 10.55
001-34375
Exhibit 10.56
001-34375
Exhibit 10.3
001-34375
Exhibit 10.2
011-34375 Exhibit
10.2
001-34375
Exhibit 10.6
001-34375
Exhibit 10.7
001-34375
Exhibit 10.1
001-34375
Exhibit 10.1
001-34375
Exhibit 10.42
08/14/2018
09/21/2018
02/01/2019
03/29/2019
03/29/2019
05/14/2019
08/15/2019
3/30/2020
5/16/2020
5/16/2020
09/13/2021
01/05/2016
03/24/2017
001-34375 Exhibit
10.25
03/30/2020
333-210211
Exhibit 99.5
333-210211
Exhibit 99.4
001-34375
Exhibit 10.1
001-34375
Exhibit 10.26
001-334275
Exhibit 10.24
001-34375
Exhibit 10.1
001-34375
Exhibit 10.113
03/15/2016
03/15/2016
05/17/2021
02/24/2022
02/22/2021
02/06/2020
03/11/2016
10.29
Medidata Services Agreement and Statement of Work.
10-Q
001-34375
04/21/2022
Exhibit 10.1
8-K
001-34375
09/22/2022
Exhibit 10.1
10.30
23.1
24.1
31.1
31.2
32.1
Cancer Research Grant Contract, effective August 31, 2022, by and
between the Cancer Prevention and Research Institute of Texas and Plus
Therapeutics, Inc.
Consent of BDO USA, LLP, Independent Registered Public Accounting
Firm.
Power of Attorney (see signature page).
Certification of Principal Executive Officer Pursuant to Securities
Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002.
Certification of Principal Financial and Accounting Officer Pursuant to
Securities Exchange Act Rule 13a-14(a), as adopted pursuant to Section
302 of the Sarbanes-Oxley Act of 2002.
Certifications Pursuant to 18 U.S.C. Section 1350/ Securities Exchange
Act Rule 13a-14(b), as adopted pursuant to Section 906 of the Sarbanes -
Oxley Act of 2002.
101.INS
Inline XBRL Instance Document
101.SCH
Inline XBRL Schema Document
101.CAL
Inline XBRL Calculation Linkbase Document
101.DEF
Inline XBRL Definition Linkbase Document
101.LAB
Inline XBRL Label Linkbase Document
101.PRE
Inline XBRL Presentation Linkbase Document
104
Cover Page Interactive Data File (formatted as Inline XBRL and contained
in Exhibit 101)
# Indicates management contract or compensatory plan or arrangement.
+ Portions of this exhibit have been excluded pursuant to Item 601(b)(1)(iv).
88
X
X
X
X
X
X
X
X
X
X
X
X
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this registration
statement to be signed on its behalf by the undersigned, thereunto duly authorized.
SIGNATURES
PLUS THERAPEUTICS, INC.
By: /s/ Marc H. Hedrick, MD
Marc. H. Hedrick, MD
President & Chief Executive Officer
February 23, 2023
Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following
persons on behalf of the registrant and in the capacities and on the dates indicated.
SIGNATURE
/s/ Richard J. Hawkins
Richard J. Hawkins
/s/ Marc H. Hedrick, MD
Marc H. Hedrick, MD
/s/ Andrew Sims
Andrew Sims
/s/ An van Es-Johansson, MD
An van Es-Johansson, MD
/s/ Greg Petersen
Greg Petersen
/s/ Howard Clowes
Howard Clowes
/s/ Robert Lenk
Robert Lenk
Chairman of the Board
February 23, 2023
TITLE
DATE
President & Chief Executive Officer (Principal Executive Officer)
February 23, 2023
Chief Financial Officer and VP of Finance (Principal Financial and Accounting
Officer)
February 23, 2023
Director
Director
Director
Director
89
February 23, 2023
February 23, 2023
February 23, 2023
February 23, 2023
Consent of Independent Registered Public Accounting Firm
EXHIBIT 23.1
Plus Therapeutics, Inc.
Austin, Texas
We hereby consent to the incorporation by reference in the Registration Statements on Forms S-1 (Nos. 333-229485, 333-227485, 333-
226205, 333-224502, 333-219967, 333-215365, 333-210628 and 333-249728, 333-253612, 333-259325 and 333-266684), Forms S-3 (Nos.
333-217988, 333-172787, 333-169822, 333-157023, 333-140875, 333-134129, 333-153233, 333-159912, 333-192409, 333-200090, 333-
195846, 333-216947 and 333-249410) and Forms S-8 (Nos. 333-223566, 333-210211, 333-202858, 333-181764, 333-122691, 333-82074 and
333-239548) of Plus Therapeutics, Inc. (the “Company”) of our report dated February 23, 2023, relating to the consolidated financial
statements, which appears in this Annual Report on Form 10-K.
/s/ BDO USA, LLP
Austin, Texas
February 23, 2023
Certification of Principal Executive Officer Pursuant to
Securities Exchange Act Rule 13a-14(a)
As Adopted Pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002
EXHIBIT 31.1
I, Marc H. Hedrick, certify that:
1.
2.
3.
4.
I have reviewed this Annual Report on Form 10-K of Plus Therapeutics, Inc.;
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report;
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-
15(f)) for the registrant and have:
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
(a)
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
(b)
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles;
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the
(c)
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most
(d)
recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to
materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to
the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
(a)
reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal
(b)
control over financial reporting.
Date: February 23, 2023
/s/ Marc H. Hedrick, MD
Marc. H. Hedrick,
President & Chief Executive Officer
Certification of Principal Financial Officer Pursuant to
Securities Exchange Act Rule 13a-14(a)
As Adopted Pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002
EXHIBIT 31.2
I, Andrew Sims, certify that:
1.
2.
3.
4.
I have reviewed this Annual Report on Form 10-K of Plus Therapeutics, Inc.;
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report;
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-
15(f)) for the registrant and have:
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
(a)
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
(b)
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles;
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the
(c)
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most
(d)
recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to
materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to
the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
(a)
reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal
(b)
control over financial reporting.
Date: February 23, 2023
/s/ Andrew Sims
Andrew Sims
Chief Financial Officer
CERTIFICATIONS PURSUANT TO 18 U.S.C. SECTION 1350/ SECURITIES EXCHANGE ACT RULE 13a-14(b), AS ADOPTED PURSUANT
TO SECTION 906 OF THE SARBANES – OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of Plus Therapeutics, Inc. for the year ended December 31, 2022 as filed with the Securities and
Exchange Commission on February 23, 2023, (the “Report”), Marc H. Hedrick, as President & Chief Executive Officer of Plus Therapeutics, Inc., and
Andrew Sims, as Chief Financial Officer of Plus Therapeutics, Inc., each hereby certifies, respectively, that:
1.
2.
The Report fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934.
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Plus
Therapeutics, Inc.
EXHIBIT 32.1
Dated: February 23, 2023
Dated: February 23, 2023
By: /s/ Marc H. Hedrick, MD
Marc H. Hedrick, MD
President & Chief Executive Officer
By: /s/ Andrew Sims
Andrew Sims
Chief Financial Officer